MXPA04001695A - Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease. - Google Patents

Abstract

compounds of the Formula I: Formula (I), wherein R1, R2, R4, R6, X, and W are defined herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases or conditions in which alpha7 is known to be involved.

Description

HETEROARIL-7-AZAr2.2.1lBICiCLOHEPTANOS SUBSTITUTED FOR THE TREATMENT OF DISEASE FIELD OF THE INVENTION Nicotinic acetylcholine receptors (nAChR) play a large role in the activity of the central nervous system (CNS). In particular, they are known to be involved in cognition, learning, mood, emotion and neuroprotection. There are several types of nicotinic acetylamide receptors and each seems to have a different role in the regulation of CNS function. Nicotine affects all receptors of this type and has a variety of activities. Unfortunately, not all activities are desirable. In fact, one of the less desirable properties of nicotine is its addictive nature and the low relation between efficacy and safety. The present invention relates to molecules that have a greater effect on nAChR ct7 compared to other close members of this large family of ligand-regulating receptors. Thus, the invention provides compounds that are active pharmacological molecules with fewer side effects.

BACKGROUND OF THE INVENTION The cell surface receptors, in general, are excellent and validated drug targets. The nAChRs comprise a large family of ion channels regulated by ligands that control neuronal activity and brain function. These receptors have a pentameric structure. In mammals, this gene family is composed of nine alpha and four beta subunits that assemble to form multiple subtypes of receptors that have a characteristic pharmacology. Acetylcholine is the endogenous regulator of all subtypes, while nicotine activates all nAChRs in a non-selective manner. NAChR a7 is a receptor system that has proven to be a difficult target for experimentation. Native a7 nAChR routinely can not be expressed stably in most mammalian cell lines (Cooper and Millar, J. Neurochem., 1997, 68 (5): 2140-51). Another feature that makes experimentation with nAChR a7 a challenge is that the receptor is rapidly inactivated (100 milliseconds). This rapid inactivation greatly limits the functional assays that can be used to measure channel activity. Recently, Eisele and cois. They have indicated that a chimera receptor formed between the ligand domain of the N-terminus of nAChR a7 (Eisele et al., Nature, 366 (6454), pages 479-83, 1993) and the pore-forming domain of the C-terminus of the receptor 5 -HT3 expressed well in Xenopus oocytes maintaining its sensitivity as a nicotinic agonist. Eisele and cois used the N-terminus of the avian (chicken) form of the nAChR a7 receptor and the C-terminus of the murine form of the 5-HT3 gene. However, under physiological conditions nAChR a7 is a calcium channel while 5-HT3R is a sodium and potassium channel. In fact, Eisele et al. Teach that the mouse a7 / chicken 5-HT3R nAChR behaves quite differently than the native a7 nAChR since the pore element does not conduct calcium but is actually blocked by the calcium ions . WO 00/73431 A2 outlines the test conditions in which 5-HT3R can be made to conduct calcium. This assay can be used to detect agonist activity in this receptor. U.S. Patent 6,255,490 B1 describes derivatives of 7-azabicyclo [2.2.1] -heptane and-heptene as ligands of cholinergic receptors. United States Patent 6,117,899 describes derivatives of 7-azabicyclo [2.2.1] -heptane and-heptene as analgesic and anti-inflammatory agents. U.S. Patent 6,060,473 discloses derivatives of 7-azabicyclo [2.2.1] -heptane and-heptene as ligands of cholinergic receptors. U.S. Patent 6,054,464 describes azabicyclic esters of carbamic acids useful in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual disability disorders., as well as intermediates and the use of intermediates in the synthesis. U.S. Patent 5,977,144 discloses benzylidene- and cinnamilide-anabasein compositions and methods for using these compositions to treat disorders associated with defects or dysfunctions of cerebral receptors of nicotinic subtypes. These compositions target the subtype of a7 receptor by activating little or nothing a4ß2 or other receptor subtypes. U.S. Patent 5,712,270 discloses a group of 2-aroylaminotiazoI derivatives that bind and stimulate the central muscarinic acetylcholine receptors and are agents useful for treating symptoms of cognitive disorders, specifically deficient memory associated with a decrease in the neurotransmitter. acetylcholine Some of the compounds of this invention also bind to the 5HT-, A and D2I dopamine receptors making them useful as antipsychotic agents. U.S. Patent 5,624,941 describes pyrazole derivatives of utility in drugs in which cannabis is known to be involved. U.S. Patent 5,561,149 describes the use of a carboxylic acid ester or amide or a carbocyclic or heterocyclic bicyclic imidazolylcarbazole in the manufacture of a medicament suitable for the treatment of psychiatric stress-related disorders, to increase wakefulness, for the treatment of rhinitis or serotonin-induced disorders and / or co-administration with another active agent to increase its bioavailability or for nasal administration. U.S. Patent 5,510,478 discloses a group of 2-aroylaminotriazole derivatives that bind and stimulate muscarinic acetylcholine receptors and are useful agents for treating symptoms of cognitive disorders, specifically deficient memory associated with a decrease in the acetylcholine neutrotransmitter. . Some of the compounds of this invention also bind to 5HTiA receptors and dopanim D2 receptors making them useful as antipsychotic agents. U.S. Patent 5,364,863 discloses bicyclic carboxylic esters and amides, their pharmaceutical formulations and a method for their use in the treatment of migraine, emesis, gastrointestinal disorders, schizophrenia or anxiety in mammals. U.S. Patent 5,106,843 discloses cyclic compounds useful as 5-HT3 agonists. U.S. Patent 5,057,519 discloses 5-HT3 antagonists that are useful for reducing opioid tolerance. U.S. Patent 5,039,680 discloses 5-HT3 antagonists to prevent or reduce dependence on dependence-inducing agents. U.S. Patent 4,988,691 discloses isoxazole-containing compounds that exhibit activity against serotonin. U.S. Patent 4,921,982 describes 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids which are useful as intermediates for 5-HT3 antagonists. U.S. Patent 4,835,162 discloses nicotine agonists and antagonists as deterrents to tobacco use. U.S. Patent 4,605,652 discloses a method for enhancing memory or correcting memory deficiency with arylamido (and arythioamido) -azabicycloaIcanos and their pharmaceutically acceptable acid, hydrate and alcoholate addition salts. WO 01/60821 discloses novel biarylcarboxamides. WO 01/36417 describes N-azabicycloamide derivatives and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual deficiency disorders. WO 01/29304 discloses quinuclidin acrylamides. WO 00/73431 A2 describes two binding assays to directly measure the affinity and selectivity of compounds in nAChR a7 and 5-HT3R. The combined use of these functional and binding assays can be used to identify compounds that are selective a7 agonists of nAChR. WO 97/30998 describes azabicyclic esters of carbamic acids useful in therapy. WO 95/01793 discloses 5-HT3 antagonists as topical medicaments for the treatment of peripheral disorders associated with pain.

WO 92/15579 describes multi-cyclic polyaromatic tertiary amine squalene synthase inhibitors and treatment method for reducing serum cholesterol levels using the compounds. DE 3810552 describes esters and amides of indolyl-, benzo [b] thiophenyl-, benzo [b] furancarboxylic acids or 4-amino-2-methoxybenzoic acids with N-heterocyclic or N-heterobicyclic alcohols or amines. The compounds described have activity against pain especially migraine and as an antiarrhythmic for gastrointestinal discomfort, stomach discomfort, gastritis, ulcer, gallbladder, spastic colon, Crohn's disease, ulcerative colitis, carcinoid syndrome, diarrhea of various types. The compounds are also described as stomach voiding accelerators, gastroduodenic and gastroesophageal reflux controllers, esophageal motility disorders, hiatus hernia, heart failure, hypotonic stomach, paralytic cancer, manic-depressive psychosis and other psychoses. It is also disclosed that the compounds are useful in diseases related to stress, senility and potentiation of the nasal absorption of other agents, for example, in the treatment of emesis. In Bioorg. & Med. Chem. Leti. 1 (2001) 319-321, the tropisetron 5-HT3 antagonist (ICS 205-930) is described as a potent and selective partial agonist of the nicotinic receptor c < 7. In Behavioral Brain Res., 113 (2000) 169-181, it is described that the cerebral nicotinic receptor ct7 may be an important therapeutic target for the treatment of Alzheimer's disease using D XBA which is known as GTS-21.

SUMMARY OF THE INVENTION In general, the invention includes a compound of the formula A-L-B or a pharmaceutically acceptable salt thereof, wherein A includes a 7-azabicyclo [2.2.1] heptane ring having 1S, 2R and R stereochemistry; B is a heteroaryl; and L is a linking moiety that includes an amide, a thioamide, an acrylamide, an acrylthioamide, an propiolamide, or a propiolthioamide having the linking moiety attached to the C-2 carbon of the heptane ring in an exo orientation. The present invention describes compounds of Formula I: wherein the stereochemistry of the 7-azabicyclo [2.2.1] heptane ring is 1S, 4R and the nitrogen substituent of carbon C-2 has the orientation exo and is R; X is O or S; Ri is H, alkyl, halogenated alkyl, cycloalkyl or aryl; R2 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl or aryl; W is -Q, -C = C-Q or -C C-Q; Q is a heteroaromatic cyclic moiety where the heteroatoms may be 1-3 atoms that are selected from oxygen, sulfur or nitrogen or the following structures: wherein U is -O-, -S- or -N (R3) -; V and Y are independently selected from = N- y = C (R5) -; Z is = N- or = CH-; R3 is H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, R7, Rg, aryl, -C (0) -alkyl, -C (0) -c chloralkyl, -C (0) -heterocycloalkyl, -C (0) -halogenated alkyl, -C (0) -halogenated cycloalkyl, -C (0) -halogenated heterocycloalkyl, -C (0) -substituted alkyl, -C (0) ) -substituted cycloalkyl, -C (O) -substituted heterocycloalkyl, -C (0) -R7) -C (0) -R9 or -C (0) -aryl; Each R 4 is independently H, alkyl or substituted alkyl; Each R 5 is independently H, F, Cl, Br, I, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl. , substituted heterocycloalkyl, lactamheterocycloalkyl, aryl, -OR8, -SR8, -N (R8) 2, -C (0) R8, -C (S) R8, -C (0) OR8, -C (0) N (R8 ) 2, -NR8C (0) R8, -S (0) 2N (R8) 2, -OS (0) 2R8, -S (0) 2R8, -S (0) R8, -NR8S (0) 2R8, - N (R8) C (0) N (R8) 2, -CN, -N02, R7 or R9; R6 is H, alkyl, an amino protecting group or an alkyl group having 1-3 substituents that are selected from F, Cl, Br, I, -OH, -CN, -NH2, -NH (alkali) or -N (alkyl) 2; R7 is 5-membered heteroaromatic monocyclic moieties containing within the ring 1-3 heteroatoms which are independently selected from the group consisting of = N-, -N (R2o) -, -O- and -S- and having 0-1 substituent selected from R-i7 and further having 0-3 substituents that are independently selected from F, Cl, Br or I, or R7 is 9-membered fused ring moieties having a 6-membered ring condensed with a ring of 5 members that includes the formula the one that Gi is O, S or NR20, wherein G is C (R14) or N, and each G2 and G3 is independently selected from C (Ri) 2, C (Ru), O, S, N and N (R2o), with the proviso that G2 and G3 are not both simultaneously O or S or wherein G is C (R- | 4) or N and each G2 and G3 is independently selected from C (R1) 2, C (R14), O, S, N and N (R2o), each bicyclic ring having 9 member 0-1 substituent selected from R17 and 0-3 substituents that are independently selected from F, Cl, Br or I, wherein the R7 moiety is bound to other substituents as defined in formula I at any position of any of the rings as valence allows. Each Re is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, R7, R9, phenyl optionally substituted with 1-4 substituents that are independently selected from F, Cl , Br, I, R13 and R-15 or naphthyl optionally substituted with 1-4 substituents that are independently selected from F, Cl, Br, I, R13 and Ri5; Rg is 6-membered heteroaromatic monocyclic moieties containing within the ring 1-3 heteroatoms that are selected from = N- and having 0-1 substituent selected from Ri and 0-3 substituent (s) being selected (n) independently of F, Cl, Br or I or R9 is 10-membered heteroaromatic bicyclic moieties containing within one or both rings 1-3 heteroatoms selected from = N- including, but not limited to, quinolinyl or isoquinolinyl, each moiety having of the 10-membered fused ring 0-1 substituent selected from R17 and 0-3 substituent (s) which is selected independently from F, Cl, Br or I, wherein the Rg moiety binds to other substituents as defined in formula I at any position of each ring as valence allows; Each River is independently H, alkyl, cycloalkyl, heterocycloalkyl, R7, Rg, alkyl substituted with 1 substituent selected from R-13, cycloalkyl substituted with 1 substituent selected from R-13, heterocycloalkyl substituted with 1 substituent selected of R-13, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl or phenyl optionally substituted with 1-4 substituents that are independently selected from F, Cl, Br, I, R 3 and R 5; Each R-p is independently H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl or halogenated heterocycloalkyl; R12 is alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SRn, -S (0) 2Rn, -S (0) Rn, -OS (0 ) 2Rn, -N (Rn) 2, -C (0) Rn, -C (S) Rn, -CFOJORn, -N02, -C (0) N (Rn) 2l -CN, -NRi- | C (0) ) Rii, -NR11C (0) N (R11) 2, -S (0) 2N (Rn) 2 or -NRi S (0) 2Rn; Ris is -OR11, -SR11, -SORn, -S02R, -OS02Rn, -N (Rn) 2, -C (0) Rn, -C (0) ORii, -C (S) Rn, -C (0) N (Rn) 2, -N02, -CN, -CF3, -NRnCIOJRn, -NRnCÍOJNÍRnJa, -S (0) 2N (Rn) 2 or - RuSÍOfeRn; R15 is R7, R9, R19, or lactamaheterocycloalkyl; Each R16 is independently H, alkyl, cycloalkyl, halogenated alkyl or halogenated cycloalkyl; R17 is alkyl, cycloalkyl or heterocycloalkyl, each optionally substituted with 1-4 substituents which are independently selected from F, Cl, Br, I, -N02, -CN, -OR16, -SR16, -S (0) 2Ri6, - S (0) R16, -OS (0) 2Ri6, -N (R16) 2, -C (0) R16, -C (S) R16, -C (0) OR16, -C (0) N (Ri6) 2, -NR16C (0) R16, -NR16C (0) N (R16) 2, -S (0) 2N (R16) 2 and -NR16S (0) 2R16 and cycloalkyl and heterocycloalkyl are optionally further substituted with = 0 or = S; R-19 is alkyl, cycloalkyl, heterocycloalkyl, phenyl or naphthyl, each optionally substituted with 1 -4 substituents which are independently selected from F, Cl, Br, I, -CN, -N02, -0R16, -SRi6, -S (0) 2R16, -S (0) R16, -OS (0) 2R16, -N (R16) 2, -C (0) R16, -C (S) R16) -C (0) OR16, -C ( 0) N (R16) 2, -NR16C (0) R16) -NR16C (0) N (R16) 2, -S (0) 2N (R16) 2 or -NR16S (0) 2R16 and the cycloalkyl and heterocycloalkyl are optionally substituted also with = 0 or = S; R20 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, -S02R8, or phenyl having 1 substituent selected from R-12 and further having 0-3 substituents that are independently selected of F, Cl, Br or I; or pharmaceutical composition, pharmaceutically acceptable salt, racemic mixture or pure enantiomer thereof. In another aspect, the invention includes a compound of the formula A-L-B or a pharmaceutically acceptable salt thereof, wherein A includes a 7-azabicyclo [2.2.1] heptane ring having 1 S, 2 R and 4 R stereochemistry; B is a heteroaryl; and L is a linking moiety that includes an amide, a thioamide, an acrylamide, an acrylthioamide, an propiolamide, or a propiolthioamide having the linking moiety attached to the C-2 carbon of the heptane ring in an exo orientation. In another aspect, the invention includes methods of treating a mammal suffering from schizophrenia or psychosis by administering compounds of the formula A-L-B or Formula I together with antipsychotic drugs (also referred to as antipsychotic agents). The compounds of the formula A-L-B or the Formula I and the antipsychotic drugs can be administered simultaneously or at different intervals. When administered simultaneously, the compounds of the present invention and the antipsychotic drugs can be incorporated into a single pharmaceutical composition. Alternatively, two different compositions may be administered simultaneously, ie, one containing the compounds of the present invention and another containing antipsychotic drugs. The present invention also includes the compounds of the present invention, pharmaceutical compositions containing the active compounds and methods for treating the identified diseases. Embodiments of the invention may include one or more combinations of the following. The compound of Formula I, wherein X is O. The compound of Formula I, wherein X is S. The compound of Formula I, wherein W is one or more any combination of -Q, -C = CQ or -C CQ optionally substituted as allowed by the definition of Q. The compound of Formula I where Q is (a) or (b) or both (a) and (b), each optionally substituted on a carbon atom where substitution is permitted with any one of the following: F, Cl, Br, I, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, cycloalkyl substituted, substituted heterocycloalkyl, lactamheterocycloalkyl, aryl, -ORa, -SR8, -N (R8) 2, -C (0) R8, -C (S) R8, -C (0) OR8, -C (0) N ( R8) 2, -NR8C (0) R8I -S (0) 2N (R8) 2, -OS (0) 2R8, -S (0) 2R8, -S (0) R8, -NR8S (0) 2R8, - N (R8) C (0) N (R8) 2, -CN, -N02) R7 or R9. Those skilled in the art can identify where substitution is permitted by comparing the remains with (a) or (b). The compound of Formula I, wherein Q is (a) or (b) or both (a) and (b), each optionally substituted on a nitrogen atom where substitution with any one of the following is permitted: alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, R7, Rg, aryl, -C (0) -alkyl, -C (0) -cycloalkyl, -C (0) - heterocycloalkyl, -C (0) -halogenated alkyl, -C (0) -halogenated cycloalkyl, -C (0) -halogenated halocycloalkyl, -C (0) -substituted alkyl, -C (0) -cycloalkyl substituted , -C (0) -substituted heterocycloalkyl, -C (0) -R, -C (0) -Rg or -C (0) -aryl. Those skilled in the art can identify where substitution is permitted by comparing the remains with (a) or (b). Another group of compounds of Formula I includes compounds wherein R3 includes any one of the following: H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, R7, Rg, aryl, -C (0) -alkyl, -C (0) -cycloalkyl, -C (0) -heterocycloalkyl, -C (0) -halogenated alkyl, -C (0) -halogenated cycloalkyl, -C (0) -halogenated haloalkyl, -C (0) -substituted alkyl, -C (0) -substituted cycloalkyl, -C (0) -substituted heterocycloalkyl, -C (0) -R7, -C (0) ) -Rg or -C (0) -aryl. Another group of compounds of Formula I includes compounds wherein R3 is H. Another group of compounds of Formula I includes compounds wherein each R5 is independently any one of the following:, F, Cl, Br, I, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactamaheterocycloalkyl , aryl, -OR8, -SR8, -NR8R8, -C (0) R8, -C (S) R8, -C (0) OR8, -C (0) NR8R8, -NR8C (0) R8, -S ( 0) 2NR8R8, -OS (0) 2R8, -S (0) 2R8, -S (0) R8, -NR8S (0) 2R8, -N (R8) C (0) NR8R8, -CN, -N02, R7 or R9. Another group of compounds of Formula I includes compounds wherein each R 5 is H. Another group of compounds of Formula I includes compounds wherein both V and Y are = C (R 5) - and Z is = CH- and those that only one = C (R5) - can be = CH-. Another group of compounds of Formula I includes compounds wherein U is -O-, Y is = C (R5) -, Z is = C (H) -, and V is other than = N-. Another group of compounds of Formula I includes compounds wherein W is Q and Q is (b), V and Y are C (R5), Z is = N-, and U is N (R3), wherein R3 is other than phenyl, substituted phenyl or substituted benzyl in the phenyl of benzyl with -CH3. Benzyl is a permitted substituent where substituted alkyl is permitted. Another aspect of the invention includes a compound of the formula A-L-B or a pharmaceutically acceptable salt thereof, wherein A includes a 7-azabicyclo [2.2.1] heptane ring having 1 S.2R and 4R stereochemistry; B is a heteroaryl; and L is a linking moiety that includes an amide, a thioamide, an achlamide, an acrothioamide, an propiolamide, or a propiolthioamide having the linking moiety attached to the C-2 carbon of the heptane ring in an exo orientation. Heteroariio is 5-membered heteroaromatic monocyclic moieties containing within the ring 1-3 heteroatoms that are independently selected from nitrogen, oxygen or sulfur, optionally substituted with up to 4 substituents, where valence allows, with substituents that are independently F, CI, Br, I, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactamheterocycloalkyl, aryl, -OR8 , -SR8, -N (R8) 2, -C (0) R8, -C (S) R8, C (O) -aryl, -C (S) R8 > -C (0) OR8, -C (0) N (R8) 2, -NR8C (0) R8, -S (0) 2N (R8) 2, -OS (0) 2R8, -S (0) 2R8, -S (0) R8, -NR8S (0) 2R8, -N (R8) C (0) N (R8) 2l -CN, -N02, R7 or R9. The compound of Formula I wherein Ri is H, alkyl or cycloalkyl and wherein R 2 is H, alkyl, substituted alkyl, cycloalkyl, halogenated alkyl or aryl. The compound of Formula I wherein (a) is one or more or any combination of the following: thiophen-2-yl, furan-2-yl, 1,3-thiazol-5-yl or 1,3-oxazole-2 -yl, 1,3-thiazol-2-yl, 1,4-oxadiazol-2-yl, 1,3-oxazol-5-yl, 1 H-pyrrol-2-yl or 1, 2,4- oxadiazol-5-yl, any of which is optionally substituted on carbon (for example V or Y is independently CR5), with H, F, CI, Br, I, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactamaheterocycloalkyl, aryl, -OR8, -SR8, -N (R8) 2, -C (0) R8 , -C (S) R8, -C (0) OR8 > -C (0) N (R8) 2, -NR8C (0) R8, -S (0) 2N (R8) 2, -OS (0) 2R8, -S (0) 2R8, -S (0) R8, -NR8S (0) 2R8, -N (R8) C (0) N (R8) 2, -CN, -N02, R7 or R9; and further optionally substituted in nitrogen (for example when U is N-R3) with alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, R7, Rg, aryl, -C ( 0) -alkyl, -C (0) -cycloalkyl, -C (0) -heterocycloalkyl, -C (0) -halogenated alkyl, -C (0) -halogenated cycloalkyl, -C (0) -halogenated heterocycloalkyl, -C (0) -substituted alkyl, -C (0) -substituted cycloalkyl, -C (O) -substituted heterocycloalkyl, -C (0) -R7I -C (0) -R9 or -C (0) -aryl. The compound of Formula I, wherein each R 4 is independently H, lower alkyl or substituted lower alkyl. The compound of Formula I, wherein each R 6 is an amino protecting group. The compound of Formula I, wherein each R6 is H or lower alkyl optionally substituted with up to 3 substituents that are independently selected from F, Cl, Br, I, -OH, -CN, -NH2, -NH (alkyl) or - N (alkyl) 2. The compound of Formula I, wherein Ri is H or lower alkyl and wherein R 2 is H or lower alkyl. The compound of Formula I, wherein at least one R is H and an F? 4 is H or lower alkyl optionally substituted with 1 substituent selected from -CN, -N02, -OR10, -SR10, -S (O) R10, -S (0) 2Rio, -OS (0) 2Rio, -NR10Rio, -C (O) R10, -C (O) OR10, -C (S) Ri0, -C (0) NR10Rio, -NR10C ( O) Ri0, -NRi0C (0) NR 0Rio, -S (0) 2NR10Rio, -NR10S (O) 2R10, or phenyl optionally substituted with up to 4 substituents that are independently selected from F, Cl, Br, I, R13 and R15 with the proviso that when said lower alkyl is optionally substituted, said lower alkyl may be further optionally substituted with up to 3 substituents that are independently selected from F, Cl, Br and I and, further, with the proviso that R10 is H, lower alkyl or halogenated lower alkyl. This allows the lower alkyl of R4 to be substituted with a substituent selected from -CN, -N02, -OR10, -SR10, -S (O) R10, -S (O) 2R10, -OS (O) 2R10, -NR10Rio, -C (O) Ri0, -C (O) OR10) -C (S) R10, -C (0) NRi0Rio, -NR10C (O) R10, -NRi0C (0) NR10Rio, -S (0) 2NRioRio, -NRioS (0) 2R10, or phenyl optionally substituted with up to 4 substituents that are independently selected from F, Cl, Br, I, R13 and R15, and optionally further substituted with up to 3 substituents that are independently selected from F, Cl , Br and I at any carbon with sufficient valence for said substitution. This is further provided that R-io is H, lower alkyl or halogenated lower alkyl for the following optional substituents on R4: -OR 0, -SR10, -S (O) Ri0, -S (O) 2R-i0, -OS (O) 2R10, -NR10R10. -C (0) Rio, -C (0) ORio, -C (S) R10, -C (0) NR 0Rio, -NR10C (O) R10, -NR10C (0) NR10Rio, -S (O) 2NR10Ri0, -NR10S (O) 2R10. The compound of Formula I, wherein Ri, R2 and each R4 are H.

The compound of Formula I or formula ALB, wherein the compound is one or more or any combination of the following as the free base or a pharmaceutically acceptable salt thereof: N - [(1 S, 2R, 4R) -7- azabicyclo [2.2.1] hept-2-yl] -5-bromo-2-thiophenecarboxamide; (+/-) exo-N- [7-azabicyclo [2.2.1] hept-2-yl] -5-bromo-2-thiophenecarboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (methylthio) thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenylthiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenyl) thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-chlorophenyl) thio] thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-methylthiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-pyridin-2-ylthiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-nitrophenyl) -2-furamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-nitrophenol) -2-furamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenyl) -2-furamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-chlorothiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-nitrophenyl) -2-furamide; N - [(1 S, 2fl, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenyl) -2-furamide; . N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenyl) -2-furamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenyl) -2-furamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenyl) -2-furamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylphenyl) -2-furamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-bromo-2-furamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2-phenyl-1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-fluorophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-phenyl-2-furamide; or N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenyl-, 3-oxazole-2-carboxamide. The compound of Formula I or the formula ALB, wherein the compound is one or more or any combination of the following as the free base or a pharmaceutically acceptable salt thereof: N - [(1 S, 2R, 4R) -7 azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2,3'-bithiophene-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-n-trophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-nitrophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -4-phenyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-benzyloxyphenyl) thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-ylJ-5- (4-benzyloxyphenyl) thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoro-4-benzyloxyphenyl) thiophene-2-carboxamide; 5- (2-aminophenyl) -N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-pyridin-3-yl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] ept-2-yl] -5'-methyl-2,2'-bithiophen-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5'-c! Oro-2,2'-bithiophen-5-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-nitro-thiophene-2-carboxamide; . 5- (aminomethyl) -N - [(1 S, 2R, 4R) -7-azabicynic [2.2.1] hept-2-N] -5-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-cyano-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-methoxy-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicicio [2.2.1] hept-2-yl] - [2,2 '] - biothiophen-5-carboxamide N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-acetyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (phenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenyl-thiophene-2-carbothioamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-acetamidophenol) tofen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-acetamidophenyl) -thiophene-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-y [] - 5- (4-acetamidophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoroacetamidophenyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoroacetamidophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoroacetamidophenyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methanesulfonylaminophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methanesulfonyl-phenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methanesulfonyl-lane-phenyl) -thiophene-2-carboxamide; N - [(1 S, 2?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoromethanesulfonyl-aminophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoromethanesulfonylaminophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoromethanesulfonylaminophenyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-difluoroacetamidophenyl) -thiophene-2-carboxamide; N - [(1S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-difluoroacetamidophenyl) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-difluoroacetamidophenyl) -thiophene-2-carboxamide; N - [(1 S, 2, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-carbamoylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicynic or [2.2.1] hept-2-yl] -5- (3-carbamoyl-phenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-carbamoylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-sulfamoyl) phenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-sulfamoyl-phenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-sulfamoyl-phenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-acetamidophenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-acetamidophenol sulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-acetamidophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-tnfluoroacetamidophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoroacetamidophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoroacetamidophenylsufanyl) -thiophene-2-carboxamide; . N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methanesulfonylamino-phenyl-sulphanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4tf) -7-azabicide [2.2.1] hept-2-yl] -5- (3-methanesulfonylaminophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4fi) -7-azabicyclo [2.2.1] hept-2-ii] -5- (4-methanesulfonylaminophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoromethanesulfonylaminophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4i?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoromethanesulfonylaminophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoromethanesulfonylaminophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicynic [2.2.1] hept-2-yl] -5- (2-difluoroacetamidophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-difluoroacetamidophenyl-sulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-difluoroacetamidophenylisulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (2-carbamoylphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-carbamoylphenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-carbamoi-phenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-sulfamoylphenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-sulfamoylphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-sulfamoyl-phenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxy-phenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxy-phenylisulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2 /? 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxyphenyl sulfonyl) -t ofen-2-carboxamide; N - [(1S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-aminophenylsufanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-aminophenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-acetamidophenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-acetamidophenoxy) -thiophene-2-carboxamide; N - [(1S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-acetamidophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoroacetamidophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoroacetamide-phenoxy) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoroacetamidophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4fi) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methanesulfonylaminophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2 / ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methanesulfonyl-phenoxy) -thiophene-2-carboxamide; N - [(1 S, 2?, 4ft) -7-azabicyclo [2.2.1] ept-2-yl] -5- (4-methanesulfonylaminophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoromethanesulfonylminophenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoromethanesulfonylminophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoromethanesulfonyl-lane-phenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-d-fluoroacetamidophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-d-fluoroacetamidophenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-difluoroacetamidophenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicicio [2.2.1] hept-2-yl] -5- (2-carbamoylphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-carbamoylphenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-carbamoylphenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-sulfamoyl-phenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-sulfamoylphenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-sulfamoyl-phenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxyphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxyphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxyphenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-aminophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-aminophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenoxy) -thiophen-2-ca rboxa m da; N - [(1 S, 2R, 4R) -7-azabicicio [2.2.1] hept-2-yl] -5- (2-chlorophenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenoxy) -thiol-2-caboxboxam ida; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenoxy) -thiophene-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenyl) -thiophene-2-carboxamide; N - [(1S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenyl) -thiophene-2-carboxamide; . N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (3-methylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoromethylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoromethylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (4-trifluoromethylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-acetylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-acetylphenyl) -thiof e-2-caboxboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-acetylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanopheni) -thiof e? -2-ca rboxa mide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-morpholin-4-yl-phenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-morpholin-4-yl-phenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-morpholin-4-yl-phenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenoxy) -thiophene-2-carboxymethyl; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylphenoxy) -thiophene-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylphenoxy) -thiophen-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoromethyl-phenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoromethylphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoromethylphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (2-acetylphenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-acetyl-phenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-acetylphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenoxy) -thiophen-2-carboxamide; N - [(1S, 2fl, 4R) -7-azabicicio [2.2.1] hept-2-yl] -5- (4-cyanophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-morpholin-4-yl-phenoxy) -thiophen-2 -carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-morpholin-4-yl-phenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-morpholin-4-yl-phenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicynic [2.2.1] hept-2-yl] -5- (4-methylphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2K, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoromethyl-phenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-H] -5- (3-trifluoromethylphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoromethylphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2?, 4R) -7-azabicynic [2.2.1] hept-2-yl] -5- (2-acetylphenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-acetylphenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, IR, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-a cetylf in ils or Ifa n I I) -tiofe? -2- rboxa mida; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenylsufanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2f ?, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-morpholin-4-yl-phenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-morfoyl-4-l-phenylsulfanyl) -thiophen -2-carboxamide; N - [(1 S, 2R, 4") - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-morpholin-4-yl-phenylsulfanyl) -thiophen-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-4-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methy1pyridin-4-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (6-methylpyridin-3-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylpyridin-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxypyridin-4-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-methoxypyridin-3-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4i?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxypyridin-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-4-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-3-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4") - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridin-2-yl) -thiophen-2-carboxamide; N - [(S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridin-3-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-2-yl) -thiophene-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicic or [2.2.1] hept-2-yl] -5- (4-chloropyridin-2-yl) -thiophene-2-carboxamide; N - [(1S, 2R, 4") - 7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-4-yloxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-3-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylpyridin-4-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-methylpyridin-3-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylpyridin-2-yloxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxypyridin-4-yloxy) -thiophene-2-ca rboxa mide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (6-methoxypyridin-3-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxypyridin-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-4-yloxy) -thiophen-2-ca rboxa mide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-3-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridin-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-4-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-3-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridin-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-cyoropyridin-3-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-c! Orapyridin-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-4-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-3-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pindin-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylpyridin-4-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-methylpyridin-3-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylpyridin-2-yl-sulfin) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxypyridin-4-yl-sulphanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (6-methoxypyridin-3-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxypyridin-2-Nsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-4-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-3-ylsulfanyl) -thiophene-2-carboxamide; 'N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridin-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-4-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-3-Hsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridin-2-ylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridin-3-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloropyridin-2-ylsu! Fanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (thiophen-4-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicynic [2.2.1] hept-2-yl] -5- (5-methylthiophen-2-yl) -thiophene-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicynic [2.2.1] hept-2-yl] -5- (5-methoxythiophen-2-yl) -thiof e? -2-ca rboxa mid a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorothiophen-2-yl) -thiophene-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl) -thiophen 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylthiazol-4-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (3-chlorophenyl) vinyl] -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-difluorophenyl-suivanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl-sulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chloro-4-fIuoro-phenylsuifanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,3-dichlorophenyl-sulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4,5-trichlorophenyl-sulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenyl-sulfa nyl) -thiophen-2-caboxate measure; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenoxy-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxyphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxy-phenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoro-4-h id roxif in yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (furan-4-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylfuran-2-yl) -thiophen-2-ca rboxa mide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxyfuran-2-yl) -thiof e? -2-ca rboxa m id a; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-ciorofuran-2-yl) -thiofe-2-caboxboxy m ida; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (oxazol-2-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyloxazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxyoxazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro-oxazole-2-ii) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (oxazol-5-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methyloxazol-5-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyoxazol-5-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloro-oxazoI-5-yl) -thiofen-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicic or [2.2.1] hept-2-yl] -5- (thiazol-2-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylthiazol-2-yl) -thiophen-2-ca rboxa mide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxythiazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorothiazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (thiazol-5-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylthiazol-5-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxy-tiazol-5-yl) -thi-en-2-yl ca rboxa mid a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorothiazol-5-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylthiazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxythiazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorothiazol-2-y!) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methyloxazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyoxazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloro-oxazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - ([1, 3,4] thiadiazol-2-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyl [1, 3, 4] thiadiazol-2-yl) -thiofen -2-carboxa m ida; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy [1, 3,4] thiadiazol-2-yl) -thiophen- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro [1, 3,4] thiadiazol-2-yl) -thiophen-2 -carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2. ] hept-2-yl] -5 - ([1, 3,4] oxadiazo! -2-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyl [1, 3,4] oxadiazol-2-yl) -thiophen-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy [1, 3,4] oxadiazol-2-yl) -thiophen-2 -carboxamide; N - [(1 S, 2f ?, 4R) -7-azabicic or [2.2.1] hept-2-yl] -5- (5-chloro [1, 3,4] oxadiazol-2-yl) - thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (thiophen-4-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylthiophen-2-Noxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxythiophen-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorothiophen-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (furan-4-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylfuran-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxyfuran-2-yloxy) -thiofen-2-ca rboxa mid a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorofuran-2-yloxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (oxazol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyloxazol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxyoxazol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro-oxazole-2-loxi) -thiophen 2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (oxazol-5-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxazol-5-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyoxazol-5-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloro-oxazol-5-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (thiazol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylthiazole-2-yloxy) -thiophen-2 carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxythiazol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorothiazol-2-yloxy) -thiofen-2-caboxate; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (thiazol-5-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylthiazol-5-yloxy) -thiophene-2-caboxate; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxythiazo-5-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorothiazoI-5-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylthiazol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxythiazol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorothiazol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methyloxazol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyoxazol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloro-oxazoi-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-y [] - 5 - ([1, 3,4] thiadiazol-2-yloxy) - thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyl [1, 3,4] thiadiazol-2-yloxy) -t ofen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy [1, 3,4] thiadiazol-2-yloxy) -thiophen 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro [1, 3,4] thiadiazol-2-yloxy) -thiophen-2 -carboxamida; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - ([1, 3,4] oxadiazol-2-yl] oxy) -thiof at -2 -carboxa measure; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyl [1, 3,4] oxadiazol-2-yloxy) - tofen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy [1, 3,4] oxadiazole-2-yloxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro [1, 3,4] oxadiazol-2-yloxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (thiophen-4-ylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylthiophen-2-ylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxyprophen-2-ylsulfanii) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorothiophen-2-ylsu! Fanyl) -thiophen-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (furan-4-ylsulfanii) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylfuran-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy-furan-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorofuran-2-ylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (oxazol-2-yl-sulphanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyloxazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxyoxazole-2-Nsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro-oxazol-2-ylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (oxazol-5-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (2-methyloxazol-5-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyoxazole-5-I sulfur an i I) -thiophen-2-ca rboxam Going; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloro-oxazol-5-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (thiazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylthiazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxythiazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-dorothiazoI-2-ylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (thiazol-5-Nsulfanyl) -thiof e? -2-caboxboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylthiazol-5-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxythiazol-5-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorothiazol-5-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylthiazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxythiazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorothiazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ylJ-5- (4-methyloxazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyoxazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloro-oxazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - ([1, 3,4] thiadiazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyl [1, 3,4] thiadiazol-2-ylsulfanyl) -thiophen-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy [1, 3,4] thiadiazol-2-ylsulfanyl) -thiophen-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicynic [2.2.1] hept-2-yl] -5- (5-chloro [1, 3,4] thiadiazol-2-ylsulfanyl) -thiophen-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - ([1, 3,4] oxadiazo! -2-ylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyl [1, 3,4] oxadiazol-2-ylsulfanyl) -thiophen -2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy [1, 3,4] oxadiazol-2-ylsulfanyl) -thiophen-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5- chloro [1, 3,4] oxadiazol-2-ylsulfanyl) -thiophen -2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyrrol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (-thiazol-3-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (isoxazol-3-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3 H -imdazole-4-y!) - thiophene-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4- (4-hydroxyphenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4- (3-acetamidophenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4- (2-methanesulfonylamnofenyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -4- (pyridin-2-yloxy) -thiop in -2 -ca rboxa mida; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4- (2-methylpyridin-4-yloxy) -thiophen-2 -carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -4- (4-trifluoromethyl-phenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4- (2-acetylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-cioro-5-phenyl-thiophene-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-methyl-5-phenyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -4-cyano-5-phenyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-methoxy-5-phenyl-thiophene-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-chloro-4-phenyl-thiophene-2-ca rboxa m id a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-methyl-4-phenyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-cyano-4-phenyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-methoxy-4-phenyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-chloro-5-bromo-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-chloro-5-methylsulfanyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-chloro-5-methyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-chloro-5-cyano-thiophen-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-chloro-4-bromo-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-cioro-4-methylsulfanyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-chloro-4-meth yl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-chloro-4-cyano-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (acetylamino) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-trifluoromethyl-2-furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-bromophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-bromophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,3-dichlorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-dichlorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,5-dichlorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2,6-dichlorophenyl) -fu ra? -2-ca rboxa m gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenyl) -furan-2-carboxamide; N - [(1S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-dichlorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-amino-2-fluorophenyl) -furan-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-amino-2-fluorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-amino-2-chlorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-amino-2-chlorophenyl) -furan-2-carboxamide; N - [(1 S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-aminophenyl) -furan-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] h8pt-2-yl] -5- (2-hydroxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoro-4-methylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoro-3-methoxyphenyl) -furan-2-carboxamide; N - [(1S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yI] -5- (2-fluoro-4-methoxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-N] -5- (2- [(methylsulfonyl) amino] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3- [(methylsulfonyl) amino] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4 - [(methylsulfonyl) amino] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2- ([(trifluoromethyl) sulfonyl] amino) phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3- ([(trifluoromethyl) sulfonyl] amino) phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4- ([(trifluoromethyl) sulfonyl] amino) phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2- [(phenylsulfonyl) amino] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3- [(phenylsulfonyl) amino] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4- [(phenylsulfonyl) amino] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] ept-2-yl] -5- (2- [(methylamino) carbonyl] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3- [(methylamino) carbonyl] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4 - [(methylamino) carbonyl] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4fl) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2- [(methylamino) sulfonyl] phenyl) -furan-2-carboxamide; N - [(1 S, 2 /? 4 /?) - 7-azabicicio [2.2.1] hept-2-yl] -5- (3- [(methylamino) sulfonyl] phenyl) -furan-2-carboxamide; N - [(1 S, 2fi, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4- [(methylamino) sulfonyl] phenyl) -furan-2-carboxamide; N - [(1 S, 2 /? 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (methylamino) phenyl] -furan-2-carboxamide; N - [(1 S, 2 /? 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (methylamino) phenyl] furan-2-carboxamide; N - [(1 S, 2ft, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (methylamino) phenyl] furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (ethylamino) phenyl] furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (ethylamino) phenyl] furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (ethylamino) phenyl] furan-2-carboxarnide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-acetylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-acetylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-acetylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (methylthio) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (methylthio) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (methylthio) phenyl] -f ura-2-caboxboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (phenyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (phenyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (phenyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-phenoxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-phenoxyphenyl) -f u ra n -2-ca rboxa m id a; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-phenoxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-anilinophenyl) -f u ra n -2-ca rboxa m id a; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-anilinophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-anilinophenyl) -furan-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (phenylthio) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-fluorophenyl) thio] -furan-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-fluorophenyl) thio] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-fluorophenyl) thio] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-chlorophenyl) thio] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-chlorophenyl) thio] -fu ran-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-chlorophenyl) thio] -fu ran-2-ca rboxa mide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-f Iorofenoxi) t] o] -fu ra? 2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-fluorophenoxy) thio] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-fluorophenoxy) thio] -furan-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-chlorophenoxy) thio] -furan-2-carboxamide; N - [(1S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-chlorophenoxy) thio] -furan-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-chlorophenoxy) thio] -furan-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-pyridin-2-yl-furan-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-pyridin-3-yl-furan-2-carboxamide; N - [(1 S, 2R, 4 / R) -7-azabicyclo [2.2.1] hept-2-yl] -5-pyridin-4-yl-furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropyridin-2-yl) -fu ran-2-carboxy-mida; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyridin-2-y1) -f u ra-2-caboxboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyridin-2-yl) -furan-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyridin-2-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyridin-3-yl) -furan-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyridin-3-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyridin-3-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyridin-3-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyridin-4-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropyridin-4-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chloropyridin-2-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloropyridin-2-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridin-2-yl) -f u-2-caboxbox m; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-2-yl) -f-ran-2-ca rboxa mide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-3-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloropyridin-3-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridin-3-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-3-yl) -f u ra n -2-ca rboxa mide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-4-yl) -fu ra? -2-ca rboxa m id to; N - [(1 S, 2R, 4 /) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chloropyridin-4-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-piperidin-1-ylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-piperidin-1-ylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-piperidin-1-ylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-morfoiin-4-ylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-morpholin-4-phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-morpholin-4-ylphenyl) -flu-2-caboxboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-pyrrolidin-1-ylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-pyrrolidin-1-phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-pyrroiidin-1-phenyl) -furan-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (1 H -pyrrol-2-yl) phenyl] -fu ra? 2-ca rboxa m id a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (1 H-pyrrol-2-yl) phenyl] -fu ra? -2-carboxa m da; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (1 H-pyrrol-2-yl) phenyl] -furan-2 carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (2-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (3-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (5-methyl-2-furl I) phen il] - fu? -2-ca rboxa m id a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (2-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (3-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4 ') - 7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (5-methyl-2-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (2-furyl) phenyl] -fu ra? -2-ca rboxa m id to; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (3-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- [4- (5-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (1, 3-thiazol-2-yl) phenyl] -furan-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (1, 3-thiazol-2-yl) phenyl] -furan-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (1, 3-thiazoI-2-yl) phenyl] -furan-2 carboxamide; N - [(1 S, 2R, 4R) -7-azabicic or [2.2.1] hept-2-yl] -5- [2- (1, 3-oxazol-2-yl) phenyl] -furan- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (1, 3-oxazol-2-yl) phenyl] -furan-2 carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (1, 3-oxazol-2-yl) phenyl] -furan-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-isothiazol-5-ylphenyl) -furan-2-carboxannide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-isothiazol-5-phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-isothiazol-5-phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (1 H-indol-2-yl) phenyl] -fu ra? -2-ca rboxa m da; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-y!] - 5- [4- (1 H -indol-3-yl) pheny] -furan- 2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (1 H -indol-5-yl) -fu-r-2-carboxy-mida; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (1 H -indol-6-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenyl) -furan-2-ca rboxa mide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-bromophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (trifluoromethyl) -phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (trifluoromethyl) -phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-difluorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicic [or [2.2.1] hept-2-yl] -5- (2,5-difluorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenyl) -f ura-2-carboxa mid a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (trifluoromethoxy) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2-chloro-5- (trifluoromethyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoro-3-methylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-thien-2-furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-thien-3-yl-furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-nitro-furan-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -4,5-dimethyl-furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloro-2-nitrophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methyl-2-n-trof in I) -fu ra? -2- ca rboxa mid a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,3-difluorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-difluorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-difluorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxy-phenyl) -furan-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (tnfluoromethoxy) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (trif I uorom ethoxy) phenyl] -fu ra? -2-ca rboxam id to; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-ert-butylphenol) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (1-benzoten-2-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5-quinolin-3-yl-furan-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-ethylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-isopropylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoro-4-methoxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (1-benzofuran-2-yl) -furan-2-carboxamide; 5- (2-ammophenyl) -N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -furan-2-carboxamide; 5- (2-amino-4-methylphenol) -N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-l] -fu-2-caboxbox measure; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (phenylethynyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenoxy-furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (methylthio) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-chloro-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-bromo-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (phenylthio) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-fluorophenyl) thio] -, 3-thiazole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-fluorophenyl) thio] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-fluorophenyl) thio] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-chlorophenyl) thio] -1,3-thiazoI-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-chlorophenyl) thio] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-chlorophenyl) thio] -, 3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenoxy-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenoxy) -1,3-thiazole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenoxy) -1,3-thiazole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyranophenoxy) -1,3-thiazole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenoxy) -1,3-thiazole-2-carboxamide; N - [(3R) -1-azabicyclo [2.2.2] oct-3-yl)] - 5-thien-3-yl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-difluorophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (3,5-difluorophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-disorophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-dichlorophenyl) -1,3-thiazole-2-carboxamide; N - [(S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-bromophenyl) -1,3-thiazole-2-carboxy m id a; N - [(S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-bromophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenyl) -1,3-thiazole-2-carboxamide; N - [(1S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-ylJ-5- (4-cyanophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxyphenyl) -1,3-thiazole-2- carboxamide; N - [(1 S, 2 /? 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxyphenyl) -1,3-thiazole-2 -carboxamide; N - [(1 S, 2?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxy-phenyl) -1,3-thiazole-2-ca rboxa mide; N - [(1 S, 2?, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-nitrophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-nytrofen]] - 1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenyl) -, 3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylphenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylphenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-aminophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-aminophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-acetylamino) phenyl] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-acetylamino) phenyl] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-acetylamino) phenyl] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-2-yl) -1,3-thiazole-2-ca rboxam ida; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-3-yl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridn-4-yl) -1,3-thiazole -2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropyridin-2-yl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyridin-2-yl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyridin-2-yl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyridin-2-yl) -1 , 3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyridin-3-yl) -1, 3-thiazole-2 -carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyridin-3-yl) -1, 3-thiazole- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyc [2.2.1] hept-2-yl] -5- (5-fluoropyridn-3-yl) -1, 3 -t-azole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyridin-3-yl) -1,3-thiazole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fIuopropyridin-4-yl) -1,3-thiazoI-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-methoxy-phenyl) th] -1,3-thiazole- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-methoxyphenyl) thio] -1,3-t-azole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-methoxyphenyl) thio] -1,3-thiazole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-methylphenyl) t'o] -1,3-t-azole-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-methyphenyl) thio] -1,3-thiazole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-methylphenyl) thio] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - ([4- (acetylamino) phenyl] thio) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-aminophenyl) thio] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-hydroxyphenyl) thio] -1,3-thiazole-2-carboxamide; N - [(1 S. 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (2-methylphenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-N] -5- (3-methy1-phenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylphenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenoxy) -1,3-thiazoI-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyphenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-idroxyphenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenoxy) -1,3-thiazole-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (acetylamino) phenoxy] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenyl) -4-methyl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenyl) -4-methyl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenyl) -4-methyl-, 3-thiazole-2-carboxamide; N - [(1 S, 2R, 4 /) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl) -4-methyl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-ylJ-5- (2-methoxyphenyl) -4-methyl I- 1, 3-ti azol-2 rboxa mida; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenyl) -4-methyl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -4-methyl-5-thien-2-yl-1,3-thiazoI-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-methyl-5-phenyl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-phenyl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-bromophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-nitrophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenyl) -1,3-thiazole-2-carboxy m id a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenyl) -1,3-yiazole-2-caboxate; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-methyl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenyl) -1,3-thiazole-2-ca rboxa mid a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-thien-2-yl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -2- (phenylsulfanyl) -1, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2 - [(4-fluorophenyl) -sulfanyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -2-phenoxy-1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -2 - [(4-fluorophenyl) -sulfanyl], 1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (methylsulfan!) - 1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-chlorophenoxy) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2,4-dimethyl-1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3-fluorophenyl) -, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-phlorophenyl) -1,3-thiazole-5-caboxboxam id a; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (2-hydroxyphenyl) -1,3-thiazoi-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-methylphenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- [4- (benzyloxy) phenyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-methyl-2-phene-1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-chlorophenyl) -4-methyl-1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-methyl-2-pyridin-2-yl-1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-methyl-2-pyridin-4-yl-1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (methylamino) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2,3-difluorophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2,4-difluorophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2,5-difluorophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicynic [2.2.1] hept-2-yl] -2- (2,6-difluorophenyl) -, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3,4-difluorophenyl) -, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3,5-difluorophenyl) -, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-chlorophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3-chlorophenol) -1, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-chlorophenyl) -1,3-t-azole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-bromopheni!) - 1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3-bromophenyl) -1,3-thiazole-5-ca rboxa m id a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-bromophenyl) -1,3-t-azo l-5-ca rboxa measure; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-cyanophenol) -1,3-thiazole-5-ca rboxam da; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3-cyanophenyl) -1,3-t-azole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-cyanophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-nitrophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3-nitrophenol) -1,3-t-azole-5-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-iI] -2- (4-nitrophenol) -1,3-t-azole-5-carboxy measure; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-y!] -2- (2-methylphenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-y!] -2- (3-methylphenyl) -1,3-thiazole-5-ca rboxa m da; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-aminophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3-aminophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-aminophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4fl) -7-azabicyclo [2.2.1] hept-2-yl] -2- [2- (methylamino) phenyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- [3- (methylamino) phenyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- [4- (methylamino) phenyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- [2- (acetylamino) phenyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicic! Or [2.2.1] hept-2-yl] -2- [3- (acetylamino) phenyl] -, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- [4- (acetylamino) phenyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (2- [(trifluoroacetyl) amino] phenyl) -1 , 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (3- [(trifluoroacetyl) amino] phenyl) -1, 3- thiazole-5-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (4 - [(trifluoroacetyl) amino] phenyl] -1,3-thiazole -5-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (2- [(methylsulfonyl) amino] phenyl) -1,3-thiazole -5-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3- [(methylsulfonyl) amino] phen) -1, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4- [(methylsulfonyl) amino] phenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (3-hydroxyphenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-hydroxyphenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (2-methoxyphenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (3-methoxy-phenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-methoxy-phenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2f ?, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- [2- (trifluoromethoxy) phen I] - 1, 3 -tazol-5-ca rboxa measure; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- [3- (trifluoromethoxy) phenyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- [4- (trifluoromethoxy) phenyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2-pyridin-2-yl-1,3-thiazole-5-caboxboxy m ida; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2-pyridin-3-yl-1,3-thiazole-5-ca rboxa m a d; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2-pyridin-4-yl-1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (6-fluoropyridin-2-, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (5-fluoropyridin-2-yl) -1, 3-thiazoI-5-carboxamide; N - [(1 S , 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-fluoropyridin-2-yl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3-fluoropyridin-2-yl) -, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-fluoropyridin-2-yl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R ) -7-azabicyclo [2.2.1] hept-2-yl] -2- (6-fluoropyridin-3-yl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4 / ?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (5-fluoropyridin-3-, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7- azabicyclo [2.2.1] hept-2-yl] -2- (4-fluoropyridin-3-yl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-fluoropyridin-3-yl) -, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2 .1] hept-2-yl] -2- (2-fluoropyridin-4-yl) -1,3-thiazole-5-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3-fiuoropyridin-4-yl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (phenylsuifanyl) -1,4,4-thiadiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenoxy-1, 3,4-thiadiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-chlorophenyl) -sulfanyl] -1,4,4-thiadiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenoxy) -1,4,4-thiadiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenoxy) -1,4,4-thiadiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-fluorophenyl) -sulfanyl] -1,4,4-thiadiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hBpt-2-yl] -5 - [(2-chlorophenyl) -sulfanyl] -1,4,4-thiadiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-phiuophenyl) -sulfanyl] -1,4,4-thiadiazole-2-carboxamide; N - [(1S, 2, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-chlorophenyl) -sulfanyl] -1,4,4-thiadiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenyl-1, 3,4-oxadiazole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (methylthio) -1,4,4-oxadiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenyl) -1,3-oxazo l-2-caboxboxy m ida; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-nitrophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyphenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-nitrophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] '- 5- (4-fluorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenyl) -1, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanopheni) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4") - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-bromophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenylsulfanyl-1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenylsulfanyl) -1, 3-oxazole-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-difluorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-d? -fluorophenylsulfanyl) -1, 3-oxazole-2-carboxam gives; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-difluorophenylsulfanyl) -1,3-oxazole-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-dichlorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-dichlorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenyl) -, 3-oxazole-2-carboxamide; N - [(1 S, 2fl, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenyl) -, 3-oxazole-2-ca rboxa mid a; N - [(1 S, 2R, 4R) -7-azabicic or [2.2.1] hept-2-yl] -5- (3,4-difluorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-difluorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-difluorophenyl) -, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenyl) -, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-dichlorophenyl) -, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-dichlorophenyl) -1,3-oxazole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-bromophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-bromophenyl) -1,3-oxazole-2-carboxy m a d; N - [(1 S, 2R, 4R) -7-azabicic or [2.2.1] hept-2-yl] -5- (2-cyanophenyl) -1, 3-oxazole-2-ca rboxa m id a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenyl) -1,3-oxazole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxyphenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxyphenyl) -, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxyphenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-nitrophenol) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methyphenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylphenyl) -1, 3-oxazo l-2 -ca rboxa m id a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylaminophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylaminophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylaminophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-aminophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-aminophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2- [acetylamino) phenyl] -1,3-oxazole-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3- [acetylamino) phenyl] -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4- [acetylamino) phenyl] -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-2-yl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-3-yl) -1, 3-oxazole-2-carboxamid a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-4-yl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropyrid-2-yl) -1, 3 -oxazoI-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyrdin-2, 3-oxazole-2-carboxam) da; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyridin-2-yl) -1, 3-oxazoI -2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyridin-2-yl) -1, 3-oxazole- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyridin-3-yl) -1,3-oxazole- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyridin-3-yl) -1, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyridn-3-yl); I) -1, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropi Ridn-3-yl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - (2-fluoropyridin-4-yl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl ] -5- (2-fluoropyridin-3, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-phenoxy-1,3-oxazole-2-carboxamide; N - [(1S, 2, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenoxy) -1, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-difluorophenoxy) -, 3-oxazole-2-carboxamide; N - [(1S, 2tf, 4 /) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-difluorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-difluorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-dichlorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-dichlorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -2-phenyl-1,3-oxazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -1-methyl-5-phenyl-1 H-p irro l-2-ca rboxa m id a; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-bromo-1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (methylthio) phenyl] -1-methyl-1 Hpyrrol- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicicio [2.2.1] hept-2-yl] -5- [4- (methylthio) phenyl] -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-phenyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2,3-difluorophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-difluorophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,6-difluorophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-difluorophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-difluorophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4,6-trifluorophenyl) -1-methyl-1 H -pyrrole- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2fi, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl) -1-methyl-1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-dichlorophenyl) -1-methyl-1H-pyrrole-2 -carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenyl) -1-methyl-1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-dichlorophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-bromophenyl) -1-methyl-1 H-pyrrol-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-bromophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-bromophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxyphenyl) -1-methyl-1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxyphenyl) -1-methyl-1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxyphenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2 /? 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyphenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2fi, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylphenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylphenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylaminophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylaminophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicic! Or [2.2.1] hept-2-yl] -5- (4-methylaminophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-nitrophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-nitrophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-nitrophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-aminophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-aminophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenyl) -1-methyl-1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2- (acetylamino) phenyl] -1-methyl-1 H-pyrrole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3- (acetylamino) phenyl] -1-methyl-1 H -pyrrol- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4- (acetylamino) phenyl] -1-methyl-1H- pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyrid-2-yl) -1-methyl-1H- pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (pind-3-yl) -1-methyl-1 H -pyrro! -2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyrid-4-yl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropyrid-2-yl) -1-methyl- 1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyrid-2-yl) - 1 - methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2Ml] -5- (5-fluoropyrid-2-yl) -1-methyl-1 H -pyrrole-2 carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyrid-2-N) -1 -methyl-1 H -pyrrole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyrid-3-yl) -1-methyl-1 H-pyrrole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyrid-3-yl) -1-methyl-1 H-pyrrole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluorop'irid-3-yl) -1-methyl-1 H -pyrrole- 2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyrid-3-yl) -1-methyl-1 H-pyrrole-2 -carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (2-fluoropyrid-4-yl) -1-methyl-1 H-pyrrole-2 -carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropyrid-4-yl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenyl) -1-methyl-1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-difluorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-difluorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-difluorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenyl) -1 H- pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl) -1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-dichlorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-dichlorophenyl) -1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4 H) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-bromophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-bromophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-bromophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxyphenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxypheni!) - 1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxy-phenyl) -1H-arnol-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyphenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenyl) -1 H-p i-rrol-2-ca rboxa mide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylphenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylphenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylaminophen) -1 H-pyrrole-2-ca rboxa mida; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylaminophenyl) -1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylaminophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-nitrophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-nitrophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-l] -5- (4-n itrof in i I) - 1 H- pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-aminophenyl) -1 H-pyrrole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-aminophenyl) -1 H -pyrrole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenyl) -1H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (acetylamino) phenyl] -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (acetylamino) phenyl] -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (acetylamino) phenyl] -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyrid-2-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyrid-3-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyrid-4-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropyrid-2-yl) -1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropind-2-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] ept-2-ii] -5- (5-fluoropyrid-2-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyrid-2-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyrid-3-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyrid-3-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyrid-3-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyrid-3-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyrid-4-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropyrid-4-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -3-phenyl-1, 2,4-oxadiazole-5-carboxamide. The compound of Formula I, wherein (b) is one or more or any combinations of one of the following:, 3-thiazol-4-yl, 1,3-oxazol-4-yl, 1 H-1, 2, 4-triazol-3-yl or isoxazol-3-yl, any of which is optionally substituted on carbon (for example V or Y is independently CR5), with H, F, Cl, Br, I, alkyl, alkenyl, alkynyl , cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactamaheterocycloalkyl, aryl, -OR8, -SR8, -N (R8) 2, -C (0) R8, -C (S) R8, -C (0) OR8, -C (0) N (R8) 2, -NR8C (0) R8, -S (0) 2N (R8) 2, -OS (0) 2R8, -S (0) 2R8, -S (0) R8, -NR8S (0) 2R8, -N (R8) C (0) N (R8) 2, -CN, -N02 , R7 or R9; and further optionally substituted in nitrogen (for example when U is N-R3) with alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, R7, Rg, aryl, -C ( 0) -alkyl, -C (0) -cycloalkyl, -C (0) -heterocycloalkyl, -C (0) -halogenated alkyl, -C (0) -halogenated cycloalkyl, -C (0) -heterocycloalkyl halogenated, -C (0) -substituted alkyl, -C (0) -substituted cycloalkyl, -C (O) -substituted heterocycloalkyl, -C (0) -R7, -C (0) -R9 or -C (0) -arilo. The compound of Formula I or the formula ALB, wherein the compound is one or more or any combination of the following in the free base form or a pharmaceutically acceptable salt thereof: N- [(1 S, 2R, 4R) - 7-azabicyclo [2.2.1] hept-2-yl] -2-pyridin-3-yl-1,3-thiazole-4-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2-phenyl-1,3-oxazole-4-carboxamide; N - [(1 S, 2, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenyl-1 H-1, 2,4-triazole-3-carboxamide; or N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-f in I isoxazo l-3-ca rboxa mide. The present invention also includes a pharmaceutical composition comprising a compound of Formula I or formula A-L-B or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. The pharmaceutical composition is administered rectally, topically, orally, sublingually or parenterally during a therapeutically effective range. The pharmaceutical composition is administered to provide a compound of the present invention in an amount of about 0.001 to about 100 mg / kg of body weight of said mammal per day. The pharmaceutical composition is also administered to provide a compound of the present invention in an amount of about 0.1 to 50 mg / kg of body weight of said mammal per day. A pharmaceutical composition comprising a compound of Formula I or formula A-L-B or a pharmaceutically acceptable salt thereof and an antipsychotic agent. The pharmaceutical composition is administered to independently provide said compound and said agent rectally, topical, oral, sublingual or parenteral during a therapeutically effective interval. The pharmaceutical composition is administered to provide a compound of the present invention in an amount of about 0.001 to about 100 mg / kg of body weight of said mammal per day. The pharmaceutical composition is also administered to provide a compound of the present invention in an amount of about 0.1 to 50 mg / kg of body weight of said mammal per day. The present invention also includes a use of a compound according to Formula I or the formula ALB or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating a disease or condition, wherein the mammal would receive symptomatic relief from of the administration of a therapeutically effective amount of nicotinic acetylcholine receptor agonist al. The present invention also includes a use of a compound according to Formula I or the formula ALB or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating a disease or condition, wherein the mammal would receive symptomatic relief from of administering a therapeutically effective amount of nicotinic acetylcholine receptor agonist to, wherein the disease or condition is one or more or any combination of the following: symptoms of cognitive impairment and Alzheimer's disease care, associated neurodegeneration to diseases such as Alzheimer's disease, presenile dementia (mild cognitive deficiency), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, postra stress disorder umático, mood disorders and affects vos, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, mood and cognitive problems in general and associated with brain tumors, AIDS and dementia complex, dementia associated with Down syndrome, dementia associated with Lewy bodies, disease of Huntington, Parkinson's disease, tardive dyskinesia, Pick's disease, eating disorder disorders including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and withdrawal of dependency-creating drugs, Guilles de la Tourette syndrome, macular degeneration related to age, glaucoma, neurodegeneration associated with glaucoma or symptoms associated with pain. The present invention also includes a method of treating a disease or condition in a mammal in need thereof, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of a7 nicotinic acetylcholine receptor agonist comprising the administration to the mammal of a therapeutically effective amount of a compound according to Formula I or the formula ALB or a pharmaceutically acceptable salt thereof. The present invention also includes a use of a compound according to Formula I or formula ALB or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating a disease or condition, wherein the mammal would receive symptomatic relief from of administering a therapeutically effective amount of nicotinic acetylcholine receptor agonist to, wherein the disease or condition is one or more or any combination of the following: symptoms of cognitive impairment and Alzheimer's disease care, associated neurodegeneration to diseases such as Alzheimer's disease, presenile dementia (mild cognitive deficiency), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post-traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, mood and cognitive problems in general and associated with brain tumors, AIDS and dementia complex, dementia associated with Down syndrome, dementia associated with Lewy bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, derangements of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and withdrawal of dependence-creating drugs, Guilles de la Tourette, macular degeneration related to age, glaucoma, neurodegeneration associated with glaucoma or symptoms associated with pain. The compounds of the formula A-L-B or Formula I have optically active centers on the 7-azabicyclo [2.2.1] heptane ring which can show a number of stereochemical configurations. The terms exo and endo are stereochemical prefixes describing the relative configuration of a substituent in a bridge (not a bridgehead) of a bicyclic system. If a substituent is oriented towards the top of the other bridges it is endo. If a substituent is oriented towards the lower of the other bridges it is exo. Depending on the substitution in the carbon atoms, the endo and exo orientations may give rise to different stereoisomers. For example, when carbons 1 and 4 are substituted with hydrogen and carbon 2 is bound to a nitrogen-containing species, the endo-orientation gives rise to the possibility of a pair of enantiomers: the 1S, 2S, 4R isomer or its enantiomer, the IR isomer, 2R, 4S. Likewise, the exo orientation gives rise to the possibility of another pair of stereoisomers that are diastereoisomers and epimers in C-2 with respect to the endo isomers: either the 1 /? Enantiomer, 2R, 4S or its enantiomer isomer 1 S, 2S, 4R. The compounds of this invention exist in the exo orientation. For example, when F½ = R = H, the absolute stereochemistry is exo- (2R) for the compounds of Formula I. The esteroselective synthesis and / or subjecting the reaction product to appropriate purification steps produces materials that are substantially optically pure . Synthetic stereoselective procedures suitable for producing optically pure materials are well known in the art, as are methods for purifying racemic mixtures into optically pure fractions.

The compounds of the present invention have the exo orientation at carbon C-2 and the S configuration at carbon C- and the R configuration at the C-2 and C-4 carbons of the 7-azabicyclo [2.2.1] heptane ring . Unexpectedly, the compounds of the invention exhibit a much higher activity relative to that of the compounds lacking the 1 S, 2 R, and 4 R stereochemistry in the 7-azabicyclo [2.2.1] heptane ring system. For example, the ratio between the activities of the compounds having the 1S, 2R and AR configuration and other stereochemical configurations of the 7-azabicyclo [2.2.1] heptane ring system may be greater than about 100. Although it is desirable that the Stereochemical purity is as high as possible, absolute purity is not required. For example, the pharmaceutical compositions may include one or more compounds, each having an exo 2R configuration, or mixtures of compounds having exo 2R configurations and others. In mixtures of compounds, species possessing stereochemical configurations other than exo 2R act as diluents and tend to reduce the activity of the pharmaceutical composition. Typically, pharmaceutical compositions that include mixtures of compounds possess a higher percentage of species having the exo 2R configuration relative to other configurations. Additional aspects and embodiments of the invention may be apparent to those skilled in the art by reviewing the following detailed description, together with the examples and the appended claims. Although the invention is susceptible to embodiments in various forms, specific embodiments of the invention are described below, it being understood that the present specification is intended to be illustrative and is not intended to limit the invention to the specific embodiments described herein. memory.

DETAILED DESCRIPTION OF THE INVENTION Surprisingly, the inventors have discovered that the compounds of Formula I: Formula I wherein the stereochemistry of the 7-azabicyclo [2.2.1] heptane ring is 1S, 4R and the nitrogen substituent of carbon C-2 has the orientation exo and is R; X is O or S; Ri is H, alkyl, halogenated alkyl, cycloalkyl or aryl; R2 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl or aryl; Alkyl is straight and branched chain residues having 1-6 carbon atoms; Alkyl substituted is an alkyl moiety having 1-6 carbon atoms and having 0-3 substituents that are independently selected from F, Cl, Br or I and further having 1 substituent selected from -ORi0 > -SR10, -S (0) 2Rio, -S (O) Ri0, -OS (0) 2Rio, -NR10R10, -C (0) Rio, -C (S) R10, -C (O) OR10, -C (0) NR10Rio, -CN, -NR10C (O) R10, -NR10C (0) NRi0Rio, -S (0) 2NR10Rio, -NRi0S (0) 2Rio, -N02, R7, R9 or phenyl optionally substituted with 1-4 substituents that are independently selected from F, Cl, Br, I, Halogenated alkyl is an alkyl moiety having 1-6 carbon atoms and having 1 to (2n + 1) substituent (s) which is independently selected from F, Cl, Br or I where n is the number maximum carbon atoms in the rest; Cycloalkyl is a cyclic alkyl moiety having 3-6 carbon atoms; Aryl is phenyl, substituted phenyl, naphthyl or substituted naphthyl; Substituted phenyl is a phenyl having 1-4 substituents that are independently selected from F, Cl, Br, I or R13 and having 1 substituent selected from R15 and 0-3 substituents that are independently selected from F, Cl, Br , io R13; Substituted naphthyl is a naphthalene moiety with 1-4 substituents that are independently selected from F, Cl, Br, I or R13, or having 1 substituent selected from R15 and 0-3 substituents that are independently selected from F, Cl, Br, I or R13, wherein the substitution may be independently in the same ring or in different rings of said naphthalene moiety; W is -Q, -C = C-Q or -C C-Q; Q is a heteroaromatic cyclic moiety where the heteroatoms may be 1-3 atoms that are selected from oxygen, sulfur or nitrogen or the following structures: wherein U is -O-, -S- or -N (R3) -; V and Y are independently selected from = N- y = C (R5) -; Z is = N- or = CH-; R3 is H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, R7, Rg, aryl, -C (0) -alkyl, -C (0) -cycloalkyl, -C (0) -hete-cycloalkyl, -C (0) -halogenated alkyl, -C (0) -halogenated cycloalkyl, -C (0) -halogenated heterocycloalkyl, -C (0) -substituted alkyl, -C (0) - substituted cycloalkyl, -C (O) -substituted heterocycloalkyl, -C (0) -R7) -C (0) -R9 or -C (0) -aryl; Alkenyl is straight and branched chain residues having 2-6 carbon atoms and having at least one carbon-carbon double bond; Halogenated alkenyl is an unsaturated alkenyl radical having 2-6 carbon atoms and having 1 to (2n-1) substituent (s) that is selected independently from F, Cl, Br or i where n is the maximum number of carbon atoms in the rest; Substituted alkenyl is an unsaturated alkenyl moiety having 2-6 carbon atoms and having 0-3 substituents which are independently selected from F, Cl, Br or I and further having 1 substituent selected from R7, R9, -OR10) -SR10, -S (O) R10, -S (0) 2Rio, -OS (0) 2Rio, -N (Rio) 2, -C (O) R10, -C (S) R10, -C (O) OR10, -C (O) N (R10) 2, -CN, -N02, -NR10C (O) R10 > -NR10C (O) N (R10) 2, -S (O) 2N (R10) 2, -NR10S (O) 2R10, and phenyl optionally substituted with 1-4 substituents that are independently selected from F, Cl, Br, I , R13 and R15; Alkynyl is straight and branched chain residues having 2-6 carbon atoms and having at least one carbon-carbon triple bond; Halogenated alkynyl is an unsaturated alkynyl moiety having 3-6 carbon atoms and having 1 to (2n-3) substituent (s) that is selected independently from F, Cl, Br or I where n is the maximum number of carbon atoms in the rest; "Substituted alkynyl" is a saturated alkynyl moiety having 3-6 carbon atoms and having 0-3 substituents that are independently selected from F, Cl, Br or I and further having 1 substituent selected from R7, R9, -ORi0, -SR10, -S (O) Ri0, -S (0) 2Rio, -OS (0) 2Rio, -N (Rio) 2, -C (O) R10, -C (S) R10, -C (O) OR10, -C (O) N (R10) 2, -CN, -N02, -NR10C (O) R10, -NR10C (0) N (Rio) 2, -S (O) 2N (R10) 2 , -NR10S (O) 2R10, and phenyl optionally substituted with 1-4 substituents that are independently selected from F, C, Br, I, R13 and R15; Halogenated cycloalkyl is a cyclic moiety having 3-6 carbon atoms and having 1-4 substituents that are independently selected from F, Cl, Br or I; Substituted cycloalkyl is a cyclic moiety having 3-6 carbon atoms and having 0-3 substituents that are independently selected from F, Cl, Br or I and further having 1 substituent selected from = 0, = S, R7, R9, -OR 0, -SR10, -S (O) R10, -S (O) 2Ri0, -OS (O) 2R10, -N (R10) 2, -C (O) R10, -C (S) ) R10, -C (O) OR10, -C (O) N (R10) 2, -CN, -N02, -NRioC (0) R10, -NR10C (O) N (R10) 2, -S (O) 2N (R10) 2, -NR10S (O) 2R10, and phenyl optionally substituted with 1-4 substituents that are independently selected from F, Cl, Br, I, R- | 3 and R15; Heterocycloalkyl is a cyclic moiety having from 4-7 atoms, being 1-2 atoms within the ring -S-, N (R20) or -O-; Halogenated heterocycloalkyl is a is a cyclic moiety having 4-7 atoms, being 1-2 atoms within the ring -S-, N (R20) or -O- and having 1-4 substituents that are independently selected from F, Cl, Br or I; Substituted heterocycloalkyl is a cyclic moiety having 4-7 atoms, with 1-2 atoms within the ring -S-, N (R20) or -O- and having 0-3 substituents which are independently selected from F, Cl, Br or I and having in addition 1 substituent selected from = 0, = S, R7, Rg, -OR-m, -SR10, -S (O) R10, -S (0) 2Rio, -OS (O) 2R10, -N (R10) 2, -C (O) R10, -C (S) R10, -C (0) ORio, -C (0) N (Rio) 2, -CN, -N02, -NR10C ( O) R10, -NRioC (0) N (R10) 2, -S (0) 2N (Rio) 2, -NR-i0S (O) 2R10, and phenyl optionally substituted with 1 -4 substituents that are independently selected from F , CI, Br, I, R13 and Each R 4 is independently H, alkyl or substituted alkyl; Each R5 is independently H, F, CI, Br, I, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl. , substituted heterocycloalkyl, lactamheterocycloalkyl, aryl, -ORB, -SR8, -N (R8) 2, -C (0) R8, -C (S) R8, -C (0) OR8, -C (0) N (R8 ) 2, -NR8C (0) R8, -S (0) 2N (R8) 2, -OS (0) 2R8, -S (0) 2R8, -S (0) R8, -NR8S (0) 2R8, - N (R8) C (0) N (R8) 2, -CN, -N02, R7 or R9; Lactamaheterocycloalkyl is a cyclic moiety having 4-7 atoms, one atom being only nitrogen being the linkage to lactamaheterocycloalkyl through said atom only nitrogen and having a = 0 on a carbon adjacent to said nitrogen and having up to 1 more atom in the ring which is oxygen, sulfur or nitrogen and which further has 0-2 substituents which are selected from F, CI, Br, I or Ri8 when the valence permits; R6 is H, alkyl, an amino protecting group or an alkyl group having 1 -3 substituents that are selected from F, Cl, Br, I, -OH, -CN, -NH2, -NH (alkyl) or -N (alkyl) 2; R7 is 5-membered heteroaromatic monocyclic moieties containing within the ring 1-3 heteroatoms which are independently selected from the group consisting of = N-, -N (R2o) -, -O- and -S- and having 0-1 substituent selected from R17 and having further 0-3 substituents that are independently selected from F, Cl, Br or I, or R7 is 9-membered fused ring moieties having a 6-membered ring condensed with a 5-membered ring which includes the formula where G is C (R- |) or N, and each G2 and G3 is independently selected from C (Ri) 2, C (R- | 4), O, S, N and N (R2o), with the condition that G2 and G3 are not both simultaneously O or S or wherein G is C (Ru) or N and each G2 and G3 is independently selected from C (R14) 2, C (R- | 4), O, S, N and N (R2o), each bicyclic ring having 9 member 0-1 substituent which is selected from R 7 and 0-3 substituents which are independently selected from F, Cl, Br or I, wherein the R 7 moiety is attached to other substituents as defined in formula I in any position of any of the rings as valence allows; Each R8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, R7, Rg, phenyl optionally substituted with 1-4 substituents that are independently selected from F, Cl , Br, I, R13 and R5 or naphthyl optionally substituted with 1-4 substituents that are independently selected from F, Cl, Br, I, Ri3 and Ri5; R9 is 6-membered heteroaromatic monocyclic moieties containing within the ring 1-3 heteroatoms that are selected from = N- and having 0-1 substituent selected from R17 and 0-3 substituent (s) being selected (n) independently of F, Cl, Br or I or R9 is 10-membered heteroaromatic bicyclic moieties containing within one or both rings 1-3 heteroatoms selected from = N- including, but not limited to, quinolinyl or isoquinolinyl, each moiety having of the 10-membered fused ring 0-1 substituent selected from R-i7 and 0-3 substituent (s) which is selected independently from F, Cl, Br or I, wherein the Rg moiety is attached to other substituents as defined in formula I at any position of each ring as allowed by the valence; Each R-io is independently H, alkyl, cycloalkyl, heterocycloalkyl, R7, Rg, alkyl substituted with 1 substituent selected from R13, cycloalkyl substituted with 1 substituent selected from R13, heterocycloalkyl substituted with 1 substituent selected from R -13, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl or phenyl optionally substituted with 1-4 substituents that are independently selected from F, CI, Br, I, R13 and R15; Each R 11 is independently H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl or halogenated heterocycloalkyl; R12 is alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR-p, -SRn, -S (0) 2Rn, -S (0) Rii, -OS (0) 2Rn, -N (Rii) 2 > -C (0) Rn, -C (S) Rn, -C (0) OR11 f -N02, -C (0) N (Rn) 2, -CN, -NRiiC (0) Rii, -NR11C (0) N (R11) 2) -S (0) 2N (Rn) 2 or -NRnS (0) 2R1 i; R13 is -OR11, -SRn, -SOR, -S02Rn, -OS02Rn, -N (Rn) 2l -C (0) Rn, -C (S) Rn, -C (0) N (Rn) 2, -N02 , -CN, -CF3, -NRnC (0) R11 f -NRnC (0) N (R) 2, -S (0) 2N (Rn) 2 or -NRnS (0) 2R1 i; R14 is H or R19; R15 is R, R9, R19, or lactamaheterocycloalkyl; Each R16 is independently H, alkyl, cycloalkyl, halogenated alkyl or halogenated cycloalkyl; R-i7 is alkyl, cycloalkyl or heterocycloalkyl, each optionally substituted with 1-4 substituents which are independently selected from F, Cl, Br, I, -N02, -CN, -OR 6, -SR 6, -S (0 ) 2Ri6, -S (0) Ri6, -OS (0) 2R16, -N (R16) 2, -C (0) R16I -C (S) R16, -C (0) OR16, -C (0) N (R16) 2, -NR15C (0) R16, -NR16C (0) N (R16) 2, -S (0) 2N (R16) 2 and -NRi5S (0) 2Ri6and the cycloalkyl and heterocycloalkyl are optionally further substituted with = 0 or = S; Ri9 is alkyl, cycloalkyl, heterocycloalkyl, phenyl or naphthyl, each optionally substituted with 1-4 substituents which are independently selected from F, Cl, Br, I, -CN, -N02, -OR16, -SR 6, -S ( 0) 2Ri6, -S (0) Rie, -OS (0) 2R16, -N (R16) 2, -C (0) R16, -C (S) R16, -C (0) OR16, -C (0) ) N (R16) 2, -NR16C (0) R16, -NR16C (0) N (R16) 2, -S (0) 2N (R16) 2 or -NRi6S (0) 2Ri6and the cycloalkyl and heterocycloalkyl are optionally further substituted with = 0 or = S; R20 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, -S02R8, or phenyl having 1 substituent selected from R- | 2 and having in addition 0-3 substituents which are selected independently of F, Cl, Br or I; or pharmaceutical composition, pharmaceutically acceptable salt, racemic mixture or pure enantiomer thereof useful for treating one or more or any combination of the following: symptoms of cognitive and attention deficit of Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's, presenile dementia (mild cognitive deficiency), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post-traumatic stress disorder, mood disorders and affective, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, mood and cognitive problems in general and associated with brain tumors, AIDS and dementia complex, dementia associated with Down syndrome, dementia associated with Lewy bodies, Huntington's disease, sick Parkinson's disease, tardive dyskinesia, Pick's disease, derangements of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with quitting smoking and leaving dependence-creating drugs, Guilles de la Tourette syndrome, macular degeneration related to age, glaucoma, neurodegeneration associated with glaucoma or symptoms associated with pain. Another group of compounds of the formula ALB or Formula I includes any one or more or any combinations of the following compounds or a pharmaceutically acceptable salt or pharmaceutical composition thereof: Abbreviations that are notorious to those skilled in the art may be used (eg. example "ph" for phenyl, "Me" for methyl, "et" for ethyl, "h" or "hr" per hour or hours, min per minute or minutes and "ta" or "TA" for room temperature). All temperatures are in degrees centigrade.

The ambient temperature is in the range of 15-25 degrees Celsius. AChR refers to acetylcholine receptor. nAChR refers to nicotinic acetylcholine receptor. Presenile dementia is also known as mild cognitive impairment. 5HT3R refers to serotonin receptor type 3. a-btx refers to a-bungarotoxin. FLIPR refers to a device marketed by Molecular Devices, Inc. Designed to accurately measure cell fluorescence in a high throughput assay in whole cells. (Schroeder et al., J. Biomolecular Screening, 1 (2), pages 75-80, 1996). TLC refers to thin layer chromatography. HPCL refers to high pressure liquid chromatography. MeOH refers to methanol. EtOH refers to ethanol. IPA refers to isopropyl alcohol. THF refers to tetrahydrofuran. DMSO refers to dimethylsulfoxide. DMF refers to tetrahydrofuran. EtOAc refers to ethyl acetate. TMS refers to tetramethylsilane. TEA refers to triethylamine.

DIEA refers to? /, / V-diisopropylethylamine. MLA refers to methyl-licaconitin. Ether refers to diethyl ether. HATU refers to 0- (7-azabenzotriazo! -1 -yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate. CDI refers to carbonyldiimidazole. NMO refers to N-methylmorpholine N-oxide TPAP refers to tetrapropylammonium perutenate. Halogen is F, Cl, Br or I. Amino protecting group includes, but is not limited to, carbobenzyloxy (CBz), 1,1-dimethylcarbamate, ferc-butoxycarbonyl (BOC) and the like. Examples of other amino protecting groups are known to those skilled in the art and can be found in "Protective Groups in Organic Synthesis", 3rd edition, by the authors Theodora Greene and Peter Wuts. Acrylamide or acrylthioamide is a residue having the general structure -N (H) C (X) C = C-, where X is O or S, respectively, so that ALB includes AN (R1) C (X) -C = CB. Propiolamide or propiolthioamide is a residue having the general structure -N (H) C (X) C C-, where X is O or S, respectively, so that ALB includes AN (R -,) C (X) -C CB. One of the most conventionally accepted forms of naming the compound described below is 5- (2-aminophenyl) -N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2 -yl] -thiophen-2-carboxamide, but for one skilled in the art, the follo name also describes the same compound, N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2 -yl] -5- (2-aminophenii) -thiophen-2-carboxamide. Both are used interchangeably in this patent.

The content of carbon atoms of the hydrocarbon residues is indicated by a prefix designating the minimum and maximum number of carbon atoms in the remainder, ie the prefix Cj.j indicates a remainder with carbon atoms from the whole number "i" up to the whole number "j" inclusive. Thus, for example, alkyl C ~ i-6 refers to an alkyl of one to six carbon atoms. Lower alkyl is straight and branched chain residues having 1-4 carbon atoms. Halogenated lower alkyl is a lower alkyl moiety having 1 to (2n + 1) substituent (s) which is selected independently from F, Cl, Br or I where n is the maximum number of carbon atoms in the remainder . Substituted lower alkyl is a lower alkyl moiety having 0-3 substituents which are independently selected from F, Cl, Br or I and further having 1 substituent selected from R7, Rg, -CN, -N02, -OR10, - SR -,?, -S (0) 2Rio, -S (O) R10, -OS (O) 2Ri0, -NR10Rio, -C (O) R10, -C (S) R10, -C (O) OR10, -C (O) NR10Ri0 > -NR10C (O) R10, -NR10C (O) NR10Ri0, -S (O) 2NR10Ri0, -NR 0S (0) 2Rio, or phenyl optionally substituted with 1 -4 substituents that are independently selected from F, Cl, Br, I , R13 and R15. Non-exhaustive examples of heteroaryl compounds falling within the definition of R7 and Rg include, but are not limited to, thienyl, benzothienyl, pyridyl, thiazolyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, benzoxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, pyrrolyl, isoquinolinyl, cinolinyl, indazolyl, indizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, quinazolinyl, quinoxalinyl, Naphthridinyl, furopyridinyl, pyrrolopyridinyl or thienopyridinyl. All isomeric forms of the non-exhaustive named moieties are included, for example benzofuranyl includes 1-benzofuran-2-yl, 1-benzofuran-3-yl, 1-benzofuran-4-yl, 1-benzofuran-5-yl, -benzofuran-6-yl, 1-benzofuran-7-yl, 2-benzofuran-1-yl, 2-benzofuran-2-yl, 2-benzofuran-3-yl, 2-benzofuran-4-yl or 2-benzofuran -5-ilo. The non-exhaustive examples of R7 and Rg can be substituted as allowed by the respective definition of R7 and R9 as the valence allows. One skilled in the art can identify the permitted substitution by comparing the non-exhaustive examples with the respective definitions of R7 and R9. Non-exhaustive examples of heterocycloalkyl include, but are not limited to, tetrahydrofuran, tetrahydropyran, morpholino, pyrrolidino, piperidino, piperazino, azetidino, azetidino, oxindole, dihydroimidazole, pyrrolidino or isoxazolinyl.

Mammal denotes human and other mammals. Brine refers to a saturated aqueous solution of sodium chloride. Equ means molar equivalents. IR refers to infrared spectroscopy. Lv refers to leaving groups within a molecule that include Cl, OH or mixed anhydride. NMR refers to nuclear magnetic resonance (proton) spectroscopy; chemical shifts are expressed in ppm (d) downfield of TMS. EM refers to mass spectrometry expressed in terms of m / e or mass / unit load. EMAR refers to high resolution mass spectrometry expressed in terms of m / e or mass / unit load. M + H + refers to the positive ion of a parent molecule plus a hydrogen atom. M-H + refers to the negative ion of a parent molecule minus a hydrogen atom. M + Na + refers to the positive ion of a parent molecule plus a sodium atom. M + K + refers to the positive ion of a parent molecule plus a potassium atom. IE refers to electron impact, IES refers to electrospray ionization. IQ refers to chemical ionization. BAR refers to bombardment with fast atoms. The compounds of the present invention may be in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable". refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases and salts prepared from inorganic acids and organic acids. Salts that are derived from inorganic bases include aluminum, ammonium, calcium, ferric, ferrous, lithium, magnesium, potassium, sodium, zinc and the like. Salts which are derived from pharmaceutically acceptable non-toxic organic bases include primary, secondary and tertiary amine salts, substituted amines including natural substituted amines, cyclic amines, such as arginine, betaine, caffeine, choline,?,? -dibencylethylenediamine, diethylamine , 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glutamine, glucosaline, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine , triethylamine, trimethylamine, tripropylamine and the like. Salts which are derived from inorganic acids include salts of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, phosphorous acid and the like. Salts which are derived from pharmaceutically acceptable non-toxic organic acids include the salts of (C 1-6 alkyl) carboxylic acids, dicarboxylic acids and tricarboxylic acids such as acetic acid, propionic acid, fumaric acid, succinic acid, tartaric acid, maleic acid, adipic acid and citric acid, and arylsulfonic and alkylsulfonic acids such as toluenesulfonic acids and the like. The term "effective amount" of a compound as set forth herein means a non-toxic but sufficient amount of the compound (s) to provide the desired effect. As indicated below, the exact amount needed will vary from subject to subject, depending on the species, age and general condition of the subject, the severity of the disease being treated, the compound (s) to be broken (s) which is used (n), the mode of administration and the like. Thus, it is not possible to specify an exact "effective amount". However, those skilled in the art can determine an appropriate effective amount using only routine experimentation. The therapeutically effective amount of compound (s) that is administered and the dosage to treat a disease state with the compounds and / or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject , the severity of the disease, the route and frequency of administration and the particular compound (s) to be used and therefore may vary widely. The compositions contain notorious carriers and excipients in addition to a therapeutically effective amount of compounds of the present invention. The pharmaceutical compositions may contain active ingredient in the range of about 0.001 to 100 mg / kg / day for an adult, preferably in the range of about 0.1 to 50 mg / kg / day for an adult. A total daily dose of about 1 to 1000 mg of active ingredient may be appropriate for an adult. The daily dose can be administered in one to four doses per day. In addition to the compound (s) of the present invention, the composition for therapeutic use may also comprise one or more non-toxic, pharmaceutically acceptable carrier or excipient materials. The term "carrier" or "excipient" herein means any substance, which is not itself a therapeutic agent, used as a carrier and / or diluent and / or adjuvant, or vehicle for administering a therapeutic agent to a patient. subject or added to a pharmaceutical composition to improve its handling or storage properties or to allow or facilitate the preparation of a single dose of the composition in a separate article such as a capsule or a tablet suitable for oral administration. Excipients may include, by way of illustration and not limitation, diluents, disintegrants, binding agents, adhesives, wetting agents, polymers, lubricants, glidants, substances that are added to hide or counteract an unpleasant taste or odor, flavors, dyes, fragrances and substances that are added to improve the appearance of the composition. Acceptable excipients include lactose, sucrose, starch powder, cellulose esters of alkanoic acids, alkyl esters of cellulose, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, gum arabic, sodium alginate, polyvinyl pyrrolidone and / or polyvinyl alcohol and then form tablets or encapsulate for convenient administration. Capsules or tablets of this type can contain a controlled release formulation as can provide a dispersion of active compound in hydroxypropylmethylcellulose or other methods known to those skilled in the art. For oral administration, the pharmaceutical composition may be in the form for example of a tablet, capsule, suspension or liquid. If desired, other active ingredients may be included in the composition. In addition to the oral dosage forms, which are described above, the compositions of the present invention may be administered by any suitable route, in the form of a pharmaceutical composition adapted for such a route and at an effective dose for the treatment intended. The compositions for example can be administered parenterally, for example intravascularly, intraperitoneally, subcutaneously or intramuscularly. For parenteral administration, saline, dextrose solution or water may be used as a suitable vehicle. Formulations for parenteral administration may be in the form of sterile injectable isotonic aqueous or non-aqueous solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the mentioned carriers or diluents for use in the formulations for oral administration. The compounds can be dissolved in water, polyethylene glycol, propylene glycol, EtOH, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride and / or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The serotonin receptor type 3 (5HT3R) is a member of the ligand-regulating receptor superfamily, which includes the muscle and neuronal nAChRs, the glycine receptor, and the α-aminobutyric receptor type A. Like other members of this A superfamily of receptors, 5HT3R exhibits a high degree of sequence homology with nAChR al but functionally the two ion channels of regulation by ligands are very different. For example, nAChR is quickly inactivated, is highly permeable to calcium and is activated by acetylcholine and nicotine. On the other hand, 5HT3R is slowly inactivated, is relatively impermeable to calcium and is inactivated by serotonin. These experiments suggest that nAChR a7 and 5HT3R proteins have some degree of homology, but they function very differently. In fact, the pharmacology of channels is very different. For example, Ondansetron, a highly selective 5HT3R antagonist, exhibits little activity in nAChR a7. The opposite is true too. For example GTS-21, a highly selective nAChR agonist has very little activity in 5HT3R. nAChR a is a Ca ++ channel regulated by ligands formed by a homopentomer of subunits al. Previous studies have established that a-bungaotoxin (a-btx) binds selectively to this subcategory of nAChR homopolymer and that nAChR al has a high affinity for a-btx and methyl-licaconitin (LA). nAChR a7 is expressed at high levels in the hippocampus, ventral tegmental area and ascending cholinergic projections from the basal nucleus to thalamocortical areas. NAChR agonists increase neurotransmitter release and increase cognition, wakefulness, attention, learning and memory. Data from human and animal pharmacological studies establish that cholinergic nicotinic neuronal pathways control many important aspects of cognitive function that include attention, learning and memory (Levin, E.D., Psychopharmacology, 108: 417-31, 1992; Levin, E.D. and Simon B.B., Psychopharmacology, 138: 217-30, 1998). For example, it is well known that nicotine increases cognition and attention in humans. ABT-418, a compound that inactivates a4ß2 and nAChR a7 improves cognition and attention in clinical trials of Alzheimer's disease and attention deficit disorders (Potter, A. et al., Psychopharmacology (Berl.), 142 (4 ): 334-42, March 1999, Wilens, TE et al., Am. J. Psychiatry, 156 (12): 193 -7, Dec. 1999). It is also clear that nicotine and selective but weak agonists of nAChR a7 increase cognition and attention in rodents and non-human primates. Schizophrenia is a complex and multifactorial disease caused by genetic and non-genetic risk factors that produce a set of positive and negative symptoms. Positive symptoms include delusions and hallucinations and negative symptoms include affective, attention, cognition and information processing deficiencies. No single biological element has appeared as a dominant pathogen in this disease. In fact, it is likely that schizophrenia is a syndrome that is produced by the combination of many risk factors of low penetrance. Pharmacological studies established that dopamine receptor antagonists are effective in the treatment of overt psychotic characteristics (positive symptoms) of schizophrenia such as hallucinations and delusions. Clozapine, an "atypical" antipsychotic drug, is novel because it is effective for the treatment of positive symptoms and some of the negative symptoms of this disease. The usefulness of Clozapine as a drug is largely limited because continued use carries a high risk of agranulocytosis and seizures. There is no other effective antipsychotic drug to treat the negative symptoms of schizophrenia. This is significant because the restoration of cognitive functioning is the best predictor of a successful clinical and functional end of schizophrenia patients (Green, M.F., Am J Psychiatry, 153: 321-30, 1996). By extension, it is clear that better drugs are needed to treat the cognitive disorders of schizophrenia to return a better state of mental health to patients with this disorder. An aspect of the cognitive deficit of schizophrenia can be measured using the potential test related to auditory events (P50) of sensory regulation. In this test, electroencephalographic (EEG) records of the hippocampal neuronal activity are used to measure the response of the subject to a series of auditory "clicks" (Adler, LE et al., Biol. Psychiatry, 46: 8-18, 1999). ). Normal individuals respond to the first click with a higher degree than the second click. In general, schizophrenic and schizotypal patients respond to both clicks almost equally (Cullum, C., et al., Schlzophr, Res., 10: 131-41, 1993). These data reflect an inability of the schizophrenic to "filter" or ignore unimportant information. The deficiency of sensory regulation seems to be one of the key pathological features of this disease (Cadenhead, K.S. et al., Am. J. Psychiatry, 157: 55-9, 2000). Multiple studies show that nicotine normalizes the sensory deficiency of schizophrenia (Adler, L.E. et al., Am. J. Psychiatry, 150: 1856-61, 1993). Pharmacological studies indicate that the effect of nicotine in sensory control is via nAChR a7 (Adler, L.E. et al., Schizophr, Bull., 24: 189-202, 1998). In fact, biochemical data indicate that schizophrenics have 50% fewer nAChR receptors in the hippocampus, thus providing an explanation for the partial loss of nAChR a7 functionality (Freedman, R. et al., Biol. Psychiatry, 38: 22-33, 1995). Interestingly, the genetic data indicate that a polymorphism of the promoter region of the nAChR c7 gene is strongly associated with the deficiency of sensory regulation in schizophrenia (Freedman, R. et al., Proc. Nat'l Acad. Sci. USA, 94 (2): 587-92, 1997; Myles-Worsley, M. et al., Am. J. Med. Genet, 88 (5): 544-50, 1999). To date, no mutation has been identified in the coding region of nAChR a7. In this way, schizophrenics express the same nAChR a7 as non-schizophrenics. Selective agonists of nAChR a7 can be found using a functional assay in FLIPR (see WO 00/73431 A2). FLIPR is designed to read the fluorescence signal from each well of a 96- or 384-well plate at a rate of two times per second for up to 30 minutes. This assay can be used to accurately measure the functional pharmacology of nAChR al and 5HT3R. To conduct such an assay cell lines expressing functional forms of nAChR are used by using the a7 / 5-HT3 channel as a target for the drug and cell lines expressing functional 5HT3R. In both cases, the ion channel regulated by ligands is expressed in SH-EP1 cells. Both ion channels can produce a robust signal in the FLIPR test. The compounds of the present invention are nAChR agonists and can be used to treat a wide variety of diseases. For example, they can be used to treat schizophrenia or psychosis. Schizophrenia is a disease that has multiple aspects.

Currently available drugs are generally aimed at controlling the positive aspects of schizophrenia, such as delusions. One drug, Clozapine, targets a wider spectrum of symptoms associated with schizophrenia. Thus, there is a need for a drug to treat the cognitive and attention deficits associated with schizophrenia. Similarly, there is a need for a drug to treat cognitive and attention deficits associated with schizoaffective disorders or similar symptoms found in the relatives of schizophrenic patients. Psychosis is a mental disorder that is characterized by a serious deficiency in the perception of reality by the patient. The patient may suffer delusions and hallucinations and may talk incoherently. His behavior can be hectic and is often incomprehensible to those around him. In the past, the term psychosis has been applied to many conditions that do not meet the stricter definition given above. For example, psychosis was called mood disorders. There is a variety of antipsychotic drugs. Conventional antipsychotic drugs include Chlorpromazine, Flufenazine, Haloperidol, Loxapine, Esoridazine, Olindone, Perphenazine, Pimozide, Thioridazine, Thiotomyne and Trifluoroperazine. All these drugs have affinity for the dopamine receptor 2. These conventional antipsychotic drugs have side effects that include sedation, weight gain, tremors, high prolactin levels, akathisia (motor agitation), dystonia, and muscle stiffness. These drugs can also cause tardive dyskinesia. Unfortunately, only about 70% of schizophrenia patients respond to conventional antipsychotic drugs. Atypical antipsychotic drugs are available for these patients. Atypical antipsychotic drugs are generally able to alleviate the positive symptoms of psychosis by also improving negative symptoms of psychosis to a greater degree than conventional antipsychotics. These drugs can improve neurocognitive deficiencies. Extrapyramidal (motor) side effects are not likely to occur with atypical antipsychotic drugs and, thus, these atypical antipsychotic drugs have a lower risk of producing tardive dyskinesia. Finally, these drugs cause little or no elevation of prolactin. Unfortunately, these drugs are not free of side effects. Although these drugs each produce different side effects, as a group, the side effects include: agranulocytosis; increased risk of attacks, weight gain, drowsiness, dizziness, tachycardia, reduced volume of ejaculation and mild prolongation of the QTc interval. In a combination therapy to treat the multiple symptoms of diseases such as schizophrenia, the compounds of the present invention and the antipsychotic drugs can be administered simultaneously or at different intervals. When the compounds of the present invention are administered simultaneously and the antipsychotic drugs can be incorporated in a single pharmaceutical composition, for example a pharmaceutical combination therapy composition. Alternatively, two different compositions can be administered simultaneously, ie, one containing compounds of the present invention and the other containing antipsychotic drugs. Examples of antipsychotic drugs, in addition to those listed above include, but not limited to, Torazin, Mellaril, Trilafon, Navane, Stelazine, Permitil, Prolixin, Risperdal, Zyprexa, Seroquel, ZELDOS, Acetofenazine, Carfenazine, Chlorprothixene, Droperidol, Loxapine, Mesoridazine, Molindone, Ondasetron, Pimozide, Prochlorperazine and Promazine. A polytherapy pharmaceutical composition may include therapeutically effective amounts of the compounds of the present invention, which are listed above, and a therapeutically effective amount of antipsychotic drugs (also referred to as antipsychotic agents). These compositions can be formulated with common excipients, diluents or vehicles, and compressed into tablets or formulated in the form of elixirs or solutions for convenient oral administration or administered intramuscularly or intravenously. The compounds can be administered rectally, topically, orally, sublingually or parenterally and can be formulated in sustained release dosage forms and the like. When administered separately, therapeutically effective amounts of compositions containing compounds of the present invention and antipsychotic drugs with a different dosage are administered. One can be administered before the other as long as the time between the two administrations falls within a therapeutically effective range. A therapeutically effective range is a period of time that begins when one of any of (a) the compounds of the present invention or (b) the antipsychotic drugs is administered to a human and that ends with the limit of the beneficial effect in the treatment of the schizophrenia or psychosis of the combination of (a) and (b). The methods of administration of the compounds of the present invention and the antipsychotic drugs may vary. Thus, either agent or both agents can be administered rectally, topically, orally, sublingually or parenterally. As described, the compounds of the present invention are nAChR ct7 agonists. Therefore, as another aspect of the present invention, the compounds of the present invention can be used to treat a variety of diseases including symptoms of cognitive and attention deficit of Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease , presenile dementia (also known as mild cognitive deficiency) and senile dementia. Alzheimer's disease has many aspects, including cognitive and attention deficits. Currently these deficiencies are treated with cholinesterase inhibitors. These inhibitors slow down the decomposition of acetylcholine and thus provide a general non-specific increase in cholinergic nervous system activity. Since the drugs are not specific, they have a wide range of side effects. Thus, there is a need for a drug that stimulates a portion of the cholinergic pathways and thus improves the cognitive and attention deficits that are associated with Alzheimer's disease without the side effects created by the non-specific stimulation of the cholinergic pathways. Neurodegeneration is a common problem that is associated with diseases such as Alzheimer's disease. Although current drugs treat some of the symptoms of this disease, they do not control the underlying pathology of the disease. Accordingly, it would be desirable to provide a drug that can slow the progression of Alzheimer's disease.

Presenile dementia (mild cognitive deficiency) refers to memory deficiencies instead of problems of attention deficit and cognitive functioning that in other aspects does not show deficiencies. Mild cognitive impairment is distinguished from senile dementia because mild cognitive impairment involves a more persistent and problematic problem of memory loss for the patient's age. There is currently no medication specifically identified for the treatment of mild cognitive impairment, due in part to the recent identification of the disease. Therefore, there is a need for a drug to treat memory problems associated with mild cognitive impairment. Senile dementia is not a single disease state. However, conditions that are classified under this name often include cognitive and attention deficits. Generally, these deficiencies are not addressed. Accordingly, there is a need for a drug that provides improvement in the cognitive and attention deficiencies associated with senile dementia. As described, the compounds of the present invention are agonists of nAChR a7. Therefore, other diseases more to be treated with compounds of the present invention include the treatment of cognitive and attention deficits as well as the neurodegeneration associated with one or more or any combination of the following: attention deficit disorder, hyperactivity disorder with attention deficit, depression, anxiety, general anxiety disorder, post-traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, mood and cognitive problems in general and associated to brain tumors, AIDS complex and dementia, dementia associated with Down syndrome, dementia associated with Lewy bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, derangements of food intake including bulimia and anorexia nervosa, Withdrawal symptoms associated with stopping smoking and leave drugs that create dependence, Guilles de la Tourette syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma or symptoms associated with pain. Attention deficit disorder is usually treated with methylphenidate, an amphetaminoid molecule that has some potential for drug addiction. Accordingly, it would be desirable to treat attention deficit disorder that has less side effects than the drug currently used. Hyperactivity disorder with attention deficit, which is also known as ADHD, is a neurobehavioral disorder that affects 3-5% of American children. ADHD involves cognitive actions only or cognitive and behavioral interfering with the person's ability to focus on a task and to exercise an appropriate inhibition for their age. There are several types of ADHD: a predominantly distracted subtype, a predominantly hyperactive and impulsive subtype and a combined subtype. Treatment may include medications such as methylphenidate, dextroamphetamine or swirls, which act by reducing impulsivity and hyperactivity to increase attention. Currently there is no "cure" for ADHD. Children with the disorder rarely heal with age; therefore there is a need for appropriate medications. Depression is a mood disorder of variable length from usually several months to more than two years and varying degrees of feelings involving sadness, despair and discouragement. Heterocyclic antidepressants (HCAs) are currently the largest class of antidepressants but, in particular types of depression, monoamine oxidase inhibitors (MAOIs) are used. The common side effects of HCA are sedation and weight gain. In elderly patients with organic brain disease, the side effects of HCA can also include attacks and behavioral symptoms. The main side effects of MAOI use are due to interactions between food and drugs. Therefore, agents with minor side effects would be useful. Anxiety disorders (disorders with prominent anxiety or avoidance by phobia), represent an area of medical needs not covered in the treatment of psychiatric illness. See Diagnostic & Statistical Manual of Mental Disorders, IV (1994), pages 393-393, for information on the various forms of anxiety. General Anxiety Disorder (GAD) occurs when a person worries about things like family, health or work when there is no reason to worry and is unable to not worry. Approximately 3 to 4% of the US population suffers from GAD during the course of a year. GAD most often affects people in childhood or adolescence but it can begin in adulthood as well. It affects women more often than men. Currently, the treatment involves cognitive and behavioral therapy, relaxation techniques and biofeedback to control muscle tension and medications such as benzodiazepines, imipramine and buspirone. These drugs are effective but all have the opposite of side effects. Anxiety also includes post-traumatic stress disorder (PTSD), which is a form of anxiety triggered by memories of a traumatic event that directly affected the patient or that the patient may have witnessed. The disorder commonly affects survivors of traumatic events including sexual assault, physical assault, war, torture, natural disasters, a car accident, a plane crash, a hostage situation or a death camp. Affliction can also affect rescue workers in a plane crash or mass shooting, someone who has witnessed a tragic accident or someone who has unexpectedly lost a loved one. Treatment for PTSD includes cognitive and behavioral therapy, group psychotherapy, and medications such as Clonazepam, Lorazepam, and selective serotonin reuptake inhibitors such as Fluoxetine, Sertraline, Paroxetine, Citalopram, and Fluvoxamine. These medications help control anxiety as well as depression. Various forms of exposure therapy (such as systemic desensitization and imaginative flooding) have been used with PTSD patients. The exposure treatment for PTSD involves repeatedly reliving the trauma, under controlled conditions, in order to facilitate the processing of the trauma. Therefore, there is a need for better pharmaceutical agents to treat post-traumatic stress disorder. Mood and affective disorders fall within a large group of diseases that include monopolar depression and bipolar mood disorder. These diseases are treated with three main classes of compounds. The first group is the heterocyclic antidepressant (HCA). This group includes the well-known tricyclic antidepressants. The second group of compounds used to treat mood disorders is that of monoamine oxidase inhibitors (MAOIs) that are used in particular types of diseases. The third drug is lithium. The common side effects of HCAs are sedation and weight gain. In elderly patients with organic brain disease, the side effects of HCAs can also include attacks and behavioral symptoms. The main side effects of MAOI use are due to interactions between food and drugs. Benign side effects of lithium use include, but are not limited to, weight gain, nausea, diarrhea, polyuria, polydipsia, and tremors. The toxic side effects of lithium can include persistent headache, mental confusion and can reach attacks and cardiac arrhythmias. Therefore, agents with lower side effects or interactions with food or other medications would be useful. Borderline personality disorder, although not as well known as bipolar disorder, is more common. People with borderline personality disorder suffer from an emotional regulation disorder. Pharmaceutical agents are used to treat specific symptoms such as depression or thought distortions. Acquired immunodeficiency syndrome (AIDS) is the result of an infection with the human acquired immunodeficiency virus (HIV). This virus attacks selected cells and prevents the proper functioning of the immune, nervous and other systems. HIV infection can cause other problems such as, but not limited to, difficulties in thinking, which are also known as AIDS complex and dementia. Therefore, there is a need for drugs to alleviate the confusion and mental decline of people with AIDS. Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, belongs to a class of disorders known as motor neuron diseases in which specific nerve cells in the brain and spinal cord gradually degenerate and adversely affect the control of the voluntary movement. There is currently no cure for amyotrophic lateral sclerosis, although patients can receive treatment for some of its symptoms and although it has been shown that Riluzol prolongs patient survival. Thus, there is a need for a pharmaceutical agent to treat this disease. Traumatic brain injury occurs when the brain is damaged by sudden physical aggression on the head. The symptoms of traumatic brain injury include confusion and other cognitive problems. Therefore, there is a need to address the symptoms of confusion and other cognitive problems. Brain tumors are abnormal growths of tissue that are found inside the skull. The symptoms of brain tumors include behavioral and cognitive problems. Surgery, radiation and chemotherapy are used to treat the tumor, but other agents are needed to address the associated symptoms. Therefore, there is a need to address the symptoms of behavioral and cognitive problems. People with Down syndrome have in all or at least in part of their cells an extra, critical part of chromosome 21. It is known that adults who have Down syndrome have a risk of dementia of the Alzheimer's type. Currently there is no proven treatment for Down syndrome. Therefore there is a need to address the dementia associated with Down syndrome. The genetically programmed degeneration of neurons in certain areas of the brain causes Huntington's disease. The early symptoms of Huntington's disease include sudden mood swings or learning problems of new things or to remember a fact. Most drugs that are used to treat the symptoms of Huntington's disease have side effects such as fatigue, agitation or hyperexcitability. Currently, there is no treatment to stop or reverse the progress of Huntington's disease. Therefore, there is a need for a pharmaceutical agent to treat the symptoms with minor side effects. Dementia with Lewy bodies is a degenerative disorder that involves abnormal structures that are known as Lewy bodies that are found in certain areas of the brain. Symptoms of dementia with Lewy bodies include, but are not limited to, fluctuating cognitive impairment with episodic delirium. Currently the treatment involves attending to the symptoms of Parkinson's and psychiatric. However, medicine to control tremors or loss of muscle movement may actually accentuate the underlying disease of dementia with Lewy bodies. Therefore, there is a need for a pharmaceutical agent to treat dementia with Lewy bodies. Parkinson's disease is a neurological disorder characterized by tremors, hypokinesia and muscular rigidity. Currently there is no treatment to stop the progress of the disease. Therefore, there is a need for a pharmaceutical agent to treat Parkinson's disease. Tardive dyskinesia is associated with the use of antipsychotic drugs. This disease is characterized by involuntary movements that are most often manifested by puckering of the lips and tongue and / or contortions of the arms or legs. The incidence of tardive dyskinesia is approximately 5% per year of drug exposure among patients who are medicated with conventional antipsychotic drugs. In approximately 2% of people with the disease, tardive dyskinesia is highly disfiguring. Currently, there is no generalized treatment for tardive dyskinesia. In addition, the withdrawal of drugs that cause the effect is not always an option due to underlying problems. Therefore, there is a need for a pharmaceutical agent to address symptoms of tardive dyskinesia. Pick's disease results from a slowly progressive deterioration of social skills and personality changes with symptoms resulting from intellectual impairment, from memory and language. Common symptoms include memory loss, lack of spontaneity, difficulty thinking or concentrating, and speech disturbances. CurrentlyThere is no specific treatment for Pick's disease but some symptoms can be treated with cholinergic antidepressants and serotonin enhancers. In addition, antipsychotic medications can alleviate the symptoms of FTD patients who are experiencing delusions or hallucinations. Therefore, there is a need for a pharmaceutical agent to treat the progressive deterioration of social skills and personality changes to address the symptoms with minor side effects. Disorders of food intake associated with 6 Food diseases that include bulimia nervosa and anorexia nervosa involve neurophysiological pathways. It is difficult to treat anorexia nervosa because patients do not enter or remain in the programs after entering. Currently, there is no effective treatment for people suffering from severe anorexia nervosa. Cognitive behavioral therapy has helped patients suffering from bulimia nervosa; however, the response rate is only approximately 50% and the current treatment does not adequately address emotional regulation. Therefore, there is a need for a pharmaceutical agent to address underlying neurophysiological problems in derangement disorders of food intake. Tobacco use has been recognized as a major public health problem for a long time. However, despite public awareness that it is a health hazard, smoking remains extraordinarily persistent and difficult to break. There are many treatment methods available and yet people continue to smoke. The administration of nicotine has a large number of actions in the body and therefore can have many side effects. It is clear that there is both a need and a long-standing demand for a convenient and relatively easy method to help smokers reduce or eliminate cigarette smoking. A drug that could selectively stimulate only some nicotinic receptors would be useful in programs to stop smoking.

Programs to stop smoking involve the oral administration of the chosen drug. The drug can be in the form of tablets. However, it is preferred to administer the daily dose during waking hours by administering a series of incremental doses during the day. The preferred method for administration of this type is a tablet, tablet or chewing gum in which the drug is dispersed. Another drug to treat addition to nicotine is Zyban. This is not a substitute for nicotine like chewing gum or the patch. Instead, it works in other areas of the brain and its effectiveness is to help control the craving for nicotine or thoughts about the use of cigarettes in person that are trying to quit smoking. Zyban is not very effective and effective drugs are needed to help smokers in their desire to stop smoking. These drugs can be administered transdermally through the use of skin patches. In certain cases, the drugs can be administered by subcutaneous injection, especially if sustained release formulations are used. The use and dependence of drugs is a complex phenomenon, which can not be encapsulated in a single definition. Different drugs have different effects and, therefore, different types of dependence. Drug dependence has two basic causes, that is, tolerance and physical dependence. Tolerance exists when the user must progressively take larger doses to produce the effect that was initially achieved with smaller doses. Physical dependence exists when the user has developed a state of physiological adaptation to a drug and there is a withdrawal syndrome when the drug is not taken. A withdrawal syndrome can occur when the drug is stopped or when an antagonist displaces the drug from its binding site in the cell receptors, thus counteracting its effect. Drug dependence does not always require physical dependence. In addition, drug dependence often implies dependence-psychological, that is, a feeling of pleasure or satisfaction when the drug is taken. These feelings lead the user to repeat the experience of the drug or to avoid the dislike of being deprived of the drug. Drugs that produce a strong physical dependence, such as nicotine, heroin and alcohol are often abused, and the dependency pattern is difficult to break. Dependent drugs act on the CNS and generally produce anxiety and tension; they produce joy, euphoria or other pleasant mood changes; they provide the user with feelings of increased mental and physical capacity; or alter sensory perception in some pleasurable way. Among the commonly abused drugs are ethyl alcohol, opioids, anxiolytics, hypnotics, cannabis (marijuana), cocaine, amphetamines and hallucinogens. The current treatment for drug addicts often involves a combination of behavioral therapies and medications. Medications, such as methadone or LAA (levo-alpha-acetyl-methadol) are effective in suppressing withdrawal symptoms and therefore the desire for drugs associated with the addition of narcotics, thereby reducing the use of licit and improving the chances that the individual remains in treatment. The main medically assisted cessation procedure for addition to narcotics is to switch the patient to a comparable drug that produces minor withdrawal symptoms and then gradually reduce the substitute medication. The most commonly used medication is methadone, taken orally once a day. Patients start with the lowest dose that prevents the most severe signs of abstinence and then gradually reduce the dose. Substitutes can also be used for the detoxification of sedatives. Patients can be switched to long-acting sedatives, such as diazepam or phenobarbital, which are then gradually reduced. Guilles de la Tourette syndrome is a hereditary neurological disorder. The disorder is characterized by uncontrollable vocal sounds that are called tics and involuntary movements. Symptoms usually manifest in the individual before the person turns 18. Movement disorder can begin with simple tics that progress to multiple complex tics that include respiratory and vocal tics. Vocal tics can start as grunting or barking noises and evolve into incomprehensible joints. Coprolalia (involuntary eschatological joints) occurs in 50% of patients. Severe tics and coprolalia can be physically and socially disabling. The tics tend to be more complex than in myoclonus but less fluid than the chorea movements, from which they must differentiate. The patient can voluntarily suppress them for seconds or minutes. Currently simple tics are often treated with benzodiazepines. Clonidine can be used for simple and complex tics. The long-term use of Clonidine does not cause late dyskinesia; its limiting side effect is hypotension. In more severe cases, antipsychotics such as Haloperidol may be necessary, but the side effects of dysphoria, parkinsonism, akathisia and tardive dyskinesia may limit the use of antipsychotics of this type. There is a need for safe and effective procedures to treat this syndrome. Age-related macular degeneration (AMD) is a common ocular disease of the macula that is a tiny area of the retina that helps produce a central acute vision needed for "forward" activities that include reading and driving. People with AMD lose their central clear vision. AMD has two forms: wet and dry. In dry AMD, there is a slow decomposition of cells that feel light in the macula. Currently there is no cure for dry AMD. In wet AMD, new and fragile blood vessels grow below the macula as dry AMD worsens and these vessels often leak blood and fluid to cause rapid damage to the macula, which quickly leads to loss of central vision . Laser surgery can treat some cases of wet AMD. Therefore there is a need for a pharmaceutical agent to service AMD. Glaucoma is within a group of diseases that are due to an increase in intraocular pressure that causes pathological changes of the optic disc and negatively affects the field of vision. Medications to treat glaucoma decrease the amount of fluid that enters the eye or increase fluid drainage from the eye to reduce infraocular pressure. Nevertheless, current drugs have drawbacks such as not working over time or causing side effects so that the ophthalmologist has to prescribe other drugs or modify the prescription of the drug that is being used. There is a need for safe and effective procedures to treat problems that manifest in glaucoma. The ischemic periods in glaucoma provoke the release of excitotoxic amino acids and stimulate the inducible form of nitric oxide synthase (NOS) causing neurodegeneration. Alpha-7 nicotinic agonists can stimulate the release of inhibitory amino acids such as GABA that will dampen hyperexcitability. The nicotinic agonists of alpha 7 are also directly neuroprotective of the neuronal somas. Thus, nicotinic agonists alpha 7 have the potential to be neuroprotective in glaucoma. People who suffer from pain often have what is called a "terrible triad" of suffering pain that results in lack of sleep and sadness, all of which are hard on the affected individual and the individual's family. The pain can manifest itself in various forms, including, but not limited to, headaches of all kinds of severity, back pain, neurogenic and pain due to other conditions such as arthritis and cancer due to its existence or from therapy to eradicate it. The pain can be chronic (persistent pain for months or years) or acute (immediate pain of short duration to inform the person of a possible injury and need for treatment). People suffering from pain respond differently to individual therapies with varying degrees of success. There is a need for safe and effective procedures to treat pain. Finally, the compounds of the present invention can be used in combination therapy with typical and atypical antipsychotic drugs (also called an antipsychotic agent). All compounds in the present invention are useful and can also be used in combination with one another to prepare pharmaceutical compositions. Polytherapies of this type decrease the effective dose of the antipsychotic drug and therefore reduce the side effects of the antipsychotic drugs. Some typical antipsychotic drugs that can be used in the practice of the invention include Haldol. Some atypical antipsychotic drugs include Ziprasidone, Olanzapine, Resperidone, and Quetiapine. The compounds of Formula I can be prepared as shown in Scheme 1. The starting materials can be prepared by the methods described below or by methods that would be well-known to those skilled in organic chemistry. The variables used in Scheme 1 are defined below or in the claims. The key step in the preparation of this class of compounds is the coupling of (1 S, 2R, 4 /?) - (+) - 2-amino-7-azabicyclo [2.2.1] heptane-7-carboxylate exo- urea-butyl (Example 1) with the required acid chloride (Lv = Cl), mixed with anhydride (for example, Lv = diphenylphosphoryl, bis (2-oxo-3-oxazolidinyl) phosphinyl, or acyloxy of the general formula of -C (0) -RL, where RLv includes phenyl or t-butyl), ester (for example Lv = alkyl, aryl or aryl deficient in electrons) or carboxylic acid (Lv = OH) in the presence of an activating agent. Suitable activating reagents are well known in the art, for the examples see Kiso, Y., Yajima, H. "Peptides" pages 39-91, San Diego, CA, Academia Press, (1995) and include, but not limited to, agents such as carbodiimides, phosphonium and uronium salts (such as the uranium salt HATU).

SCHEME 1 Preferably (1S, 2R, 4R) - (+) - 2-amino-7-azabicyclo [2.2.1] heptane-7-carboxylate of exo-fer-butyl can be coupled to the acid in the presence of an appropriate base such as DIEA, and a uronium salt, such as HATU, in an aprotic medium, such as DMF, to provide the desired amides. Alternatively, the acid is converted to a mixed anhydride by treatment with bis (2-oxo-oxazolidinyl) phosphinic chloride in the presence of TEA with CH2Cl2 or CHCl3 as the solvent. The resulting anhydride solution is directly reacted with exo-fer-butyl (1S, 2R, 4R) - (+) - 2-amino-7-azabicyclo [2.2.1] heptane-7-carboxylate which is added alone or using CH2C½ or CHCI3 as solvent. In addition, condensation of the amine with an ester (W-C (O) -O-alkyl or W-C (0) -0- (electron-deficient aryl)) in an alcohol solvent such as ethanol at an elevated temperature will give the desired amides. The treatment of the carboxamide with a sulfurizing agent such as Lawesson's reagent (2,4-bis (4-methoxypheni) -1, 3-dithio-2,4-diphosphetane-2,4-disulfide) in, for example, dioxane at an appropriate temperature provides the corresponding thioamide, for example X in formula I is S. See Lawesson et al. In Bull. Soc. Chim. Belg., 229 (1978)), or P S10 (see Chem. Rev., 45 (1961) Alternatively, a dithiocarboxylic ester can be reacted with the corresponding azabicyclo moiety to form the same thioamide. the construction of an optionally substituted 7-azabicyclo [2.2.1] heptane ring system, for example, Trudell's independent work (R4 = H, Zhang, C, Trudell, ML, J. Org. Chem., 61, 7189- 7191, 1996), and Schultz (FU = Me, Schultz, AG, Shen, MS, Tetrahedron Lett., 22, 3347-3350, 1981) describes the usefulness of a Diels-Alder strategy for the preparation of this ring system with functionalities suitable for further processing to the desired 2-amino-7- azabicyclo [2.2.1] heptane (Scheme 2) For example, Trudell reviews (Zhang, C, Trudell, ML, Tetrahedron, 54, 8349-8354, 1998). ) that the Diles-Alder 1A adduct (where R6 = methylcarbamate, R4 = H and Lv = Br) could be easily functionalized in C-3 by reaction with organocobre ecies to introduce the substituent l¾ in 2a, b. Similarly, the hydrogenolysis of adduct 1a, bo 2a, b followed by isomerization of the endo products as described by Singh (Singh, S., Basmadjian, GP, Tetrahedron Lett., 38, 6829-6830, 1997) could provide access to the exo acid 3a-d. The treatment of 3 with diphenylphosphoryl azide in the presence of a tertiary amine base (for example Et ^ N) in a suitable solvent such as toluene, followed by heating of the intermediate acylazide in the presence of a suitable alcohol (for example benzyl alcohol) would effect the well-known reconfiguration of Curtius to provide a differentially protected bis carbamate that could be cleaved under typical hydrogenolysis conditions (eg, 10% Pd / C, EtOH, H2, room temperature at 50 psi) to provide the desired amine. Alternatively, the differentially protected bis carbamate could provide an attractive point of intervention for the chromatographic resolution of the individual 2-exo isomers before cleavage to the amine 4.

SCHEME 2 R = Me, R = independently H, alkyl, substituted alkyl 1a, Lv = Br, R4 = H Re = carbamate amino protecting group, for example 1b, Lv = Br, R4 = Me BOC and In the case where Re = ferc-butyloxycarbonyl, the deprotection of the 7-aza group can be conveniently achieved under acidic conditions in a suitable solvent such as methanol. After deprotection, the secondary amine can be functionalized with alkyl and substituted alkyl by reductive amination or alkylation procedures. It will be apparent to those skilled in the art that the necessary carboxylic acids can be obtained through synthesis by procedures in the literature or by slight modification thereof.

Preparation of (1 S, 2 4R) -2-amino-7-azabicyclo2.2.1"[Heptane-7-carboxylic acid of fer-butyl ester: Preparation of methyl-3-bromo-propiolate: Methyl propiolate (52 ml, 0.583 mol) is combined with recrystallized N-bromo-succinimide (120 g, 0.674 mol) in 1.700 ml of acetone under nitrogen. The solution is treated with silver nitrate (9.9 g, 0.0583 mol) only once and the reaction is stirred 6 h at RT. The acetone is removed under reduced pressure (25 ° C bath temperature) to give a thick gray mixture. The thick mixture is washed with 2 x 200 ml of hexane, the gray solid is separated by filtration and the filtrate is concentrated in vacuo to give 95 g of pale yellow oily residue. The crude material is distilled by a short route under reduced pressure (65 ° C, approximately 25 mm Hg) in a receiver cooled by dry ice / acetone to give 83.7 (88%) of methyl-3-bromo-propiolate in the form of pale yellow oil. Anal. cale, for C4H3Br02: C, 29.48; H, 1.86. Found: C. 29.09; H, 1.97.

Preparation of 7-fer-butyl-2-methyl-3-bromo-7-azabiciclof2.2.11hepta-2,5-diene-2,7-dicarboxylate. Methyl-3-bromo-propiolate (83.7 g, 0.513 mol) is added to N-t-butyloxypyrrole (430 mL, 2.57 mol) under nitrogen. The dark mixture is heated in a 90 ° C bath for 30 h, and most of the excess α-β-butyloxypyrrole is removed under vacuum using a dry ice / acetone condenser. The dark oily residue is chromatographed on 1 kg of silica gel (230-240 mesh) with 0-15% EtOAc / hexane. Combine the appropriate fractions and concentrate to provide 97 g (57%) of 7-fer-butyl-2-methyl-3-bromo-7-azabicyclo [2.2.1] hepta-2,5-diene-2.7 -dicarboxylate in the form of dark yellow oil. HRMS (BAR) calculated for C13H16BrN04 + H: 330.0341, found 330.0335 (M + H) +.

Preparation of (+/-) entfo-7-phere-butyl-2-methyl-7-azabicyclochloro.2.2nheptane-2J-dicarboxylate 7-ert-Butyl-2-methyl-3-bromo-7-azabicyclo [ 2.2.1] hepta-2,5-diene-2,7-dicarboxylate (97 g, 0.294 mol) is added to 0% Pd / C (6.8 g) in 900 ml of absolute EtOH in a PARR bottle. The suspension is diluted with a solution of NHC03 (25 g, 0.301 mol) in 250 I of water and the mixture is hydrogenated at 50 PSI for 2.5 h. The catalyst is removed by filtration, washed with fresh EtOH and the filtrate concentrated in vacuo to give a residue. The residue is fractionated between 1 x 200 ml of saturated NaHCO3 and CH2CI2 (4 x 100 ml). The combined organic phase is dried over anhydrous K2CO3 / anhydrous gSO4 1: 1 and concentrated in vacuo to give 72.8 g (98%) of (+/-) endo-7-tert-butyl-2-methyl-7-azabicyclo [ 2.2.1] heptane-2,7-dicarboxylate. MS (IE) for Ci4H2204 > m / z: 255 (M) +.

Preparation of acid (+/-) exo-7- (tert-butoxycarbon \\) - 7-azabicyclo ["2.2.11heptane-2-carboxylic acid (+/-) In (/ o-7-ert-butyl-2) -methyl-7-azabicyclo [2.2.1] heptane-2,7-dicarboxylate (72.8 g, 0.285 mol) is dissolved in 1000 ml of dry MeOH in a dry flask under a nitrogen atmosphere.The solution is treated with solid NaOMe ( 38.5 g, 0.713 mol) only once and the reaction is refluxed for 4 h.The mixture is cooled to 0 ° C, treated with 400 ml of water and the reaction is stirred for 1 h while heating to RT. The mixture is concentrated in vacuo to approximately 400 ml and the pH of the aqueous residue is adjusted to 4.5 with 12 N HCl. The precipitate is collected and dried The lightly tacky tan solid is washed with 2 x 100 ml of ether at 60 % in hexane and dried to give 47 g (68%) of (+/-) exo-7- (urea-butoxycarbonyl) -7-azabicyclo [2.2.1] heptane-2-carboxylic acid (BAR) calculated for Ci2H19N04 + H: 242.1392, found 242.390 (M + H) +.

Preparation of exo-7-rerc-butyl-2- (r (benzyloxy) carboninamino) -7-azabicyclo2.2.1heptane-7-carboxylate Acid (+/-) exo-7- (ferc-butoxycarbonyl) -7-azabicyclo [ 2.2.1] heptane-2-carboxylic acid (103.9 g, 0.430 mol) is combined with TEA (60 ml, 0.430 mol) in 1200 ml of dry toluene in a dry flask under a nitrogen atmosphere. The solution is treated dropwise with diphenylphosphoryl azide (92.8 ml, 0.430 mol) and allowed to stir for 20 minutes at RT. The mixture is treated with benzyl alcohol (47.9 ml, 0.463 mol), and the reaction is stirred overnight at 55 ° C. The mixture is cooled, extracted successively with 2 x 500 ml of 5% citric acid, 2 x 500 ml of water, 2 x 500 ml of saturated sodium bicarbonate and 500 ml of saturated NaCl. The organic phase is dried over anhydrous MgSO 4 and concentrated in vacuo to provide an amber oil. The crude material is chromatographed on 900 g of silica gel (230-400 mesh) eluting with 10-30% EtOAc / hexane. The appropriate fractions are combined and concentrated to give 106 g (71%) of (+/-) exo-7-tert-butyl-2-. { [(benzyloxy) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylate in the form of a pale oil. 1 H NMR (CDCl 3) d 1.29-160, 1.44, 1.62-2.01 3.76-3.88, 4.10, 4.24, 5.10, 7.36 ppm.

Preparation of (+/-) exo-ferc-butyl-2-amino-7-azabicyclo2.2. 1-hepta-7-carboxylate (+/-) Exo-7-fer-butyl-2-. { [(benzyloxy) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylate (1.5 g, 4.33 mol) is combined with 10% Pd / C (50 mg) in 40 ml of EtOH in a Parr shaker flask. The mixture is hydrogenated at 50 PSI for 1.5 h. The catalyst is filtered off and the filtrate is concentrated in vacuo. The crude material is chromatographed on 30 g of silica gel (230-400 mesh), eluting with 7% eOH / CH2Cl2 + conc. NH4OH. At 1%. The appropriate fractions are combined and concentrated to provide 606 mg (66%) of (+/-) exo-tert-butyl-2-amino-7-azabicyclo [2.2.1] heptane-7-carboxylate. HRMS (BAR) calculated for C11H20N2O2 + H: 213.1603, found 213.1580 (+ H) +. This racemic mixture will be referred to as (+/-) - 7-aza- [2.2.1] -Amine.

Resolution of the racemic mixture of carboxylate: The (+/-) exo-7-tert-butyl-2-. { [(benzyloxy) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylate is isolated by preparative chiral HPLC (Column Chiracel OJ 50 x 500 mm, 30 degrees, C, 70 ml / min, 10/90 (v / v) isopropanol / heptane). The resolution provides 40 g of (1 S, 2R, 4f?) - (+) - 2-. { [(benzyloxy) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylic acid / butyl ester and 42 g of (1R, 2S, 4S) - (-) - 2-. { [(benzyloxy) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylate tert -butyl. The 2R enantiomer is triturated with 40 ml of ether followed by 40 ml of hexane (to remove the remaining diastereomeric and enantiomeric impurities) and dried to provide 30 g (56%) of (1 S, 2R, 4F?) - (+ )-2-. { [(benzyloxy) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylate of tert-butyl purified with an excess enantiomer of 99%. MS (EI) for C19H26N204, m / z: 346 (M) +. [a] 25D = 22, (c 0.42, chloroform). The 2S enantiomer is triturated with 40 ml of ether followed by 40 ml of hexane to provide 35 g (66%) of (1 /? 2S, 4S) - (-) - 2-. { [(benzyloxy) carbon] I] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylic acid-butyl ester purified with an excess enantiomer of 99%. MS (EI) for Ci9H26 204, m / z: 346 (M) +. [a] 25D = -23, (c 0.39, chloroform).

Preparation of (1S, 2 4R) - (+) - 2-7-azabicyclof2.2.11-tert-butyl-7-carboxylic acid tert-butylate ((2R) -7-aza-r2.2.11-Amine) Combined (1S, 2R, 4R) - (+) - 2-. { [(benzyloxy) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylic acid-butyl ester (9.5 g, 27.4 mmol) with 950 mg of 0% Pd / C in 75 ml of absolute EtOH in a Parr jar of 500 ml. The reaction mixture is hydrogenated at 50 PSI for 3 h, the catalyst is filtered off and the filtered cake is washed with MeOH. The filtrate is concentrated in vacuo to give 6.4 g of a residue. The crude material is chromatographed on 200 g of silica gel (230-400 mesh) eluting with 7% CH 2 OH / CHCl 3 containing conc. NH 4 OH. at 1%. Combine and concentrate the appropriate fractions to give 5.61 (96%) of (1 S, 2R, 4f?) - (+) - 2-amino-7-azabicyclo [2.2.1] heptane-7-carboxylic acid-butyl ester in the form of pale oil. MS (EI) for C-, iH2oN204, m / z: 212 (M) +. [a] 25D = 9, (c 0.67, CHCI3). This will be referred to as (2R) -7-aza- [2.2.1] -Amine.

Acids Preferably, when Q is furan, oxazole, oxadiazole, pyrrole, 5-thiazole, thiophene or triazole, the acid is activated with a uranium salt, preferably HATU (see J. Am. Chem. Soc, 4391 (1993)), in the presence of a base such as DIEA in DMF, and reacted directly with (2R) -7-aza- [2.2.1.] - Amine to provide the desired amides. In the case where Q is a 2-thiazole or 2-oxazole, the amide bond is formed by reaction of the amine and the ester (Lv = OEt) in an alcohol solvent (see Liebigs Ann. Chem., 1216-1231). (1980)). It will be apparent to those skilled in the art that the necessary carboxylic acids can be obtained commercially or can be synthesized by known methods. Certain thiophene acids can be synthesized from the corresponding aldehydes by oxidation with NaClC > 2 as described in J. Chem. Soc. Perkin Trans. I, 789-794 (1999). The necessary aldehydes can be prepared as described in J. Med. Chem., 1585-1599 (1997). An arylboronic acid is reacted with a bromothiophene in the presence of a source of palladium (0), such as tetrakis (triphenylphosphine) palladium (0) and a base, preferably aqueous sodium carbonate. The reaction works better if reflux is heated in THF / water for 24 hours. Other thiophene acids are synthesized from the corresponding esters by base catalyzed hydrolysis. Typical hydrolysis procedures are well known in the art. Preferably, the thiophene ester is treated with aqueous lithium hydroxide in a solvent such as comoxane. The esters are commercially available or can be synthesized by reaction of a bromothiophene ester with the appropriate thiophenol or phenol as described in Col. Czech Chem. Comm., 2360-2363 (1980).

Specifically, the sodium salt of thiophenol or phenol is formed by treatment with a strong base such as sodium hydride. The sodium salt is then reacted with a bromothiophene in a solvent such as acetone. Examples of furan are prepared by convergent means by direct coupling of palladium-catalyzed Suzuki N - [(2R) -7-azabicyclo [2.2.2] hept-2-yl] -5-bromo-furan-2-carboxamide with the boronic acid required by the procedure described in Org. Lett. 965-7 (1999) to directly provide the desired arylamides. The 1,3-oxazole-2-carboxylate intermediates can be prepared by the process described in J. Pharm. Sci. Japan 305-7, (1956).

Coupling The following examples are provided as examples and are not intended to limit the scope of this invention solely to the examples provided and named. Also, the salts that are prepared in the examples are only exemplary and are not intended to limit the invention. Any pharmaceutically acceptable salt can be prepared by one skilled in the art. The invention includes the following examples in pure stereoisomeric form or in the form of racemic mixtures.

EXAMPLE 1 N-KI S, 2R 4R) -7-azabicylchlor2.2.11hept-2-n-5-bromo-2-thiophenecarboxamide hydrochloride: 5-Bromothiophen-2-carboxylic acid (388 mg, 1.9 mmol) is combined with 10 ml of CH2Cl2 in a dry flask under a nitrogen atmosphere. The solution is treated with TEA (265 μ ?, 1.9 mmol) followed by bis (2-oxo-3-oxazolidinyl) phosphine chloride (479 mg, 1.9 mmol) and the reaction is stirred 1 h at rt. The mixture is treated with (2R) -7-aza- [2.2.1] -ammine (320 mg, 1.5 mmol) in 2 ml of CH2Cl2 and the reaction is stirred 18 h at rt. The mixture is washed with 1 x 10 mL of saturated NaHCO3, the organic phase is dried over K2CC > 3 anhydrous and concentrated in vacuo to provide a residue. The crude material is chromatographed on 25 g of silica gel (230-400 mesh) eluting with 20% EtOAc / hexane. The appropriate fractions are combined and concentrated to give 400 mg (65%) of (1 S, 2R, 4R) - (+) - 2-. { [(5-bromo-2-thienyl) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylic acid tere-butyl ester. It is combined (1 S, 2R, 4R) - (+) - 2-. { [(5-bromo-2-thienyl) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylic acid tere-butyl ester (222 mg, 0.55 mmol) with 5 ml of 2N methanolic acid HCl in 5 ml of MeOH under nitrogen atmosphere. The reaction is heated in a 60 ° C bath for 2 h, cooled, and concentrated in vacuo to provide a residue. The residue is dissolved in 1 ml of IAP, diluted with 2 ml of diethyl ether and allowed to crystallize. The white solid is washed with ether and dried to give 165 mg (88%) of Example 1 as a white solid. EM for CiiHi3BrN2OS. m / z: 300 (M-H) ~. [a] 25D = -5, (c 0.33, water).

EXAMPLE 2 (+/-) Exo-N-r7-azabicyclo2.2.11hept-2-in-5-bromo-2-thiophenecarboxamide hydrochloride 5-Bromothiophen-2-carboxylic acid (738 mg, 3.6 mmol) is combined with 20 ml of CH 2 Cl 2 in a flask dried in homo under a nitrogen atmosphere. The solution is treated with TEA (496 pl, 3.6 mmol) followed by bis (2-oxo-3-oxazolidinyl) phosphinic chloride (906 mg, 3.6 mmol) and the reaction is stirred 1 h at rt. The mixture is treated with (+/-) - 7-aza- [2.2.1] -amine (606 mg, 2.9 mmol) in 5 ml of CH2Cl2 and the reaction is stirred 24 h at rt. The mixture is washed with 1 x 10 ml of saturated sodium bicarbonate, the organic phase is dried over anhydrous potassium carbonate and concentrated in vacuo to provide an oily residue. The crude material is chromatographed on 50 g of silica gel (230-400 mesh) eluting with 25% EtOAc / hexane. The appropriate fractions are combined and concentrated to provide 733 mg (64%) of (+/-) exo-er-butyl-2-. { [(5-bromo-2-t-phenyl) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylate. HRMS (BAR) calculated for Ci6H2iBrN203S + H: 401.0535, found 401.0533 (M + H) +. It combines (+/-) exo-tert-butyl-2-. { [(5-bromo-2-thienyl) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylate (210 mg, 0.52 mmol) with 5 ml of 2N methanolic acid HCl in 5 ml of MeOH under nitrogen atmosphere. The reaction is heated in a 60 ° C bath for 2 h, cooled, and the volatiles are removed in vacuo. The residue is dissolved in 1 ml of IPA, diluted with 2 ml of Et20 and allowed to crystallize. The white solid is washed with ether and dried to provide 154 mg (88%) of Example 2 as a white solid. MS for CnH ^ Brl ^ OS, miz: 300 (M) +.

EXAMPLE 3 N-fClS, 2S, 4R) -7-azabicylchlor2.2.nhept-2-in-5-bromo-2-thiophenecarboxamide hydrochloride: Resolution (+/-) Exo-ferc-butyl-2-. { [(5-bromo-2-thienyl) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylate: The (+/-) E o-ierc-butyl-2-. { [(5-bromo-2-thienyl) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylate (500 mg) is resolved by resolution in preparative chiral HPLC (Chiralpak AD IPA / heptane column) to provide 175 mg (70%) of (+/-) exo- urea-butyl- (1S, 2R, 4R) -. { [(5-bromo-2-thienyl) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylate as a white solid (MS for Ci6H2iBr 203S, (IE) m / z: 400 (M) +.) The structure is confirmed by crystallography by X-rays with crystals obtained from Et20) and 195 mg (78%) of tert-butyl- (1S, 2R, 4R) -. { [(5-bromo-2-thienyl) carbonyl] amino} -7-azabicyclo [2.2.1] heptane-7-carboxylate as a white solid (MS for C16H2iBrN203S, (IE) m / z: 400 (M) +. Ferc-Butyl- (1S, 2R, 4R ) - { [(5-Bromo-2-thienyl) carbonyl] amino.} - 7-azabicyclo [2.2.1] heptane-7-carboxylate is deprotected and the product isolated in the form of its hydrochloride salt as described described in Example 1 to provide 134 mg (97%) of Example 3 as a white solid MS for CnHi3BrN2OS (IE) m / z: 300 (M) +. [a] 25D = 5o, (c 0.30 , Water).

EXAMPLE 5 N-K1 S, 2R, 4ff) -7-azabicyclo2.2.nhept-2-n-5- (methylthio) thiophene-2-carboxamide hydrochloride: 5-Methylthio-thiophene-2-carboxylic acid (192 mg, 1.1 mmol) is coupled with (2R) -7-aza- [2.2.1] -amine (212 mg, 1.0 mmol) and deprotected as described in Example 1 without critical variations to provide 192 mg (63%) of Example 5 in the form of a white solid. MS for C 2 H 16 N 20 S 2, (IE) m / z: 286 (M) +.

EXAMPLE 6 N-K1S, 2R, 4ffl-7-azabicyclor2.2.nhept-2-n-5-phenylthiophene-2-carboxamide hydrochloride: 5-Bromothiophen-2-carboxaldehyde (1.0 g, 5.2 mmol) is added to a solution of tetrakis (triphenylphosphine) palladium (0) (180 mg, 0.16 mmol) in degassed THF (10 mL). The resulting solution is stirred for 5 minutes and then a solution of phenylboronic acid (760 mg, 6.2 mmol) in THF (10 ml) is added followed by Na 2 CO 3 (2 M, 5.2 ml). The mixture is refluxed for 24 h. The reaction mixture is dried over Na 2 SO 4 and concentrated in vacuo. The crude product is purified by flash column chromatography (hexanes / CH 2 Cl 2 1: 1) to give 900 mg (91%) of 5-phenylthiophene-2-carboxaldehyde. 1 H NMR (300 MHz, CDCl 3) d 7.38-7.45, 7.65-7.68, 7.73, 9.88. 5-Phenylthiophen-2-carboxaldehyde (750 mg, 4 mmol) is dissolved in a mixture of THF, tBuOH and water (2.1: 1, 60 ml). Add KH2P04 (1.36 g, 10 mmol) followed by NaCl02 (900 mg, 10 mmol). The mixture is stirred at rt for 5 days. Aqueous NaOH (2 M, 10 mL) is added and a majority of the organic solvents are removed in vacuo to give an aqueous suspension. This suspension is diluted with water and washed three times with CH2Cl2. The aqueous phase is acidified at pH < 2 with 25% H2SO4 and the product is extracted three times with CH2Cl2. The combined organic washings are dried over Na2SO4, filtered and concentrated in vacuo to provide 417 mg (51%) of 5-phenylthiophene-2-carboxylic acid. MS for CnHaC ^ S, (IE) m / z: 203 (M-H) ~. 5-phenyl-thiophene-2-carboxylic acid (224 mg, 1.1 mmol) is coupled with (2R) -7-aza- [2.2.1] -amine (212 mg, 1.0 mmol) and deprotected as described in Example 1 without critical variations to provide 258 g (77%) of Example 6 in the form of a white solid. MS for Ci7Hi8N2OS, (IE) m / z: 298 (M) +. HRMS (BAR) calculated for C17H18N2OS + H: 299.1218, found 290.1220 (M + H) +.

EXAMPLE 7 N-1 S, 2 4RW-azabicyclo2.2.11hept-2-in-5- (2-chlorophenyl) thiophen-2-carboxamide hydrochloride: 5- (2-Chlorophenyl) thiophen-2-carboxylic acid is prepared as described in Example 3 starting with 2-chlorophenylboronic acid and bromothiophen-2-carboxaldehyde. 5- (2-Chlorophenol) thiophene-2-carboxylic acid (263 mg, 1.1 mmol) is coupled with (2R) -7-aza- [2.2.1] -amine (212 mg, 1.0 mmol) and deprotected as is described in Example 1 without critical variations to provide 258 mg (70%) of Example 7 as a white solid. MS for C17H17CIN2OS, (IE) m / z: 332 (M) +.

EXAMPLE 8 N-K1 S, 2R, 4R) -7-azabicyclo2.2.11hept-2-m-5-r (4-chlorophenyl) thio-thiophen-2-carboxamide hydrochloride: Sodium hydride (60%, 1.2 g, 30 mmol) is added to a solution of 4-chlorothiophenyl (4.3 g, 30 mmol) in THF (20 mL). The resulting solution is stirred for 10 minutes and then the solvent is removed in vacuo. Acetone (60 ml) is added followed by 5-bromothiophen-2-carboxaldehyde (3.0 ml, 25 mmol). The mixture is stirred at rt for 2 h. The solvent is removed in vacuo and the resulting thick mixture is diluted with CH2Cl2. This solution is washed three times with 1 N NaOH, then dried over MgSO 4, filtered and concentrated in vacuo. The crude product is purified by flash column chromatography (gradient of 1 to 5% EtOAc in heptane) to provide 6.2 g (98%) of 5- (4-chlorophenylsulfanyl) thiophene-2-carboxaldehyde. H-NMR (300 MHz, CDCl 3) d 7.13, 7.31-7.39, 7.63, 9.78. 5- (4-Chlorophenylsulfanyl) thiophene-2-carboxaldehyde (6.1 g, 24 mmol) is dissolved in a mixture of THF, tBuOH and water (3: 3: 1, 255 mL). 2-Methyl-2-butene (20.3 ml, 192 mmol) is added followed by KH2P04 (9.8 g, 72 mmol) followed by NaCl02 (80%, 8.17 g, 72.3 mmol). The mixture is stirred at rt for 2 hours. Aqueous KHS04 (0.5 M, 200 mL) is added and the organic solvents are removed in vacuo to provide an aqueous suspension of the product. The precipitate is collected by filtration, dissolved in 1 N NaOH and washed twice with ether. The aqueous solution is then acidified to pH < 2 with HCl and a precipitate forms. The precipitate is collected by filtration and washed with 0.5 M NaH2SO4 and then water. The solid is dried under vacuum to provide 5.7 g (87%) of 5- (4-chlorophenylsulfanyl) -thiophene-2-carboxylic acid. MS for C11H7CIO2S2, (IE) m / z: 269 (MH). "5- (4-Ciophenylsulfanyl) thiophene-2-carboxylic acid (290 mg, 1.07 mmol) is added to 10 mL of CH2Cl2 in a dry flask in an atmosphere The solution is treated with TEA (153 μ ?, 1.1 mmol) followed by bis (2-oxo-3-oxazolidinyl) phosphine chloride (280 mg, 1.1 mmol) and the reaction is stirred 1 h The mixture is treated with (2R) -7-aza- [2.2.1] -amine (212 mg, 1.0 mmol) in 2 mL of CH2Cl2 and the reaction is stirred 4 h at rt.The mixture is washed with 1 x. 10 mL saturated NaHCO 3, the organic phase is dried over anhydrous K 2 CO 3 and concentrated in vacuo to provide a residue The crude material is chromatographed on 25 g of silica gel (230-400 mesh) eluting with 35% EtOAc / hexane The appropriate fractions are combined and concentrated to provide the intermediate e o- (1 S, 2R, 4R) - (+) - 2- { [5- (4-chlorophenylsulfanyl) thiophene-2-carbonyl] amine .}. -7-azabicyclo [2.2.1] heptane-7-tere-butyl carboxylate in the form of a residue. it is combined with 5 ml of HCl of 2 N methanolic acid in 5 ml of eOH in a flask under a nitrogen atmosphere. The reaction is heated in a 60 ° C bath for 2 h, cooled, and concentrated in vacuo to provide a residue. The residue is dissolved in 1 ml of IPA, diluted with 2 ml of diethyl ether and allowed to crystallize. The white solid is washed with ether and dried to provide 238 mg (59%) of Example 8 as a white solid. MS for C17H17CIN20S2, (IE) m / z: 364 (M) +.

EXAMPLE 9 N-K1 S, 2R, 4f?) - 7-azabicyclo2.2.nhept-2-n-5-methylthiophen-2-carboxamide hydrochloride: 5-Methyl-thiophene-2-carboxylic acid (156 mg, 1.1 mmol) is coupled with (2R) -7-aza- [2.2.1] -amine (212 mg, 1.0 mmol) and deprotected as described in Example 1 without critical variations to provide 199 mg (73%) of Example 9 in the form of a white solid. HRMS (BAR) calculated for C12H16N2OS + H: 237.1062, found 237.1065 for (M + Hf.

EXAMPLE 10 N-K1 S, 2R, 4R) -7-azabicyclo2.2.nhept-2-n-5-pyridin-2-ylthiophene-2-carboxamide hydrochloride: H-CI 5- (Pyridin-2-yl) thiophene-2-carboxylic acid (226 mg, 1.1 mmol) is coupled with (2F ^) - 7-aza- [2.2.1] - Amine (212 mg, 1.0 mmol) and deprotect as described in Example 1 without critical variations to provide 243 mg (65%) of Example 10 as a white solid. HRMS (BAR) calculated for C 16 H 17 N 3 OS + H: 300.1 170, found 300.1 172 for (M + Hf.

EXAMPLE 11 N-K1 S, 2R, 4?) - 7-azab-cyclor2.2.nhept-2-n-5- (3-nitrophenin-2-furamide hydrochloride: 5- (3-Nitrophenyl) furan-2-carboxylic acid (226 mg, 1.1 mmol) is coupled with (2R) -7-aza- [2.2.1] -amine (212 mg, 1.0 mmol) and deprotected as described in Example 1 without critical variations to provide 232 mg (64%) of Example 11 in the form of a white solid. HRMS (BAR) calculated for C17H17N3O4 + H: 328.1297, found 328.1292 for (M + H) +.

EXAMPLE 12 N-KI S, 2R, 4?) - 7-azabicyclochloride.2.2.nhept-2-in-5- (4-nitrophenol-2-furamide hydrochloride: H-CI 5- (4-Nitrophenyl) furan-2-carboxylic acid (226 mg, 1.1 mmol) is coupled with (2R) -7-aza- [2.2.1] -amine (212 mg, 1.0 mmol) and deprotected as described in Example 1 without critical variations to provide 256 mg (71%) of Example 12 as a white solid. HRMS (BAR) calculated for C 7Hi7N304 + H: 328.1297, found 328.1303 for (M + H) +.

EXAMPLE 13 N-M1 S, 2 4f?) - 7-azabicyclo2.2.11hept-2-in-5- (4-chlorophenyl) -2-furamide hydrochloride: 5- (4-Chlorophenyl) furan-2-carboxylic acid (226 mg, 1.1 mmol) is coupled with (2R) -7-aza- [2.2.1] -amine (212 mg, 1.0 mmol) and deprotected as described in Example 1 without critical variations to provide 10 mg (31%) of Example 13 as a white solid. MS for C17H17CIN2O2, (IE) m / z: 316 (M) +.

EXAMPLE 14 N-K1 S, 2R hydrochloride. 4ffl-7-azabicyclo2.2.nhept-2-n-5-chlorothiophen-2-carboxamide: 5-Chlorothiophen-2-carboxylic acid (226 mg, 1.1 mmol) is coupled with (2R) -7-aza- [2.2.1] -amine (212 mg, 1.0 mmol) and deprotected as described in Example 1 without critical variations to provide 357 mg (46%) of Example 14 as a white solid. MS for C11H14CIN2OS, (IE) miz. 256 (M) +.

EXAMPLE 15 N-fdS, 2R, 4?) - 7-azabicyclochloro.2.2nhept-2-in-5-f2-nitrophenyl) -2-furamide hydrochloride: 5- (2-Nitrophenyl) furan-2-carboxylic acid (226 mg, 1.1 mmol) is coupled with (2R) -7-aza- [2.2.1] -amine (212 mg, 1.0 mmol) and deprotected as described in Example 1 without critical variations to provide 243 mg (63%) of Example 5 as a yellow solid. Anal. cale, for C17H17N304-HCI: C, 56.13; H, 4.99; N, 11.55 with 0.34% of H20. Found: C. 55.84; H, 5.09; N 11.38.

EXAMPLE 16 N-K S, 2R, 4R) -7-azabicyclochloride2.2.11hept-2-iH-5- (4-aminophenyl) -2-furamide dihydrochloride: Example 12 (120 mg, 0.33 mmol) is dissolved in EtOH (20 mL) with 2 M NaOH (0.17 mL, 0.34 mmol) and hydrogenated at 35 psi for 2 h. The catalyst is removed by filtration and the mother liquor is concentrated to an oil. The yellow oil is dissolved in 1 M HCl in MeOH (10 mL) and stirred at rt until the next morning. The volatile components are removed in vacuo and the blue-green residue is treated with IPA (2 ml), forming a yellow precipitate. The thick solution is filtered and the cake is washed with ether, yielding 104 mg (85%) of Example 16 in the form of an off-yellow solid. HRMS (BAR) calculated for Ci7H19N302 + H: 298.1555, found 298.1554 for (M + H) +.

EXAMPLE 17 N-K1 S, 2R, 4 /?) - 7-azabicyclo2.2.11hept-2-n-5- (2-fluorophenyl) -2-furamide hydrochloride: 5- (2-Fluorophenyl) -2-furoic acid (140 mg, 0.68 mmol) is dissolved in DMF (5 mL) with DIEA (0.36 mL, 2.05 mmol) and (2R) -7-aza- [2.2.1] Amine (159 mg, 0.75 mmol) and cooled to 0 ° C. HATU (259 mg, 0.68 mmol) is added in portions and the reaction is stirred until the next morning at ta allowing the ice bath to melt. The volatile components are removed in vacuo and the crude material is chromatographed on 25 g of silica embedded in a thick mixture, flowing with 40% EtOAc / hexane. The appropriate fractions are collected and concentrated. The residue is dissolved in 1 M HCl in MeOH (5 mL) and stirred until the next morning. The volatile components are removed in vacuo and the residue treated with IPA (2 ml). The resulting precipitate is isolated by filtration, rinsed with Et20 and dried to give 11 mg (48%) of Example 17 as a white solid. HRMS (BAR) calculated for C17H17FN202 + H: 301.1352, found 301.1343 for (M + H) +.

EXAMPLE 18 N-Y1 S, 2R, 4R) -7-azabicyclo1.2.2nhept-2-yl-5- (3-fluorophenyl) -2-furamide hydrochloride: 5- (3-Fluorophenyl) -2-furoic acid (140 mg, 0.68 mmol) is coupled with (2R) -7-aza- [2.2.1] -Amine (159 mg, 0.75 mmol) and subsequently deprotected as described. described in Example 17 without critical variations to provide 102 mg (45%) of Example 18. HRMS (BAR) calculated for Ci7H17FN202 + H: 301.1352, found 301.1353 (M + H) +.

EXAMPLE 19 N-K1S, 2R, 4R) -7-azabicyclo2.2.nhept-2- -5- (4-fluorophenyl) -2-furamide hydrochloride: 5- (43-Fluorophenyl) -2-furoic acid (140 mg, 0.68 mmol) is coupled with (2R) -7-aza- [2.2.1] -Amine (159 mg, 0.75 mmol) and subsequently deprotected as described. described in Example 17 without critical variations to provide 150 mg (66%) of Example 19. HRMS (BAR) calculated for Ci7H17FN202 + H: 301.1352, found 301.1357 (+ H) +.

EXAMPLE 20 N-K1S Hydrochloride. 2R. 4ffl-7-azabicichlor2.2.nhept-2-in-5- (4-methyphenylV 2 -furamide: 5- (4-Methylphenyl) -2-furoic acid (138 mg, 0.68 mmol) is coupled with (2R) -7-aza- [2.2.1] -amine (159 mg, 0.75 mmol) and subsequently deprotected as described. described in Example 7 without critical variations to provide 147 mg (65%) of Example 20. HRMS (BAR) calculated for C 16 H 17 N 3 OS + H: 300.1 170, found 300.1165 (M + H) +.

EXAMPLE 21 N-fdS, 2R, 4R) -7-azabicyclo2.2.nhept-2-n-2-phenyl-1, 3-thiazole-5-carboxamide dihydrochloride: 2-Phenyl-1,3-thiazole-5-carboxylic acid (140 mg, 0.68 mmol) is coupled with (2R) -7-aza- [2.2.1] -Amine (159 mg, 0.75 mmol) and subsequently deprotected as described in Example 17 without critical variations to provide 138 mg (55%) of Example 21. HRMS (BAR) calculated for C 16 H 17 N 3 OS + H: 300.1 170, found 300.1 65 (M + H) +.

EXAMPLE 22 N-K1 S, 2R, 4R) -7-azabicyclo2.2.nhept-2-yl] -2- (2-fluorophenyl) -1,3-thiazole-5-carboxamide hydrochloride: 2- (2-Fluorophenyl) -1,3-thiazole-5-carboxylic acid (167 mg, 0.68 mmol) is coupled with (2R) -7-aza- [2.2.1] -amine (159 mg, 0.75 mmol) and subsequently deprotected as described in Example 17 without critical variations to provide 176 mg (66%) of Example 22. HRMS (BAR) calculated for C1SH16FN30S + H: 318.1076, found 318.1080 (M + H) +.

EXAMPLE 23 N-1S Hydrochloride. 2R, 4 /?) - 7-azabicyclo2.2.1Ihept-2- -5-phenylfl-2-furamide: A solution of 5-bromo-furan-2-carba Idehyde (1.08 g, 6.16 mmol, 1 eq), phenylboronic acid (0.90 g, 7.39 mmol, 1.1 eq), tetrabutylammonium bromide (1.99 g, 6.16 mmol, 1 eq), Palladium acetate (30 mg, 0.012 mmol, 0.02 eq), K2C03 (2.13 g, 15.4 mmol, 2.5 eq) in water (10 ml) is stirred under nitrogen until the next morning. The reaction is diluted with 40 ml of water and extracted with EtOAc (3 x 100 ml). The organic phases are combined and stirred with charcoal for 30 minutes, then dried over MgSO4 and filtered. The solvent is removed under reduced pressure to provide an oil. The intermediate is purified by chromatography on silica gel using a 40 M Biotage Flash column (10% EtOAc / heptane). Yield 70.1%. HRMS (BAR) calculated for CnH802 + H: 173.0603, found 173.0607. To a solution of the intermediate (0.650 g, 3.78 mmol, 1 eq) in water (5.5 ml), t-BuOH (18.0 ml) and THF (18.0 ml) is added 2-methyl-2-butene (3.2 ml, 30.2 mmol). , 8 eq), potassium phosphate monobasic (1.54 g, 11.3 mmol, 3 eq), then NaCl02 (1.03 g, 1.3 mmol, 3 eq) in that order. After four hours, the reaction is completed and diluted with 1 N NaOH (100 ml). The aqueous solution is extracted with ether (2 x 100 mL) and the aqueous phase is acidified with conc. HCl. The resulting solution is extracted with CH2Cl2 (3 x 100 mL). The organic phases are dried with MgSO 4 and the solvent is removed. 5-phenyl-2-phloric acid is purified by chromatography on silica gel using a 40 M Biotage flash column (10% EtOAc / 1% formic acid / heptane). The solid remaining after removing the solvent is filtered and recrystallized from EtOH and water to provide the acid as a white crystalline solid (0.499 g, 70.2%). HRMS (BAR) calculated for CnH8N3 + H: 189.0473, found 189.0403. 5-phenyl-2-furoic acid (167 mg, 0.68 mmol) is coupled with (2R) -7-aza- [2.2.1] -amine (59 mg, 0.75 mmol) and subsequently deprotected as described in Example 17 without critical variations to provide 92 mg (42%) of Example 23. HRMS (BAR) calculated for C17H 8N202 + H: 283.1446, found 283.1452 (M + H) +.

EXAMPLE 24 N-K1 S, 2R, 4ft) -7-azabicyclo2.2.11hept-2-n-5-bromo-2-furamide hydrochloride: 2-Bromofuroic acid (143 mg, 0.75 mmol) is coupled with (2R) -7-aza- [2.2.1] -Amine (159 mg, 0.75 mmol) and subsequently deprotected as described in Example 17 without critical variations to give 166 mg (69%) of Example 24. HRMS (BAR) calculated for CnH ^ BrNzOa + H: 285.0239, found 285.0241 (M + H) +.

EXAMPLE 25 N-K1 S, 2R, 4ffl-7-azabicyclo2.2.11hept-2-yl-1-5-phenyl-1,3-oxazole-2-carboxamide hydrochloride: HCI Combine 5-phenyl-1,3-oxazole-2-carboxylic acid ethyl ester (217 mg, 1.0 mmol) with (2R) -7-aza- [2.2.1] -amine (212 mg, 1.0 mmol) in EtOH absolute (5 ml) in a sealed tube. The reaction is heated at 100 ° C for 10 days. The volatile components are removed in vacuo and the crude material is chromatographed on 25 g of silica embedded in a thick mixture eluting with 30% EtOAc / hexane. The appropriate fractions are collected and concentrated to give a white solid. The solid is treated with 1 M HCl in MeOH (10 mL) and stirred until the next morning. The volatile components are removed in vacuo and the resulting foam is triturated with E † .20 (3 mL). The thick mixture is filtered and the cake is washed with ether and dried until the next morning, yielding 153 (48%) of Example 25. HRMS (BAR) calculated for Ci 6 H 17 N 302 + H: 284.1399, found 284.1391 (M + H) + .

EXAMPLE 26 N-r (1S, 2R, 4?) - 7-azabicyclo2.2.nhept-2-in-5-phenylisoxazole-3-carboxamide: See Vaughan, W.R .; Spencer, J.L., J. Org. Chem .; 25; 1960; 1160-1164) for the synthesis of 5-phenylisoxazole-3-carboxylic acid. The amide is obtained using coupling conditions that are described herein to provide Example 26.

Materials and procedures to determine nAChR agonist activity at Cell based assay to measure the CEg of nAChR a7 agonists Construction and expression of the 5HT3R a7 receptor: The cDNA encoding the N-terminal 201 amino acids of the nAChR containing the ligand-binding domain of the ion channel was fused to the cDNA encoding the mouse 5HT3 receptor pore-forming region as describes Eisele JL, and cois., Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities, Nature (1993), December 2; 366 (6454): 479-83, and modified by Groppi et al., WO 00/73431. The chimeric ion channel 5HT3 al was inserted into pGS175 and pGS179 containing the resistance genes for G-418 and hygromycin B respectively. Both plasmids were transfected simultaneously into SH-EP1 cells and cell lines that were resistant to both G-418 and hygromycin B were selected. Cell lines expressing the chimera ion channel were identified for their ability to bind a-bungarotoxin on their cellular surface. The cells with the highest amount of a-bungarotoxin fluorescent binding were isolated using a Fluorescence Activated Cell Sorter (FACS). Cell lines stably expressing 5HT3 to the chimeric were identified by measuring binding to fluorescent a-bungarotoxin after culturing the cells in minimal essential medium containing non-essential amino acids supplemented with 10% fetal bovine serum, L-glutamine, 100 units / ml of penicillin / streptomycin, 250 ng / mg of fungizone, 400 pg / ml of hygromycin B and 400 g / ml of G-4 8 at 37 ° C with 6% C02 in a standard mammalian cell incubator for at least 4 weeks in continuous culture.

Assay of chimeric 5HTg a7 receptor activity To assess the activity of the aH 5 3 a3 channel, cells expressing the channel were plated in each well of a 96- or 284-well plate (Corning # 3614) and cultured at confluence before of the essay. On the day of the assay, cells were loaded with a 1: 1 mixture of Calcium Green 1 2 mM, AM (Molecular Probes) dissolved in anhydrous DMSO and 20% pluronic F-127 (Molecular Probes). This solution was added directly to the growth medium of each well to achieve a final concentration of 2 μ ?. The cells were incubated with the dye for 60 minutes at 37 ° C and then washed with a modified version of Earle's balanced salt solution (MMEBSS) as described in WO 00/73431. The ionic conditions of the MMEBSS were adjusted to maximize the flow of calcium ion through the 5HT3 a7 ion channel as described in WO 00/73431. The activity of the compounds in the 5HT3 a7 ion channel was analyzed in FLIPR. The instrument was adjusted with an excitation wavelength of 488 nanometers using 500 milliwatts of power.

The fluorescence emission was measured above 525 nanometers with an appropriate F-stop to maintain a maximum signal-to-noise ratio. The agonist activity of each compound was measured by directly adding the compound to the cells expressing the 5HT3 ion channel at and measuring the resulting increase in intracellular calcium caused by the agonist-induced activation of the chimeric ion channel. The assay is quantitative in such a way that the increase dependent on the concentration of intracellular calcium is measured as a function of the change dependent on the fluorescence concentration of Calcium Green. The effective concentration needed for a compound to cause a maximum 50% increase in intracellular calcium is called EC50. The examples (1S, 2R, 4R) of the present invention have CE5o values between 29 nM and 11,421 nM.

Binding constants: Another way to measure nAChR agonist activity is to determine the binding constants of a potential agonist in a competitive binding assay. For nAChR agonists there is a good correlation between the functional CE50 values using the 5HT3R ion channel as a target for drugs and the binding affinity of the compounds to the nAChR to the endogenous.

Membrane preparation Male Sprague-Dawley rats (300-350 g) were killed by decapitation and the brains were quickly dissected (whole brain minus the cerebellum), weighed and homogenized in 9 volumes / g wet weight of sucrose 0.32 M Freezing using a rotating mortar set to 50 (10 pulses up and down). The homogenate is centrifuged at 1,000 x g for 10 minutes at 4 ° C. The supernatant is collected and centrifuged at 20,000 x g for 20 minutes at 4 ° C. The resulting precipitate is resuspended at a protein concentration of 1-8 mg / ml. Aliquots of 5 ml of homogenate are frozen at -80 ° C until they are needed for the assay. On the day of the assay, the aliquots are thawed at rt and diluted with Kreb's solution, 20 mM Hepes buffer at pH 7.0 (at ta) containing 4.16 mM NaHCO3, KH2P04) 127 mM NaCl, 5.36 mM KCI, 1.26 mM CaCl2 and MgCI2 0.98 mM so that 25-150 pg of protein per test tube is added. Proteins are determined by the Bradford method (Bradford, M.M., Anal. Biochem., 72, 248-254, 1976) using bovine serum albumin as standard.

Binding Assay For saturation studies, 0.4 ml of homogenate is added to test tubes containing buffer and various concentrations of radioligand and incubated in a final volume of 0.5 ml for 1 hour at 25 ° C. Non-specific binding was determined in tissues incubated in parallel in the presence of 0.05 ml of MLA for a final concentration of 1 μ ?, added before radioligand. In competitive studies, the drugs are added in increasing concentrations to the test tubes before the addition of 0.05 ml of [3 H] -MLA to obtain a final concentration of 3.0 to 4.0 nM. Incubations are terminated by rapid vacuum filtration with Whatman GF / B glass filter paper on a 48-well Brandel cell harvester. The filters are previously embedded in 50 mM Tris HCI at pH 7.0 - 0.05% polyethyleneimine. The filters are rapidly washed twice with 5 ml aliquots of cold 0.9% saline and then the radioactivity is measured by liquid scintillation spectrometry.

Analysis of the data In the competitive binding studies, the inhibition constant (K) was calculated from the concentration-dependent inhibition of the binding of [3 H] -MLA obtained from a non-regression adjustment program. linear according to the Cheng-Prussoff equation (Cheng, YC and Prussoff, WH, Biochem. Pharmacol., 22, pages 3099-3108, 1073). Hill coefficients were obtained using non-linear regression (GraphPad Prism dose sigmoid response with variable slope).

Claims (33)

NOVELTY OF THE 1NVENTION CLAIMS

1. - A compound of Formula I: Formula I wherein the stereochemistry of the 7-azabicyclo [2.2.1] heptane ring is 1S, 4R and the nitrogen substituent of carbon C-2 has the orientation exo and is R; X is O or S; R † is H, alkyl, halogenated alkyl, cycloalkyl or aryl; R2 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl or aryl; W is -Q, -C = C-Q or -C C-Q; Q is a heteroaromatic cyclic moiety where the heteroatoms may be 1-3 atoms that are selected from oxygen, sulfur or nitrogen or the following structures: wherein U is -O-, -S- or -N (R3) -; V and Y are independently selected from = N- y = C (R5) -; Z is = N- or = CH-; R3 is H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, R7, Rg, aryl, -C (0) -alkyl, -C (0) -cycloalkyl, -C (0) -heterocyanoalkyl, -C (0) -halogenated alkyl, -C (0) -halogenated cycloalkyl, -C (0) -halogenated heterocycloalkyl, -C (0) -substituted alkyl, -C (0) ) -substituted cycloalkyl, -C (0) -substitutedheterocycloalkyl, -C (0) -R7, -C (0) -R9 or -C (0) -aryl; Each R 4 is independently H, alkyl or substituted alkyl; Each R5 is independently. H, F, Cl, Br, I, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactamaheterocycloalkyl, aryl, -OR8l -SR8, -N (R8) 2, -C (0) R8, -C (S) R8, -C (0) OR8, -C (0) N (R8) 2, -NRBC (0) R8, -S (0) 2N (R8) 2, -OS (0) 2R8, -S (0) 2R8, -S (0) R8, -NR8S (0) 2R8) -N (R8) C (0) N (R8) 2, -CN, -N02, R7 or R9; Re is H, alkyl, an amino protecting group or an alkyl group having 1-3 substituents that are selected from F, Cl, Br, I, -OH, -CN, -NH2, -NH (alkyl) or -N (alkyl) 2; R7 is 5-membered heteroaromatic monocyclic moieties containing within the ring 1-3 heteroatoms which are independently selected from the group consisting of = N-, -N (R20) -, -O- and -S- and having 0-1 substituent selected from Ri and having in addition 0-3 substituents that are independently selected from F, Cl, Br or I, or R7 is 9-membered fused ring moieties having a 6-membered ring condensed with a 5-membered ring which includes the formula where G-t is O, S or NR20, wherein G is C (R14) or N, and each G2 and G3 is independently selected from C (R-i4) 2, C (Ri4), O, S, N and N (R2o), with the proviso that G2 and G3 are not both simultaneously O or S or wherein G is C (R) or N and each G2 and G3 is independently selected from C (Ri4) 2, C (Ri4), O, S, N and N (R2o), each 9-membered bicyclic ring having 0 -1 substituent selected from R17 and 0-3 substituents that are independently selected from F, Cl, Br or I, wherein the R7 moiety binds to other substituents as defined in formula I at any position of any of the rings as valence allows; Each R8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, R7, Rg, phenyl optionally substituted with 1-4 substituents that are independently selected from F, Cl , Br, 1, 13 and R15 or naphthyl optionally substituted with 1-4 substituents that are independently selected from F, Cl, Br, I, R-I3 and R15; R9 is 6-membered heterocyclic monocyclic moieties containing within the ring 1-3 heteroatoms that are selected from = N- and having 0-1 substituent selected from R17 and 0-3 substituent (s) being selected (n) independently of F, Cl, Br or I or R9 is 10-membered heteroaromatic bicyclic moieties containing within one or both rings 1-3 heteroatoms selected from = N- including, but not limited to, quinolinyl or isoquinolinyl, each moiety having of the 10-membered fused ring 0-1 substituent selected from R17 and 0-3 substituent (s) selected independently from F, Cl, Br or I, wherein the R9 moiety binds to other substituents as defined in formula I at any position of each ring as allowed by the valence; Each R 0 is independently H, alkyl, cycloalkyl, heterocycloalkyl, R 7, R g, alkyl substituted with 1 substituent selected from R 13, cycloalkyl substituted with 1 substituent selected from R 13, heterocycloalkyl substituted with 1 substituent selected from R 13, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl or phenyl optionally substituted with 1-4 substituents that are independently selected from F, Cl, Br, I, R13 and R 5; Each R-p is independently H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl or halogenated heterocycloalkyl; R12 is alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SR11, -S (0) 2Rn, -S (0) Rn, -OS (0 ) 2R11 f -N (Rn) 2 > -C (0) Rn, -C (S) Rn, -C (0) ORn, -NO2, -C (0) N (Rn) 2, -CN, -NRnC (0) Rn, -NRnC (0) N (Rn) 2, -S (0) 2 (Rn) 2 or -NRnS (0) 2Rii; R13 is -ORn, -SRn, -SORn, -S02Rn, -OSOzRn, -N (Rn) 2) -C (0) R11 f -C (0) ORn, -C (S) Rn, -C (0) N (Rn) 2, -N02, -CN, -CF3, -NRnC (0) Rn, -NR1C (0) N (R1) 2, -S (0) 2N (Rn) 2 or -NRuSÍO ^ Rn " Each Ru is independently H, alkyl, cycloalkyl, halogenated alkyl or halogenated cycloalkyl, R17 is alkyl, cycloalkyl or heterocycloalkyl, each optionally substituted with 1-4. substituents that are independently selected from F, Cl, Br, I, -N02, -CN, -OR 6, -SR16, -S (0) 2Ri6, -S (0) Ri6, -OS (0) 2Ri6, -N (Ri6) 2, -C (0) R16, -C (S) R16, -C (0) OR16.-C (0) N (R16) 2, -NR16C (0) R16, -NR16C (0) N (Rn6) 2, -S (0) 2N (R16) 2 and -NR16S (0) 2R16 and cycloalkyl and heterocycloalkyl are optionally further substituted with = 0 or = S; R 9 is alkyl, cycloalkyl, heterocycloalkyl, phenyl or naphthyl, each optionally substituted with 1 -4 substituents that are independently selected from F, Cl, Br, I, -CN, -N02, -OR16, -SRi6, -S (0) 2R16, -S (0) R16 > -OS (0) 2Rie, -N (R16) 2, -C (0) R16, -C (S) R16, -C (0) OR16, -C (0) N (Ri6) 2, -NR16C (0 ) R16, -NR16C (0) N (R16) 2, -S (0) 2N (R16) 2 or -NRi6S (0) 2R16 and cycloalkyl and heterocycloalkyl are optionally further substituted with = 0 or = S; R20 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, -S02Rs, or phenyl having 1 substituent selected from R-i2 and further having 0-3 substituents that are independently selected of F, Cl, Br or I; or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, further characterized in that X is O.

3. The compound according to claim 2, further characterized in that Ri is H, alkyl or cycloalkyl and wherein R2 is H, alkyl , substituted alkyl, cycloalkyl, halogenated alkyl or aryl.

4. The compound according to claim 3, further characterized in that W is Q.

5. The compound according to claim 4, further characterized in that each R4 is independently H, lower alkyl or substituted lower alkyl.

6. The compound according to claim 5, further characterized in that Rs is an amino protecting group.

7. The compound according to claim 5, further characterized in that R6 is H or lower alkyl optionally substituted with up to 3 substituents that are independently selected from F, Cl, Br, I, -OH, -CN, -NH2, - NH (alkyl) or -N (alkyl) 2.

8. The compound according to claim 7, further characterized in that at least one R4 is H and one R4 is H or lower alkyl optionally substituted with 1 substituent selected from -OR10, -SR10 > -S (O) R10, -S (0) 2Rio, -OS (0) 2Rio, -NR10R10, -C (O) R10, -C (O) ORi0, -C (S) Rio, -C (0) NR10Rio, -CN, -NR10C (O) R10, ~ NR10C (0) NR10Rio, -S (0) 2NRi0Rio, -NR 0S (0) 2Rio, -N02, or phenyl optionally substituted with up to 4 substituents which are independently selected from F, Cl, Br, I, R13 and R15 with the proviso that when lower alkyl is optionally substituted, said lower alkyl is further optionally substituted with up to 3 substituents which are independently selected from F, Cl, Br and I, in which is H, lower alkyl or halogenated lower alkyl.

9. The compound according to claim 8, further characterized in that Ri, R2 and each R are H.

10. The compound according to claim 9, further characterized in that Ri is H or lower alkyl and wherein R2 is H or lower alkyl.

11. The compound according to claim 10, further characterized in that Q is (a).

12. The compound according to claim 1, further characterized in that (a) is thiophen-2-yl, furan-2Hlo, 1,3-thiazol-5-yl or 1,3-oxazol-2-yl,, 3-thiazoI-2-yl, 1,3,4-oxadiazol-2-yl, 1,3-oxazoI-5-yl, 1 H-pyrrol-2-yl or 1, 2,4-oxadiazol-5-yl, optionally substituted on carbon with H, F, Cl, Br, I, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactamheterocycloalkyl, aryl, -OR8, -SR8) -N (R8) 2, -C (0) Rs, -C (S) R8, - C (0) OR8, -C (0) N (R8) 2, -NR8C (0) R8, -S (0) 2N (R8) 2, -OS (0) 2R8, -S (0) 2R8, - S (0) R8, -NR8S (0) 2R8, -N (R8) C (0) N (R8) 2 > -CN, -N02, R7 or R9; and further optionally substituted in nitrogen with alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, R7I Rg, arite, -C (0) -alkyl, -C (0) - cycloalkyl, -C (0) -heterocycloalkyl, -C (0) -halogenated alkyl, -C (0) -halogenated cycloalkyl, -C (0) -halogenated haloalkyl, -C (0) -alkyl substituted, -C (0) -substituted cycloalkyl, -C (0) -substituted cycloalkyl, -C (0) -R, -C (0) -R9 or -C (0) -aryl.

13. The compound according to claim 12, further characterized in that the compound is N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-bromo- 2-thiophenecarboxamide; (+/-) exo-N- [7-azabicyclo [2.2.1] hept-2-yl] -5-bromo-2-thiophenecarboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (methylthio) thiophene-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenylthiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenyl) thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-ü] -5 - [(4-chlorophenyl) thio] thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-methyltiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-pyridin-2-ylthiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-nitrophenyl) -2-furamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-nitrophenyl) -2-furamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenyl) -2-furamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-chlorothiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7- azabicyclo [2.2.1] hept-2-yl] -5- (2-nitrophenyl) -2-furamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenyl) -2-furamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenyl) -2-furamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenyl) -2-furamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenyl) -2-furamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylphenyl) -2-furamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-bromo-2-furamide; N - [(1 S, 2R, 4R) -7-azabicicio [2.2.1] hept-2-yl] -2-phenyl'-1,3-tazo! -5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-fluorophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicic or [2.2.1] hept-2-yl] -5-phenyl-2-furamide; or N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-y!] - 5-phenyl-1,3-oxazole-2-carboxamide; or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 12, further characterized in that the compound is N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4- chlorophenyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 ^) - 7-azabicyclo [2.2.1] hept-2-yl] -2,3'-bithiophen-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-n-trophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-nitrophenol) -thiophen-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -4-phenyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-benzyloxyphenyl) thiophene-2-carboxamide; N - [(1 S, 2R, 4tf) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-benzyloxyfenii) thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoro-4-benzyloxyphenyl) thiophene-2-carboxamide; 5- (2-aminophenyl) -N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-pyridin-3-yl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5'-methyl-2,2'-bithiophen-5-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5'-chloro-2,2'-bithiophen-5-carboxamide; N - [(1 S, 2R, 4:?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-nitro-thiophene-2-carboxamide; 5- (aminomethyl) -N - [(1 S, 2R, 4R) -7-azabicicio [2.2.1] hept-2-yl] -5-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-cyano-thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-methoxy-thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] - [2,2 '] -bitiofen-5-carboxamide; N - [(1 S, 2f ?, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-acetyl thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (phenylisulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-phenyl-thiophene-2-carbothioamide; N - [(1S, 2 /? 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-acetamidophenyl) thiophene-2-carboxamide; N - [(1 S, 2 4 /?}. -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-acetamidophenyl) -thiophen-2-carboxamide; N - [(1 S , 2 / ?, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-acetamidophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 ^ ) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoroacetamidophenyl) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4f?) - 7-azabicyclo [ 2.2.1] hept-2-yl] -5- (3-trifluoroacetamidophenyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicicio [2.2.1] hept-2-il ] -5- (4-trifluoroacetamidophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methanesulfonylamino-phenyl) ) -thiophene-2-carboxamide; N - [(1 S, 2fi, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methanesulfonylaminophenyl) -thiophene-2-carboxam da; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methanesulfonylaminophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4tf) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoromethanesulfonylaminophenyl) -thiophen-2-carboxamide; N - [(1S, 2R, 4R ) -7-azabicyclo [2.2.1] hept-2-yl3-5- (3-trifluoromethanesulfonylaminophenyl) -thiophen-2-ca rboxamide; N - [(1 S, 2f ?, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoromethanesulfonylamino-phenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-difluoroacetamidophenyl) -thiophene-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-difluoroacetamidophenyl) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-difluoroacetamidophenyl) -thiophen-2-carboxamide; N - [(1 S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-carbamoylphenyl) -thiophen-2-carboxamide; N - [(1 S, 2 /? 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-carbamoylphenyl) -thiophen-2-carboxarriide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-carbamoylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-su] famoylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-sulfamoylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-suifamoylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-acetamidophenylisulfanyl) -thiophene-2-carboxamide; N - [(1S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-acetamidophenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-acetamidophenylsulfanyl) -iiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoroacetamidophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoroacetamidophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoroacetamidopheniisulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methanesulfonylaminophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methanesulfonylaminophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicicio [2.2.1] hept-2-yl] -5- (4-methanesulfonylaminophenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-ii] -5- (2-tnfluoromethanesulfonylaminophenesulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoromethanesulfonyl-lane-phenylsulfanyl) -thiophene-2-carboxamide gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoromethanesulfonylaminophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-difluoroacetamidophenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-difluoroacetamidophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-difluoroacetamidophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-carbamoylphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-carbamoylphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-carbamoylphenylsuifanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-sulfamoylphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-sulfamoylphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-sulfamoylphenylsulfanyl) -thiophene-2-carboxamide; N - [(S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxyphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxyphenylsuiphanyl) -thiophen-2-carboxamide; N - [(1S, 2, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxyphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-aminophenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-aminophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicynic [2.2.1] hept-2-yl] -5- (2-acetamidophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-acetamidophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ylJ-5- (4-acetamidophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (2-trifluoroacetamidophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoroacetamidophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (4-trifluoroacetamidophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methanesulfonylaminophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methanesulfonylaminophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methanesuifonilaminophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoromethanesulfonylaminophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoromethanesulfonylaminophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoromethanesulfonylaminophenoxy) -thiophene-2-carboxamide; N - [(1S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-difluoroacetamidophenoxy) -thiophene-2-carboxamide; N - [(1S, 2ft, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-difluoroacetamidophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-d-fluoroacetamidophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-carbamoylphenoxy) -thiophene-2-carboxamide; N - [(1S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-carbamoylphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4ft) -7-azabicyclo [2.2.1] hept-2-ii] -5- (4-carbamoylphenoxy) -thiophene-2-carboxarriide; N - [(1 S, 2ft, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-sulfamoylphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2ft, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-sulfamoylphenoxy) -thiophene-2-carboxamide; N - [(1S, 2 /? 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-sulfamoylphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4f?) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxyphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2ft, 4R) -7-azabicyc! Or [2.2.1] hept-2-yl] -5- (3-hydroxyphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2ft, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxyphenoxy) -thiophen-2-carboxamide; N - [(1 S, 2ft, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-aminophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2ft, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-aminophenoxy) -thiophene-2-carboxamide; N - [(1S, 2ft, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (3-cyanophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /:) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoromethylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2] hept-2-yl] -5- (3-trifluoromethyl-phenyl) -thiophen-2-carboxamide; N - [(1 S, 2 /? 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoromethylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-acetyl-phenol) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (3-acetylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-acetylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenyl) -thiophen-2-carboxamide; N - [(1 S, 2 /, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4í?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-morpholin-4-yl-phenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-morpholin-4-yl-pheny] -thiophen-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-morpholin-4-yl-pheny] -thiophen-2-carboxamide; N - [(1S, 2, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methyloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methyloxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoromethylphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoromethylphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4 /?) - 7 ~ azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoromethylphenoxy) -thiophene-2-carboxamide; N - [(S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-acetylphenoxy) -thiophene-2-carboxamide; N - [(1 S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-acetylphenoxy) -thiophen-2-carboxamide; N - [(1 S, 2fl, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-acetylphenoxy) -thiophen-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (3-cyanophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenoxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7- azabicyclo [2.2.1] hept-2-i!] - 5- (2-morfoin-4-yl-phenoxy) -thiophene- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-morpholin-4-yl-phenoxy) -thiophene-2 carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-morpholin-4-yl-phenoxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methyphenylsulfanyl) -iophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylphenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-trifluoromethylphenylsulfanyl) -thiophene-2-carboxamide N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-trifluoromethyl) phenylfluoryl) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-trifluoromethyiphenyl-sulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyolo [2.2.1] hept-2-yl] -5- (2-acetylphenylsulfanyl) -thiophene-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-acetylphenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-acetylphenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenyl-sulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-morpholin-4-yl-phenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azab.c.c! Or [2.2.1] hept-2-yl] -5- (3-morpholin-4-yl-phenylsulfanyl) -thiophen 2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-morpholin-4-yl-phenylsulfani) -thiophen 2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-4-yl) -thiophene-2-carboxamide; N - [(1 S, 2f ?, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylpyridin-4-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-methylpyridin-3-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylpyridin-2-yl) -thiophen-2-carboxamide; N - [(1 S, 2 /? 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxypyridin-4-yl) -thiophen-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-methoxypyridin-3-yl) -thiophen-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy-pyridin-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-4-yl) -thiophen-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-cioropyridin-3-yl) -thiophene-2-carboxamide; N - [(1 S, 2 / ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridn-2-yl) ) -thiophen-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridin-3-yl) -thiophen-2- carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridn-2-yl) -thiophen-2 -carboxamida; N - [(1 S, 2R, 4 /) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloropyridin-2-y!) - thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-4-yloxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-3-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4) -7-azab! Cyclo [2.2.1] hept-2-yl] -5- (pyridin-2-yloxy) -thiophene-2-carboxamide; N - [(S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylpyridin-4-yloxy) -iiophen-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (6-methy1-pyridin-3-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylpyridin-2-yloxy) -thiophene-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (2-methoxypyridin-4-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-methoxy-pyridin-3-yloxy) -thiophen-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxypyrdin-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 / ^ -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-4-yloxy) -thiophene-2-carboxamide; [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-3-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridin-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-4-yloxy) -thiophen-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-3-yloxy) -thiophen-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-cioropyridin-2-yloxy) -thiophene-2-carboxarnide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-cioropyridin-3-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloropyridin-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-4-ylsuiphenyl) -thiophene-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-3-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4fi) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-2-ylsulfanyl) -thiophen-2 -carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylpyridin-4-yisulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-methylpyridin-3-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylpyridin-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxypropyl-4-ylsufanyl) -thiophen 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-meioxypyridin-3-ylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxypyridin-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-4-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (6-cyoropyridin-3-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridin-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-4-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-3-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropyridin-2-ylsulfanyl) -thiophen-2 carboxamide; N - [(1 S, 2?, 4R) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (5-chloropyridn-3-ylsulfanyl) -thiophen -2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-2-ylsulfanyl) -thiophen-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloropyridin-2-ylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2 /? 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (thiophen-4-yl) -thiophen 2-carboxamide; N - [(1S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyltofen-2-yl) -thiophen-2-carboxamide; N - [(1 S, 2 /? 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxythiophen-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorotophen-2-yl) -thiophen-2 carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-i!] - 5- (2-methyl-5-tnfluoromethyl-2H-pyrazole-3-yl! l) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylthiazol-4-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (3-chlorophenyl) vinyl] -thiophene-2-carboxamide N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (2,4-difluorophenyl-sulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl-sulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chloro-4-fluoro-phenylsulfanyl) -thiophen-2-carboxam gives; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-! L] -5- (2,3-dichlorophenyl-sulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4,5-trichlorophenyl-sulfanyl) -thiophen-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenyl-sulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenoxy-thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxy-phenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxyphenyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoro-4-hydroxyphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (furan-4-ü) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylfuran-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy-furan-2-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorofuran-2-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (oxazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyloxazol-2-y!) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-meiox-oxazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro-oxazol-2-yl) -thiophen-2-carboxam gives; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (oxazol-5-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methyloxazol-5-yl) -thiophene-2-carboxamide; N - [(1 S, 2, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyoxazol-5-yl) -thiophen-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloro-oxazol-5-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (t-azo-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylthiazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxythiazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorothiazol-2-yl) -thiophene-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (thiazol-5-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methyltol-5-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxy-thiazol-5-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorothiazo! -5-y!) - thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylthiazole-2-ii) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxy-azazol-2-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicic or [2.2.1] hept-2-yl] -5- (4-chlorothiazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methyloxazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyoxazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloro-oxazol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - ([1, 3,4] thiadiazol-2-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyl [1, 3,4] thiadiazol-2-yl) -thiophen-2 -carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy [1, 3,4] thiadiazol-2-yl) -t- phen 2-carboxamide; N - [(1 S, 2 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro [1, 3,4] thiadiazol-2-yl) -thiophen-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - ([1, 3 ^] oxadiazol-2-yl) -thiophen-2-carboxamide; N - [(1 S, 2 ft 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyl [1 l3,4] oxadiazol-2-yl) -thiophen-2-carboxamide; N - [(1S, 2ft 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy [1, 3,4] oxadiazol-2-yl) -thiophen-2- carboxamide; N - [(1S, 2 / = ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro [1, 3,4] oxadiazol-2-yl) - thiophen-2-carboxamide; N - [(1 S, 2 ft 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (thiophen-4-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2 ft 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylthiophen-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2 ft 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxythiophen-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorothiophen-2-yloxy) -thiophen-2-carboxamide; N - [(1 S, 2 ft 4) -7-azabicynic [2.2.1] hept-2-yl] -5- (furan-4-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2 ft 4 R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (5-methylfuran-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2 ft 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy-furan-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2ft 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorofuran-2-yloxy) -thiophen-2-carboxamide; N - [(1 S, 2 ft 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (oxazol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2 ft 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyloxazo-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, AR) -7- azabicyclo [2.2.1Jhept-2-yl] -5- (5-methoxyoxazol-2-yloxy) -iophen-2-carboxamide; N- [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro-oxazol-2-yloxy) -thiophen-2-carboxamide; N - [(1 S, 2 4 /? 7-azabicyclo [2.2.1] hept-2-yl] -5- (oxazol-5-yloxy) -thiophene-2-carboxamide; N - [( 1 S, 2 / ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxazole-5-yloxy) -thiophen-2-carboxamide; N - [(1 S, 2R, R) -1-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyoxazol-5-yloxy) -thiophene-2-carboxamide; N- [ (1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloro-oxazole-5-y [oxy] -thiophen-2-carboxamide; N- [(1 S, 2, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (thiazol-2-yloxy) -thiophene-2-carboxamide; N - [( 1 S, 2 / ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylthiazol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2f ?, 4f?) -7-azabicyclo [2. 1] hept-2-yl] -5- (5-methoxythiazol-2-loxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorothiazol-2-yloxy) -thiophen-2-carboxamide; N - [(1 S, 2R , 4") - 7-azabicyclo [2.2.1] hept-2-yl] -5- (thiazol-5-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 ?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylthiazol-5-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7- azabicyclo [2.2.1] hept-2-i l] -5- (2-methoxythiazol-5-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (2-cyorothiazol-5-yloxy) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylthiazo! -2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxythiazol-2-yloxy) -thiophen-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorot-azozol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxazole-2-yloxy) -thiophen 2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyoxazol-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ylJ-5- (4-chloro-oxazol-2-yloxy) -thiophen-2-carboxamide N- [(1S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5 - ([1, 3,4] thiadiazol-2-yloxy) -thiophen-2 -carboxamide; N - [(1 S, 2 /? 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyl [1 l3,4] thiazol-2-yloxy] ) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (5-methoxy [1, 3,4] thiazole-2-yloxy! ) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro [1,3,3] tadriazole-2 -iloxy) -thiophen-2-carboxamide; N - [(1 S, 2fi, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - ([1> 3,4] oxadiazol-2-yloxy) -thiophen-2-yl carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyl [1, 3,4] oxadiazol-2-yloxy) -thiofen -2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy [1, 3,4] oxadiazol-2-yloxy) -thiophen-2 -carboxamide; N - [(1 S, 2 /? 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro [1, 3,4] oxadiazol-2-yloxy ) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (thiophen-4-ylsulfanyl) -thiophene-2-carboxamide; N - [(S, 2 /? 4) -7-azabicyclo [2.2.1] hept-2-ü] -5- (5-methyltiophen-2-ylsulfanyl) -thiophen-2 carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy-thiophen-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2 / ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorothiophen-2-yisulfanyl) -thiophen-2-carboxam gives; N - [(1 S, 2 /? 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (furan-4-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylfuran-2-ylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxyfuran-2-ylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorofuran-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1S, 2 /? 4R) -7- azabicyclo [2.2.1] hept-2-yl] -5- (oxazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyloxazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxyoxazol-2-ylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro-oxazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (oxazol-5-ylsulfanii) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methyloxazol-5-ylsulfanyl) -thiophene-2-carboxarnide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyoxazol-5-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloro-oxazol-5-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 / ¾) -7-azabicyclo [2.2.1] hept-2-yl] -5- (thiazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methylthiazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxythiazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chlorothiazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (thiazo! -5-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4 /?) - 7-azabicic! Or [2.2.1] hept-2-yl] -5- (2-meitylthiazol-5-ylsulfanyl) -thiophen-2-carboxamide; N - [(S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxythiazol-5-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorotyzazo! -5-ylsulfan-1) -iiophen-2 carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylthiazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxythiazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorothiazol-2-lysulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methyloxazol-2-ylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxy-oxazol-2-ylsulfanyl) -thiophen-2 -carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloro-oxazole-2-yisulfanyl) -thiophen-2 carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - ([1, 3,4] thiadiazol-2-ylsulfanyl) -thiophen-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methyl [1, 3,4] thiadiazole-2-ylsulfanyl) ) -thiophen-2-carboxamide; N - [(1 S, 2fi, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy [1,4] thiadiazol-2-ylsulfanyl) -thiophen-2 carboxamide; N - [(1 S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro [1, 3,4] thiadiazol-2-ylsulfanH) -thiofen -2-carboxamide; N - [(1 S, 2 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - ([1, 3,4] oxadiazol-2-ylsulfanyl) -thiophen 2-carboxamide; N - [(1 S, 2f ?, 4") - 7-azabicyclo [2.2.1] hept-2-ylJ-5- (5-methyl [1, 3,4] oxadiazol-2-ylsulfanyl) -thiophen 2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-methoxy [1, 3,4] oxadiazol-2-ylsulfanil ) -thiophen-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloro [1, 3,4] oxadiazol-2-ylsulfanyl) - thiophen-2-carboxamide; N - [(S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyrrol-2-yl) -thiophene-2-carboxamide; N - [(1 S, 2f ?, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (isothiazol-3-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (isoxazol-3-yl) -thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3 H -imidazol-4-yl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -4- (4-hydroxyphenylsulfanyl) -thiophen-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -4- (3-acetamidophenylsulfanyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7- azabicyclo [2.2.1] hept-2-yl] -4- (2-methanesulfonylaminophenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4- (pyridin-2-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4- (2-methylpyridin-4-yloxy) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4- (4-trifluoromethylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4- (2-acetylphenyl) -thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-chloro-5-phenyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.13hept-2-yl] -4-methyl-5-phenyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -4-cyano-5-phenyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-methoxy-5-phenyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicic! Or [2.2.1] hept-2-yl] -5-chloro-4-phenyl-thiophen-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5-methyl-4-phenyl-thiophene-2-carboxamide; N - [(1 S, 2 /? 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-cyano-4-phenyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-methoxy-4-phenyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-chloro-5-bromo-thiophen-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-chloro-5-methylsulfanyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-chloro-5-methyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -4-chloro-5-cyano-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-chloro-4-bromo-thiophene-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-y!] - 5-chloro-4-methylsulfanyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-chloro-4-methyl-thiophene-2-carboxamide; N - [(1 S, 2R, 4 / :?) - 7-azabicyclo [2.2.1] hept-2-I] -5-chloro-4-cyano-thiophen-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-ü] -5- (acetylamino) -furan-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5-trifluoromethyl-furan-2-carboxamide; N - [(1 S, 2R, 4 ^) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-bromophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-bromophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2,3-dichlorophenyl) -furan-2-carboxamide; N - [(1 S, 2 /? 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-dichlorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2,5-dichlorophenyl) -furan-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,6-dichlorophenyl) -furan-2-carboxamide; N - [(1 S, 2ft, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicicio [2.2.1] hept-2-yl] -5- (3,5-dichlorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-amino-2-fluorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-amino-2-fluorophenyl) -furan-2-carboxarriide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-amino-2-chlorophenol) -furan-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-amino-2-c-orophenyl) -furan-2-carboxamide; N - [(1 S, 2 /? 4 ^) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-aminophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxy-phenyl) -furan-2-carboxamide; N - [(1 S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoro-4-methylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoro-3-methoxy-phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoro-4-methoxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, AR) -1-azabicyclo [2.2.1] hept-2-yl] -5- (2 - [(methylsulfonyl) amino] phenyl) -furan-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3 - [(methylsulfonyl) amino] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4 - [(methylsulfonyl) amino] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (2 - ([(trifluoromethyl) sulfonyl-3-amino) phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3 - ([(trifluoromethyl) sulfonyl] amino) phenyl) -furan-2 carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2. 1] hept-2-yl] -5- (4 - ([(trifluoromethyl) sulfoniI] amino) phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2 - [(phenylsulfonyl) amino] pheny] -furan-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2. 1] hept-2-yl] -5- (3 - [(phenylsulfonyl) amino] phenyl) -furan-2-carboxamide; N - [(1 S, 2 /? 4?) - 7-azabicyclo [2.2.1] hept-2-N] -5- (4 - [(phenyl) phonyl) amino] phenyl) -furan-2 carboxamide; N - [(1 S, 2ft, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2 - [(methylamino) carbonyl] phenyl) -furan-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3 - [(methylamino) carbonyl] phenyl) -furan-2-carboxamide; N - [(1S, 2 / ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4 - [(methylamino) carbonyl] phenyl) -furan-2 -carboxamide; N - [(1S, 2ft, 4 /?) - 7-azab! Cycle [2.2.1] hept-2-yl] -5- (2 - [(methylamino) suifonyl] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3 - [(methylamino) sulfonyl] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4 - [(methylamino) sulfonyl] phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (methylamino) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (methylamino) phenyl] furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (methylamino) phenyl] furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (ethylamino) phenyl] furan-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (ethylamino) phenyl] furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (ethylamino) phenyl] furan-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-acetylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4fl) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-ace † ilphenyl) -furan-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-acetylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (methylthio) pheny] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (methylthio) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (methylthio) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (phenyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (phenyl) phenyl] -furan-2-carboxamide-; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (phenolito) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-phenoxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-phenoxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-phenoxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-anilinophenyl) -furan-2-carboxamide; N - [(1 S, 2f ?, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-anilinophenyl) -furan-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicic or [2.2.1] ept-2-i!] - 5- (4-anilinophenyl) -furan-2-carboxamide; N - [(1 S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (phenylthio) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-fluorophenyl) thio] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-fluorophenyl) thio] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-fluorophenyl) thio] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-chlorophenyl) thio] -furan-2-carboxamide; N - [(1 S, 2, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-chlorophenyl) thio] -furan-2-carboxamide; N - [(1S, 2, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-chlorophenyl) th] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-fluorophenoxy) tl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-fluorophenoxy) tl] -furan-2-carboxamide; N - [(1 S, 2 /? 4) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-fluorophenoxy) thio] -furan-2-carboxamide; N - [(1 S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-chlorophenoxy) thio] -furan-2-carboxy-tide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-chlorophenoxy) thio] -furan-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-chlorophenoxy) th] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-pyridin-2-yl-furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-pyridin-3-yl-furan-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicic or [2.2.1] hept-2-yl] -5-pyridin-4-yl-furan-2-carboxamide; N - [(1 S, 2 ft 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropyridin-2-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyridin-2-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyridin-2-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyridin-2-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyridin-3-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyridin-3-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyridin-3-yl) -furan-2-carboxamide; N - [(1 S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyridin-3-yl) -furan-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyridin-4-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropyridin-4-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chloropyridin-2-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloropyridin-2-yl) -furan-2-carboxamide; N - [(1 S, 2, 4R) -7-azabicynic [2.2.1] hept-2-yl] -5- (5-cyoropyridin-2-yl) -furan-2-carboxamide; N - [(1 S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-2-yl) -furan-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-3-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloropyridin-3-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-chloropindin-3-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-chloropyridin-3-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chloropyridin-4-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chloropyridin-4-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-piperidin-1-ylphenyl) -furan-2-carboxamide; N - [(1 S, 2, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-piperidin-1-ylphenyl) -furan-2-carboxam gives; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-piperidin-1-ylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hep-2-yl] -5- (2-morpholin-4-ylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-morpholin-4-ylpheni) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (4-morpholin-4-phenyl) -furan-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-pyrrolidin-1-ylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-pyrrolidin-1-phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-pyrrolidin-1-ylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2. 1] hept-2-yl] -5- [2- (1 H -pyrrol-2-yl) pheny] -furan-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (1 H -pyrrol-2-yl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (1 H -pyrrol-2-yl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (2-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (3-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (5-methyl-2-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (2-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (3-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (5-methyl-2-furyl) phenyI] -furan-2-carboxamide; N - [(1S, 2 /? 4R) -7- azabicyclo [2.2.1] hept-2-yl] -5- [4- (2-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (3-furyl!) Phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (5-methyl-2-furyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2ft, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (1, 3-thiazol-2-yl) phenyl] -furan- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (1, 3-thiazol-2-yl) phenyl] -furan-2- carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (1, 3-thiazol-2-yl) phenyl] -furan-2 carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (1, 3-oxazol-2-yl) phenyl] -furan-2- carboxamide; N - [(1S, 2ft, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (1, 3-oxazol-2-yl) phenyl] -furan-2- carboxamide; N - [(1S, 2ft, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (1, 3-oxazol-2-yl) pheny] -furan -2-carboxamide; N - [(1S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-isothiazol-5-ylphenyl) -furan-2-carboxamide; N - [(1S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-H] -5- (3-isothiazol-5-ylphenyl) -furan-2-carboxamide; N - [(1 S, 2 /? 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-isothiazol-5-ylpheni) -furan-2-carboxamide; N - [(1S, 2ft, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (1 H -indol-2-yl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (1 H -indole-3-yl) phenyl] -furan- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (1 H -indol-5-yl) -furan-2-carboxamide; N - [(1 S, 2 /? 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (1 H -indol-6-yl) -furan-2-carboxamide; N - [(1S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenyl) -furan-2-carboxamide; N - [(1S, 2ft, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl) -furan-2-carboxamide; N - [(S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-bromophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (trifluoromethyl) -phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (trifluoromethyl) -phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-difluorophenyl) -furan-2-carboxamide; N - [(1S, 2 / = ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,5-difluorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (trifluoromethoxy) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2-chloro-5- (trifluoromethyl) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoro-3-methylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-thien-2-yl-furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-thien-3-yl-furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-nitro-furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4,5-dimethyl-furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chloro-2-nitrophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicic or [2.2.1] hept-2-yl] -5- (4-methyl-2-nitrophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicicio [2.2.1] hept-2-yl] -5- (2 [3-difluorophenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-difluorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-difluorophenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicic or [2.2.1] hept-2-yl] -5- (4-methoxy-phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methyl-phenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (trifluoromethoxy) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (trifluoromethoxy) phenyl] -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-ert-butylphenyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (1-benzoten-2-yl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-quinolin-3-yl-furan-2-carboxamide; N - [(1 S, 2R 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-ethylphenyl) -furan-2-carboxamide; N - [(1 S, 2 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-isopropylphenyl) -furan-2-carboxamide; N - [(1 S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoro-4-methoxy-phenol) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (1 -benzofuran-2-yl) -furan-2-carboxamide; 5- (2-aminophenyl) -N - [(1 S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -furan-2-carboxamide; 5- (2-amino-4-methylphenyl) -N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -furan-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (phenylethynyl) -furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenoxy-furan-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-i [] - 5- (methylt) -1,3-thiazole-2-carboxamide; N - [(1S, 2ft, 4fi) -7-azabicyclo [2.2.1] hept-2-yl] -5-chloro-1,3-thiazole-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-bromo-1,3-tiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (phenol) -1, 3-thiazole-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-fluorophenyl) th] -1, 3-thiazole-2 -carboxamide; N - [(1 S, 2 /? 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-fluorophenyl) thio] -, 3-thiazo! -2-carboxam gives; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-fluorophenyl) thio] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-chlorophenyl) thio] -, 3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-chlorophenyl) thio] -1,3-t-azole-2- carboxamide N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-chlorophenyl) thio] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenoxy-1,3-thiazole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenoxy) -1,3-thiazoi-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenoxy) -1, 3-thiazole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenoxy) -1,3-thiazole-2-carboxamide; N - [(3f?) -1-azabicyclo [2.2.2] oct-3-yl)] - 5-thien-3-yl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-d? -fluorophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-d-fluoro-phenyl) -1,3-thiazole -2-carboxamide; N - [(1S, 2R, 4 / ^) - 7-azabicyclop ^ .ijhept ^ -i -S ^^ - dichloropheni-I .S-thiazole ^ -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (3-l5-dichlorophenyl) -1,3-t-azole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-bromophenyl) -, 3-thiazole-2-carboxamide N - [( 1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-bromophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenyl) -1, 3-thiazoI-2- carboxamide; N - [(1 S, 2R, 4R) -7- azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenyl) -1,3-thiazole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxyphenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4 /:?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxyphenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxyphenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-n -trofenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-nitrophenii) -, 3-t-azole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (2-methylphenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4 / ¾) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylphenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4fi) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylphenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-aminophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-aminophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-acetylamino) phenyl] -1,3-t-azole -2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-acetylamino) phenyl] -1,3-thiazole-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-acetylamino) phenyl] -1,3-t-azole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-2-yl) -1, 3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-3-yl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-4-yl) -1, 3-thiazole -2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropindin-2-yl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyridin-2-yl) -1, 3-thiazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyridin-2-yl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyridn-2-yl) -1, 3 -thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyridin-3-yl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] ept-2-yl] -5- (4-fluoropyridin-3-yl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyridin-3-yl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyridin-3-yl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyridin-4-yl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-methoxyphenyl) thio] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-methoxyphenii) thio] -1,3-thiazole-2-carboxamide; N - [(1 S, 2 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-methoxyphenyl) thio] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2-methylphenyl) thio] -1,3-thiazole-2- carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-methylphenyl) thio] -1,3-thiazole-2-carboxamide; N - [(1 S, 2 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-methylphenyl) thio] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - ([4- (acetylamino) phenyl] t, or) -1, 3-t Azole-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-aminophenyl) thio] -1,3-t-azole- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-hydroxyphenyl) thio] -1,3-thiazoI-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylphenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methyloxy) -1, 3-thiazoI-2-carboxamide; N - [(1 S, 2R, AR) -1-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4:?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyphenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxyphenoxy) -1,3-thiazole-2-carboxamide N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenoxy) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-N] -5- [4- (acetylamino) phenoxy] -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropheni!) - 4-methyl-1,3-thiazole-2-carboxam gives; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenyl) -4-methyl-1,3-thiazole- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenyl) -4-methyl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl) -4-methyl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenyl) -4-methyl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenyl) -4-metii-1,3-t! Azo! -2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-methy1-5-thien-2-yl-1, 3- thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-methyl-5-phenyl-1,3-thiazole-2-carboxamide; N - [(1 S, 2 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-phenyl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-bromophenyl) -1,3-thiazole-2-carboxamide; N - [(1S, 2 /? 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-nitrophenyl) -1, 3-t-azoi-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxy-phenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-methylene-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabic¡cio [2.2.1] hept-2-yl] -5- (3-chlorophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenyl) -1, 3-thiazole-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenyl) -1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-thien-2-yl-1,3-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (phenylsulfanyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2 - [(4-fluorophenyl) -sulfanl] -1,3-t-azole-5 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2-phenoxy-1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2 - [(4-fluorophenyl) -suIfanyl], 1, 3- thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (methylsulfanyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-chlorophenoxy) -, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2,4-dimethyl-1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hep-2-yl] -2- (3-fluorophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-fluorophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-hydroxyphenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-methyphenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- [4- (benzyloxy) phenyl] -1,3-thiazole-5 -carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -4-methyl-2-phenyl-1,3-tiazole-5- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-chlorophenol) -4-methyl-1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-methyl-2-pyridin-2-yl-1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -4-methyl-2-pyridin-4-yl-1,3-tiazole -5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (methylamino) -1,3-thiazo-5-carboxamide; N - [(1 S, 2R, 4R) -7-azab-cyclo [2.2.1] hept: 2-1] -2- (2,3-d-phorophenol) -1, 3 thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2,4-d, fluoro-phenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2,5-difluorophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2,6-difluorophenyl) -1,3-thiazo-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3,4-difluorophenyl) -, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3,5-difluorophenyl) -1,3-thiazo-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-chlorophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3-chlorophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-chlorophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-bromophenyl) -1,3-t-azole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicic or [2.2.1] hept-2-yl] -2- (3-bromophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-bromophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-, cyanophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (3-cyanophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-cyanophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-nitrophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3-nitrophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (4-nitrophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-methylphenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2 /? 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (3-methylene] -1,3-t-azole -5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-aminophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3-aminophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-aminophenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- [2- (methylamino) pheny] -1,3-thiazole-5- carboxamide; N - [(1 S, 2 ft 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -2- [3- (methylamino) phenyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 2 ft 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -2- [4- (methylamino) phenyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 2 /? 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- [2- (acetylamino) phenyl] -1,3-thiazole- 5-carboxamide; N - [(1 S, 2R, AR) -7-azabicyclo [2.2.1] hept-2-N] -2- [3- (acetylamino) phenyl] -, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- [4- (acetylamino) phenyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 2 /? 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (2 - [(trifluoroacetyl) amino] phenyl) -1,3-thiazole -5-carboxamide; N - [(1 S, 2R, 4R) -7- azabicyclo [2.2.1] hept-2-yl] -2- (3 - [(trifluoroacetyl) amino] phenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4 - [(trifluoroacetyl) amino] phenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2 - [(methylsulfonyl) amino] phenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3 - [(methylsulfonyl) amino] phenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4 - [(methylsulfonyl) amino] phenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2 /? 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (3-hydroxyphenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2f ?, 4R) -7-azabicynic [2.2.1] hept-2-yl] -2- (4-hydroxyphenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-methoxyphenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2?, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- (3-methoxyphenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-methoxyphenyl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -2- [2- (trifluoramethoxy) phenyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -2- [3- (trifluoromethoxy) phenyl] -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicynic [2.2.1] hept-2-yl] -2- [4- (trifluoromethoxy) pheny!] -1,3-azole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2-pyridin-2-yl-1,3-thiazole-5-carboxamide; N - [(1S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2-pyridin-3-yl-1,3-thiazole-5-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -2-pyridin-4-yl-1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-iI] -2- (6-fluoropindin-2-yl) -1,3-t-azole-5 -carboxamida; N - [(1 S, 2fi, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (5-fluoropyridin-2-yl) -1,3-thiazole-5-carboxamide; N- [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-fluoropyridin-2-yl) -1, 3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3-fluoropyridin-2-yl) -1, 3- thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-fluoropyridin-2-yl) -1,3-t-azole-5 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (6-fluoropyridin-3-yl) -1,3-t-azole-5 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (5-fluoropyridin-3-yl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4fi) -7-azabicyclo [2.2.1] hept-2-yl] -2- (4-fluoropyridin-3-yl) -1,3-t-azole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-fluoropyridin-3-yl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (2-fluoropyridin-4-yl) -1,3-thiazole-5- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2- (3-fluoropyridin-4-yl) -1,3-thiazole-5-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (phenylsulfanyl) -1, 3,4-thiazole-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenoxy-1, 3,4-thiadiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-chlorophenyl) -sulfanyl] -1, 3,4-thiazole- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenoxy) -1,4,4-thiadiazole-2-carboxamide N- [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenoxy) -1,4,4-thiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-fluorophenyl) -sulfanyl] -1,4,4-thiadiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclop ^. ^ Hept ^ -i -S- -chlorophenyl-sulphanyl-1 .S ^ -thiadiazole ^ -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4-fluorophenyl) -sulfanyl] -1,4,4-thiadiazole-2-carboxamide; N - [(1S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3-chlorophenyl) -sulfan] -1, 3.4- triazo I-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenyl-1, 3,4-oxadiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (methylthio) -1,4,4-oxadiazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-nitrophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-N] -5- (4-methoxyphenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-nitrophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (2-methoxyphenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-N] -5- (4-bromophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4 /:) - 7-azabicyclo [2.2.1] hept-2-yl] -5-phenylsulfanyl-1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoraphenylsulfanyl) -1, 3-oxazo! -2- carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-f! Uorophenylsulfanyl) -1,3-oxazole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenylsulfanyl) -, 3-oxazole-2-carboxamide; N - [(1 S, 2fi, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-difluorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-difluorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7- azabicyclo [2.2.1] hept-2-yl] -5- (3,5-difluorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4") - 7-azabicyclo [2.2.1] hept-2-ii] -5- (4-chlorophenylsulfanyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenylsulfanyl) -1, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-dichlorophenylsulfanyl) -1, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-dichlorophenylsulfanyl) -1, 3-oxazole-2-carboxam gives; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -1-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-difluorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-difluorophenyl) -1,3-oxazoi-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-difluorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2?, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2 4K) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-dichlorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-dichlorophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-bromophenyl) -1, 3-oxazole-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-bromophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7- azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenyl) -1, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxyphenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxyphenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxyphenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-n-trophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenyl) -1 J3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylphenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylene] -, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylaminophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylaminophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylaminophenyl) -1,3-oxazoI-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-aminophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-aminophenol) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenyl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-N] -5- (2- [acetylamino) phenyl] -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3- [acetylamino) phenyl] -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4- [acetylamino) phenyl] -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-2-yl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-3-yl) -1, 3-oxazole-2-carboxam gives; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyridin-4-yl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropyridin-2-yl) -1, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyridin-2-yl) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-i [] - 5- (5-fluoropyridin-2-yl) -, 3-oxazole-2 -carboxamida; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyridin-2-yl) -1, 3-oxazole -2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyridin-3-yl) -1, 3-oxazole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyridin-3-yl) -1, 3-oxazole -2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyridin-3-yl) -1,3-oxazo! -2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyridin-3-yl) -1,3-oxazole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyridin-4-yl) -1, 3-oxazole-2- carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-y]] - 5- (2-fluoropyridin-3-yl) -1,3-oxazole-2 -carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenoxy-1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenoxy) -, 3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-difluorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-d-fluoro-phenoxy) -1,3-oxazole-2 carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-difluorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenoxy) -1,3-oxazoI-2- Garboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-dichlorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicynic [2.2.1] hept-2-yl] -5- (3,5-dichlorophenoxy) -1,3-oxazole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -2-phenyl-1,3-oxazole-5-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -1-methyl-5-phenyl-1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-bromo-1-methyl-1H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hepi-2-ylJ-5- [2- (methylthio) phenyl] -1-methiI-1 H -pyrrole- 2-carboxamide; N - [(1 S, 2 / ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (methylthio) phenyl] -1- Methyl-1 H-pyrrol-2-carboxamide N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenyl-1 H-pyrrol-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluorophenyl) -1-methylene-1 H-pyrrol-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenyl) -1-methyl-1 H -pyrrole-2-carboxamide; N - [(1 S, 2f ?, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluorophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-I] -5- (2,3-difluorophenyl) -1-methylene-1H-pyrrol- 2-carboxamide; N - [(1S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-difluorophenyl) -1-methyl-H-pyrrole-2 carboxamide; N - [(1 S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,6-difluorophenyl) -1-methyl-H-pyrrole-2 -carboxamide; N - [(1 S, 2R, 4R) -7- azabicyclo [2.2.1] hept-2-yl] -5- (3,4-difluorophenyl) -1-methyl-1H-pyrrole-2-carboxam gives; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-difluorophenyl) -1-methylene-1H-pyrrole-2- carboxamide; N - [(1S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4,6-trifluorophenyl) -1-methylene-1H-pyrrole-2 -carboxamide; N - [(1S, 2 / ?, 4R) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (2-chlorophenyl) -1-methyl-1H-pyrrolidone -2-carboxamide; N-1 (1S, 2 / ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-chlorophenyl) -1-methy1-1H-pyrrole-2-carboxamide; N - [(1S, 2f ?, 4?) - 7-azabicyclo [2.2.1] hept-2-ii] -5- (4-chlorophenyl) -1-methyl-1H-pyrrol-2- carboxamide; N - [(1S, 2R, 4R) -7-azab1cic! Or [2.2.1] hept-2-yl] -5- (2,4-dichlorophenyl) -1-methylene-1H-pyrrole -2-carboxamide; N - [(1S, 2 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenyl) -1-meth yl-1H-pyrrole-2-carboxamide; N - [(1S, 2R, 4 / ^) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3,5-dichloropheni!) - 1-methyl-1H-pyrrole-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-bromophenyl) -1-methyl-1H-pyrrol-2-carboxamide; N - [(1S, 2R, AR) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-bromophenyl) -1-methyl-1H-pyrrole-2-carboxamide; N - [(1S, 2fl, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-bromophenyl) -1-methy1H-pyrrole-2-carboxamide; N - [(1S, 2f ?, 4fí) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-hydroxyphenyl) -1-methyl-1H-pyrrole-2-carboxamide; N - [(1S, 2 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-hydroxy-phenyl) -1-methyl-1H-pyrrole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyc! Or [2.2.1] hept-2-yl] -5- (4-hydroxyphenyl) -1-methyl-1H-pyrrole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxy-phenyl) -1-methyl-1H-pyrrole-2-carboxamide; N - [(1S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxy-phenyl) -1-methyl-H-pyrrol-2-carboxam gives; N - [(1S, 2 /? 4?) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyphenii) -1-methyl-1H-pyrrole-2-carboxamide; N - [(1S, 2 4R) -7- azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicido [2.2.1] hept-2-yl] -5- (3-methylphenyl) -1-methyl-1 H -pyrral-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methyl-phenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylaminophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylaminophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1S, 2 /? 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylaminophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2f ?, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-nitrophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-nitrophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-nitrophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2 /? 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-aminophenyl) -1-methyl-1 H-pyrro! -2 -carboxamide; N - [(1 S, 2R. 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-aminophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1 S, 2 /? 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenyl) -1-methyl-H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(2- (acetylamino) phenyl] -1-methyl-1 H-pyrrole-2 -carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(3- (acetylamino) phenyl] -1-methyl-1 H- pyrrole-2-carboxamide; N - [(1 S, 2f ?, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5 - [(4- (acetylamino) phenyl] -1-methyl-H-pyrrole-2 -carboxamide; N - [(1S, 2f ?, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyrid-2-yl) -1-methyl-1H-pyrrol- 2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyrid-3-yl) -1-methyl-1 H -pyrrol- 2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (pyrid-4-yl) -1-methyl-1H-pyrrol- 2-carboxamide; N - [(1S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropyrid-2-yl) -1-methyl-H- pyrrole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyrid-2-yl) -1-methyl-1H- pyrrole-2-carboxamide; N - [(1S, 2fl, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyrid-2-yl) -1-methyl-1H -pyrrole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyrid-2-yl) -1-methyl-1H -pyrrole-2-carboxamide; N - [(1S, 2 /? 4 / ^) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyrid-3-yl) -1 -methyl-1H-pyrrole-2-carboxamide; N - [(1S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-N] -5- (4-fluoropyrid-3-yl) -1 -methyl-1H-pyrrole -2-carboxamide; N - [(1S, 2 /? 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyrid-3-yl) -1-methyl-1H-pyrrole-2- carboxamide; N - [(1S, 2 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyrid-3-yl) -1-methyl-1H-pyrrole-2-carboxamide; N - [(1S, 2 /? 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyrid-4-yl) -1-methyl-1H-pyrrol- 2-carboxamide; N - [(1S, 2 / ?, 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (3-fluoropyrid-4-yl) -1-methyl-1H-pyrrole-2- carboxamide; N - [(1S, 2 /? 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenyl) -1-meityl-1H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenyl) -1-methyl-1 H-pyrrole-2-carboxamide; N - [(1S, 2R, 4:?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenyl) -1-methy-1H-pyrrole-2-carboxamide; N - [(1S, 2R, 4 /?) - 7-azabicyclo [2.2.1] ept-2-yl] -5- (2-fluorophenyl) -H-pyrrole-2-carboxamide; N - [(1S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicicio [2.2.1] hept-2-yl] -5- (4-fluorophenyl) -H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2. ] hept-2-i!] - 5- (3,5-difluorophenyl) -1 H -pyrrole-2-carboxamide; N - [(S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-difluorophenii) -1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-difluorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-chlorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2 /? 4?) - 7-azabicyclo [2.2.1] hept-2-y!] - 5- (3-chlorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-chlorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-ii] -5- (3,5-dichlorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2ft, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3,4-dichlorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2 /? 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2,4-dichlorophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-bromophenyl) -1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (3-bromophenyl) -1 H -pyrro-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-bromophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-y!] - 5- (2-hydroxyphenyl) -1 H -pyrroi-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-y!] - 5- (3-hydroxyphenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2 /? 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-hydroxyphenyl) -1 H-pyrrol-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methoxyphenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methoxyphenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methoxyphenyl) -1 H -pyrrole-2-carboxamide; N - [(1S, 2ft, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylphenyl) -H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylphenyl) -H-pyrrole-2-carboxamide; N - [(1 S, 2ft, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylphenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4ft) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-methylaminophenyl) -1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-methylaminophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2 ft 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-methylaminophen!) - 1 H -pyrrole-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-nitrophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2 /? 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-n-throphenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-n -triphenyl) -1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-aminophenyl) -1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2. 1] hept-2-yl] -5- (3-aminophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2 / ?, 4") -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-aminophenyl) -H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- [2- (acetylamino) phenyl] -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- [3- (acetylamino) phen] -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- [4- (acetylamino) phenyl] -1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (pyrid-2-yl) -1 H-pyrrole-2-carboxamide; N - [(1S, 2, 4R) -7-azabicyclo [2.2.1Jhept-2-yl] -5- (pyrid-3-yl) -1 H-pyrrol-2-carboxamide; N - [(1 S, 2 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (pyrid-4-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropyrid-2-yl) -1 H -pyrrole-2 -carboxamide; N - [(1 S, 2R, 4f?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (4-fluoropyrid-2-yl) -1 H -pyrroI-2-carboxamide; N - [(1 S, 2 /? 4f?) - 7-azabicyclo [2.2.1] hep? -2-yl] -5- (5-fluoropyrid-2-yl) -1 H-pyrrole-2 -carboxamide; N - [(1 S, 2 /? 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyrid-2-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyrid-3-yl) -1 H-pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicicio [2.2.1] hept-2-iI] -5- (4-fluoropyrid-3-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (5-fluoropyrid-3-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (6-fluoropyrid-3-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (2-fluoropyrid-4-yl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (3-fluoropind-4-ii) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5- (2-cyanophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5- (3-cyanophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2R, 4) -7-azabicyclo [2.2.1] hept-2-yl] -5- (4-cyanophenyl) -1 H -pyrrole-2-carboxamide; N - [(1 S, 2 4 R) -7-azabicyclo [2.2.1] hept-2-yl] -3-phenyl-1, 2,4-oxadiazole-5-carboxamide; or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 10, further characterized in that Q is (b).

16. The compound according to claim 15, further characterized in that (b) is 1,3-thiazol-4-yl, 1,3-oxazol-4-yl, H-1, 2,4-triazole-3. -yl or isoxazole-3-iio, optionally substituted on carbon with H, F, Cl, Br, I, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, alkyl substituted, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactamaheterocycloalkyl, aryl, -ORs, -SRs, -N (Rs) 2, -C (0) Rs, -C (S) R8, -C (0) OR8, -C (0) N (R8) 2, -NR8C (0) R8, -S (0) 2N (R8) 2, -OS (0) 2R8, -S (0) 2R8, -S (0) R8I -NR8S (0) 2R8, -N (R8) C (0) N (R8) 2l -CN, -N02, Rr or R9; and further optionally substituted in nitrogen with alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, R7, R9, aryl, -C (0) -alkyl, -C (0) -cycloalkyl, -C (0) -heterocycloalkyl, -C (0) -halogenated alkyl, -C (0) -halogenated cycloalkyl, -C (0) -halogenated heterocycloalkyl, -C (0) -substituted alkyl, -C ( 0) -substituted cycloalkyl, -C (0) -substituted heterocycloalkyl, -C (0) -R7, -C (0) -R9 or -C (0) -aryl.

17. The compound according to claim 16, further characterized in that the compound is N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2-pyridin -3-α-, 3-thiazole-4-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -2-phenyl-1,3-oxazole-4-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenyl-1 H-1, 2,4-triazole-3-carboxamide; N - [(1 S, 2R, 4R) -7-azabicyclo [2.2.1] hept-2-yl] -5-phenylisoxazole-3-carboxamide; N - [(1 S, 2R, 4 /?) - 7-azabicyclo [2.2.1] hept-2-yl] -5-phenylisoxazole-3-carboxamide; or a pharmaceutically acceptable salt thereof.

18. A compound of the formula A-L-B or a pharmaceutically acceptable salt thereof, wherein A is a 7-azabicyclo [2.2.1] heptane ring having stereochemistry S, 2R and AR; B is a heteroaryl; and L is a linking moiety, wherein the linking moiety is attached to the C-2 carbon of the heptane ring in an exo orientation.

19. - A pharmaceutical composition comprising a compound according to any one of claims 1-18, an antipsychotic agent and a pharmaceutically acceptable excipient.

20. - The pharmaceutical composition according to claim 19, further characterized in that said compound and said agent must be administered independently rectally, topically, orally, sublingually or parenterally during a therapeutically effective interval.

21. - The pharmaceutical composition according to claim 19, further characterized in that said compound is administered in an amount of about 0.001 to about 100 mg / kg of body weight of said mammal per day.

22. - The pharmaceutical composition according to claim 19, further characterized in that said compound is administered in an amount of about 0.1 to about 50 mg / kg of body weight of said mammal per day.

23. The pharmaceutical composition according to claim 19, further characterized in that the composition comprises a compound according to any one of claims 1-18 and a pharmaceutically acceptable excipient.

24. - The pharmaceutical composition according to claim 23, further characterized in that said compound is administered rectally, topically, orally, sublingually or parenterally during a therapeutically effective interval.

25. - The pharmaceutical composition according to claim 23, further characterized in that said compound is administered in an amount of about 0.001 to about 100 mg / kg of body weight of said mammal per day.

26. - The pharmaceutical composition according to claim 23, further characterized in that said compound is administered in an amount of about 0.1 to about 50 mg / kg of body weight of said mammal per day.

27. The use of a compound of any one of claims 1-18 for the preparation of a medicament for treating a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of a nicotinic acetylcholine receptor agonist al.

28. - The use as claimed in claim 27, wherein the disease or condition is symptoms of cognitive impairment and care of Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease, presenile dementia (mild cognitive impairment) or senile dementia.

29. - The use as claimed in claim 27, wherein the disease or condition is schizophrenia or psychosis.

30. The use as claimed in claim 29, wherein the antipsychotic agent is added during a therapeutically effective range.

31. The use as claimed in claim 27, wherein the disease or condition is depression, general anxiety disorders or post-traumatic stress disorder.

32. The use as claimed in claim 27, wherein the disease or condition is attention deficit disorder or hyperactivity disorder with attention deficit.

33. The use as claimed in claim 27, wherein the disease or condition is mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS and dementia complex, dementia associated with Down syndrome, dementia associated with Lewy bodies, Huntington's disease, disease Parkinson's disease, tardive dyskinesia, Pick's disease, derangements of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with cessation of tobacco use and cessation of drug use, Gilles de la Tourette syndrome, macular degeneration associated with age, glaucoma, neurodegeneration associated with glaucoma or symptoms associated with pain.